CDK9 inhibitors and their uses
CDK9 inhibitory compounds with selective activity address the safety issues of broad-spectrum inhibitors by targeting CDK9 specifically, promoting tumor cell apoptosis and reducing side effects.
Patent Information
- Application Number
- JP2024536015
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-08-03
- Filing Date
- 2022-12-16
- Publication Date
- 2024-12-09
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current CDK9 inhibitors are broad-spectrum and cause severe side effects due to structural similarities among CDK family members, necessitating the development of CDK9 inhibitors with high activity and selectivity to improve safety and efficacy for treating CDK9-mediated diseases like cancer.
Development of cyclin-dependent kinase 9 (CDK9) inhibitory compounds represented by formula (I) or their pharmaceutically acceptable salts and isomers, which exhibit selective inhibitory activity against CDK9 with reduced off-target effects.
The compounds effectively inhibit CDK9, potentially reducing the expression of MCL-1 and MYC proteins, promoting apoptosis in tumor cells while minimizing adverse effects on other CDKs, thereby providing a safer therapeutic approach for CDK9-related tumors.
Smart Images

Figure 2024545518000001_ABST
Abstract
Description
[Technical Field]
[0001] The present invention relates to the technical field of medicine, and in particular to a cyclin-dependent kinase 9 inhibitor compound of formula (I) or a pharmaceutically acceptable salt or isomer thereof, and uses thereof. [Background technology]
[0002] Cyclin-dependent kinases (CDKs) are a group of serine / threonine protein kinases that act synergistically with cyclins. The CMGC kinase family of kinases, including cyclin-dependent kinases, mitogen-activated protein kinases, glycogen synthase kinases, and CDC-like kinases, includes 20 members of the CDK family. CDK inhibitors can be classified into two categories based on their mechanisms of action: cell cycle regulation (e.g., CDK1, 2, 4, 6) and cellular transcription regulation (e.g., CDK7, 8, 9, 12, 13). [1] Structural insights into the functional diversity of the CDK-cyclin family [J]. Open Biology, 2018, 8(9):180112.
[0003] Heterodimers formed by cyclin-dependent kinase 9 (CDK9) and cyclin T or K are involved in the formation of positive transcription elongation factor b (P-TEFb), which can phosphorylate the C-terminal domain (CTD) of RNA polymerase II (RNA poly II) to drive mRNA transcription elongation. CDK9 plays an important role in transcription and can regulate the expression of downstream short-cycle anti-apoptotic proteins such as MCL-1 and BCL-2. MCL-1, which is highly expressed in many cancers, is closely related to tumor cell proliferation and survival, and tumor cells require continuously activated P-TEFb to maintain high expression of MCL-1, which has a long half-life. Inhibition of CDK9 inhibits transcription, reduces MCL-1 expression levels, and thereby promotes tumor cell apoptosis. [2]CDK9:A Comprehensive Review of Its Biology, and Its Role as a Potential Target for Anti-Cancer Agents[J].Frontiers in Oncology,2021,11:678559.
[0004] Like MCL, tumor cells also require continuously activated P-TEFb to maintain high MYC expression. MYC protein is a key transcriptional regulator in cells, playing a crucial role in cell proliferation, differentiation, maintenance, and other physiological processes. Normal MYC protein and mRNA have a short half-life, and after stimulation of the upstream signaling pathway is removed, MYC transcription levels decline, protein levels rapidly decrease, and cell proliferation and differentiation cease. Meanwhile, MYC gene mutations, amplification, or translocation in cancer cells leads to overexpression or hyperactivation of MYC, causing cancer cells to initiate uncontrolled proliferation and differentiation. Therefore, the MYC gene is one of the important proto-oncogenes. Due to the protein-protein interactions of MYC protein and the lack of a protein-binding pocket that small molecules can recognize and bind to, developing inhibitors that directly target MYC protein is extremely difficult. Therefore, MYC protein is considered an undruggable target by the pharmaceutical industry, and no drugs targeting MYC are currently approved. [3] Dang CV, Reddy EP, Shokat KM, et al. Drugging the “undruggable” cancer targets[J]. Nature Reviews Cancer, 2017. Therefore, inhibition of CDK9 also offers a new therapeutic approach for MYC-associated tumors.
[0005] Although several CDK9 inhibitors have been introduced into clinical research, they are broad-spectrum CDK inhibitors due to the conservation of CDK family structure and may cause unexpected side effects. For example, clinical research on loniclib has been suspended due to serious toxic side effects. [4] Wu T, Qin Z, Tian Y, et al. Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update [J]. Journal of Medicinal Chemistry, 2020, 63(22):13228-13257. Therefore, there is a clinical need for the development of CDK9 inhibitors with high activity and selectivity to improve the safety and efficacy of the compounds. Summary of the Invention
[0006] One object of the present invention is to provide a class of CDK9 inhibitors or pharmaceutically acceptable salts or isomers thereof. The compounds disclosed herein have good inhibitory activity against CDK9 and good selectivity for CDK9 compared to CDK1, 2, 3, and 5. The compounds disclosed herein can treat or prevent CDK9-mediated diseases, such as cancer.
[0007] The technical solution of the present invention is as follows:
[0008] The present invention provides a compound represented by formula (I), a pharmaceutically acceptable salt thereof, or an isomer thereof: [ka] X1 is selected from N or CR4; X2 is selected from N or CR5; L is selected from a bond, —C(O)—, and —(CH)—; A is selected from a bond, a 3- to 12-membered cycloalkyl, a 3- to 12-membered cycloalkenyl, a 3- to 12-membered heterocyclyl, an aryl, and a 5- to 10-membered heteroaryl; the heteroatoms of said 3- to 12-membered heterocyclyl are selected from one or any combination of O, S, and N; the C atom can be optionally oxidized to C(O); the S atom can be optionally oxidized to S(O) or S(O)2; and the heteroatoms of said 5- to 10-membered heteroaryl are selected from one or any combination of O, S, and N; R1 is hydrogen, halogen, hydroxyl, carboxyl, amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkylaminocarbonyl, (C 1~6 Alkyl)2 aminocarbonyl, C 1~6 Alkoxycarbonyl, C 1~6 Alkyl carbonyl, C 1~6 Alkyl sulfonyl, amino sulfonyl, C 1~6 The heteroatoms of the 3- to 12-membered heterocyclyl are selected from one of O, S, and N or any combination thereof, the C atom can be optionally oxidized to C(O), the S atom can be optionally oxidized to S(O) or S(O)2, the heteroatoms of the 5- to 10-membered heteroaryl are selected from one of O, S, and N or any combination thereof, the amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C2~8 Alkynyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkylaminocarbonyl, (C 1~6 Alkyl)2 aminocarbonyl, C 1~6 Alkoxycarbonyl, C 1~6 Alkyl carbonyl, C 1~6 Alkyl sulfonyl, amino sulfonyl, C 1~6 The alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, and 3- to 12-membered cycloalkenyl are unsubstituted or substituted with hydroxyl, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl)2amino, C 1~6 Alkylsulfonyl, HS(O)(=NH)-, C 1~6 Alkyl-S(O)(=NH)-, (C 1~6 Alkyl)2 aminocarbonyl, C 1~6 optionally substituted by one or more groups selected from alkylcarbonyl, 3- to 12-membered cycloalkyl, and 3- to 12-membered heterocyclyl; R2 is halogen, cyano, hydroxyl, carboxyl, amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylthio, C 1~6 Alkylamino, (C 1~6 alkyl)2amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl, 3- to 12-membered heterocyclyloxy, 3- to 12-membered cycloalkyloxy, 3- to 12-membered cycloalkylamino, and 3- to 12-membered heterocyclyl-CH2-amino, wherein said amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylthio, C 1~6 Alkylamino, (C 1~6alkyl)2amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl, 3- to 12-membered heterocyclyloxy, 3- to 12-membered cycloalkyloxy, 3- to 12-membered cycloalkylamino, 3- to 12-membered heterocyclyl-CH2-amino is unsubstituted or substituted with halogen, cyano, hydroxyl, carboxy, amino, C 1~6 Alkyl, C 1~6 Alkoxy, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 alkyl)2 optionally substituted by one or more groups selected from amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, aryl, 3- to 12-membered cycloalkenyl, and 5- to 10-membered heteroaryl; R3 is hydrogen, hydroxy, amino, carboxy, aminocarbonyl, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkyl carbonyl, C 1~6 Alkyl sulfonyl, C 1~6 alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, and 3- to 12-membered heterocyclyl; 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkyl carbonyl, C 1~6 Alkyl sulfonyl, C 1~6Alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, and 3- to 12-membered heterocyclyl are unsubstituted or substituted with hydroxyl, amino, carboxyl, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkoxy C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl)2amino, C 1~6 Alkylcarbonylamino, and C 1~6 alkylsulfonylamino; n is 0 or 1, m is 0, 1, 2, or 3; p is 1, 2, or 3; R4, R5, and R6 are each independently hydrogen, halogen, hydroxy, amino, carboxy, cyano, nitro, C 1~6 Alkyl, C 2~8 Alkenyl, C 2~8 Alkynyl and halogenated C 1~6 alkyl.
[0009] Some embodiments of the present invention relate to compounds of formula (I) or pharmaceutically acceptable salts or isomers thereof, excluding compounds of formula (I) if: In the case (i) X1 is N, X2 is N, n is 0, A is piperidinyl, and R1 is C 1~6 Alkyl sulfonyl, amino sulfonyl, or C 1~6 alkylaminosulfonyl, In the case (ii) X1 is N, X2 is N, n is 0, A is a bond, and R1 is piperidinyl, and the piperidinyl is C 1~6 Alkyl sulfonyl, amino sulfonyl, or C 1~6 It is substituted by alkylaminosulfonyl.
[0010] Some embodiments of the present invention relate to a compound of formula (I) or a pharmaceutically acceptable salt or isomer thereof: X1 is selected from N or CR4; X2 is selected from N or CR5; L is selected from a bond, —C(O)—, and —(CH)—; A is selected from a bond, a 3- to 12-membered cycloalkyl, a 3- to 12-membered cycloalkenyl, a 3- to 12-membered heterocyclyl, an aryl, and a 5- to 10-membered heteroaryl; the heteroatoms of said 3- to 12-membered heterocyclyl are selected from one or any combination of O, S, and N; the C atom can be optionally oxidized to C(O); the S atom can be optionally oxidized to S(O) or S(O)2; and the heteroatoms of said 5- to 10-membered heteroaryl are selected from one or any combination of O, S, and N; R1 is hydrogen, halogen, hydroxyl, carboxyl, amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkylaminocarbonyl, (C 1~6 Alkyl)2 aminocarbonyl, C 1~6 Alkoxycarbonyl, C 1~6 Alkyl carbonyl, C 1~6 Alkyl sulfonyl, amino sulfonyl, C 1~6The heteroatoms of the 3- to 12-membered heterocyclyl are selected from one of O, S, and N or any combination thereof, the C atom can be optionally oxidized to C(O), the S atom can be optionally oxidized to S(O) or S(O)2, the heteroatoms of the 5- to 10-membered heteroaryl are selected from one of O, S, and N or any combination thereof, the amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkylaminocarbonyl, (C 1~6 Alkyl)2 aminocarbonyl, C 1~6 Alkoxycarbonyl, C 1~6 Alkyl carbonyl, C 1~6 Alkyl sulfonyl, amino sulfonyl, C 1~6 The alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, and 3- to 12-membered cycloalkenyl are unsubstituted or substituted with hydroxyl, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl)2amino, C 1~6 optionally substituted by one or more groups selected from alkylsulfonyl, 3- to 12-membered cycloalkyl, and 3- to 12-membered heterocyclyl; R2 is halogen, cyano, hydroxyl, carboxyl, amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6alkyl)2amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, and 3- to 12-membered cycloalkenyl, wherein said amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 alkyl)2amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl are unsubstituted or substituted with halogen, cyano, hydroxyl, carboxy, amino, C 1~6 Alkyl, C 1~6 Alkoxy, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 alkyl)2 optionally substituted by one or more groups selected from amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, aryl, and 5- to 10-membered heteroaryl; R3 is hydrogen, hydroxy, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkyl carbonyl, C 1~6 Alkyl sulfonyl, C 1~6 alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, and 3- to 12-membered heterocyclyl; 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkyl carbonyl, C 1~6 Alkyl sulfonyl, C1~6 Alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, and 3- to 12-membered heterocyclyl are unsubstituted or substituted with hydroxyl, amino, carboxyl, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkoxy C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl)2amino, C 1~6 Alkylcarbonylamino, and C 1~6 alkylsulfonylamino; n is 0 or 1, m is 0, 1, 2, or 3; p is 1, 2, or 3; R4, R5, and R6 are each independently hydrogen, halogen, hydroxy, amino, carboxy, cyano, nitro, C 1~6 Alkyl, C 2~8 Alkenyl, C 2~8 Alkynyl and halogenated C 1~6 alkyl.
[0011] Some embodiments of the present invention relate to compounds of formula (I) or a pharmaceutically acceptable salt or isomer thereof: X1 is N, X2 is N, L is selected from a bond, —C(O)—, or —(CH)—; A is selected from a bond, a 3- to 12-membered cycloalkyl, or a 3- to 12-membered heterocyclyl; the heteroatoms of the 3- to 12-membered heterocyclyl are selected from any one of O, S, and N, or any combination thereof; R1 is hydrogen, hydroxyl, C 1~6 Alkyl, C 1~6 Alkoxy, amino, (C 1~6 Alkyl)2amino, C 1~6alkylcarbonyl, 3- to 12-membered heterocyclyl, halogen, carboxyl, or 3- to 12-membered cycloalkyl, wherein the heteroatom of the 3- to 12-membered heterocyclyl is selected from any one of O, S, and N, or any combination thereof; 1~6 Alkyl, C 1~6 Alkoxy, amino, (C 1~6 Alkyl)2amino, C 1~6 Alkylcarbonyl, 3- to 12-membered heterocyclyl, and 3- to 12-membered cycloalkyl are hydroxyl, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl)2 aminocarbonyl, C 1~6 Alkylcarbonyl, (C 1~6 Alkyl)2amino, C 1~6 optionally substituted by any one or more groups selected from alkylsulfonyl, 3- to 12-membered cycloalkyl, or 3- to 12-membered heterocyclyl; R2 is amino, C 1~6 alkylamino, 3- to 12-membered heterocyclyl, or 3- to 12-membered cycloalkylamino, halogen, cyano, hydroxyl, or (C 1~6 The heteroatoms of the 3- to 12-membered heterocyclyl are selected from any one of O, S, and N, or any combination thereof; and the amino, C 1~6 alkylamino, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkylamino, and (C 1~6 Alkyl)2amino is C 1~6 Alkyl, C 1~6 optionally substituted by any one or more groups selected from alkoxy, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, or 3- to 12-membered cycloalkenyl; R3 is cyano, C 1~6 Alkyl, aminocarbonyl, hydrogen, hydroxy, amino, halogen, or C 1~6 alkoxy, wherein C1~6 Alkyl, aminocarbonyl, amino, and C 1~6 The alkoxy is optionally substituted with any one or more groups selected from halogen, R6 is hydrogen, halogen, hydroxy, amino, or C 1~6 alkyl, n is 0 or 1, m is 0, 1, 2, or 3; p is 1, 2, or 3; wherein n is 0, A is a bond, R1 is piperidinyl, m is 1, and said piperidinyl is C 1~6 The exception is when it is substituted by alkylsulfonyl.
[0012] Some embodiments of the present invention relate to compounds of Formula (II) or pharmaceutically acceptable salts or isomers thereof, wherein L is a bond and n is 0: [ka] X1 is selected from N or CR4; X2 is selected from N or CR5; A is selected from 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, 3- to 12-membered heterocyclyl, aryl, and 5- to 10-membered heteroaryl; the heteroatoms of the 3- to 12-membered heterocyclyl are selected from one or any combination of O, S, and N; the C atom can be optionally oxidized to C(O); the S atom can be optionally oxidized to S(O) or S(O)2; and the heteroatoms of the 5- to 10-membered heteroaryl are selected from one or any combination of O, S, and N; R1 is hydrogen, halogen, hydroxyl, carboxyl, amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C2~8 Alkynyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkylaminocarbonyl, (C 1~6 Alkyl)2 aminocarbonyl, C 1~6 Alkoxycarbonyl, C 1~6 Alkyl carbonyl, C 1~6 Alkyl sulfonyl, amino sulfonyl, C 1~6 The heteroatoms of the 3- to 12-membered heterocyclyl are selected from one of O, S, and N or any combination thereof, the C atom can be optionally oxidized to C(O), the S atom can be optionally oxidized to S(O) or S(O)2, the heteroatoms of the 5- to 10-membered heteroaryl are selected from one of O, S, and N or any combination thereof, the amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkylaminocarbonyl, (C 1~6 Alkyl)2 aminocarbonyl, C 1~6 Alkoxycarbonyl, C 1~6 Alkyl carbonyl, C 1~6 Alkyl sulfonyl, amino sulfonyl, C 1~6 The alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, and 3- to 12-membered cycloalkenyl are unsubstituted or substituted with hydroxyl, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl)2amino, C1~6 Alkylsulfonyl, HS(O)(=NH)-, C 1~6 optionally substituted by one or more groups selected from alkyl-S(O)(=NH)-, 3- to 12-membered cycloalkyl, and 3- to 12-membered heterocyclyl; R2 is halogen, cyano, hydroxyl, carboxyl, amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 alkyl)2amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl, 3- to 12-membered heterocyclyloxy, 3- to 12-membered cycloalkylamino, and 3- to 12-membered heterocyclyl-CH2-amino, wherein said amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 alkyl)2amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl, 3- to 12-membered heterocyclyloxy, 3- to 12-membered cycloalkylamino, 3- to 12-membered heterocyclyl-CH2-amino is unsubstituted or is selected from the group consisting of halogen, cyano, hydroxyl, carboxy, amino, C 1~6 Alkyl, C 1~6 Alkoxy, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 alkyl)2 optionally substituted by one or more groups selected from amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, aryl, and 5- to 10-membered heteroaryl; R3 is hydrogen, hydroxy, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C1~6 Alkyl carbonyl, C 1~6 Alkylsulfonyl, C 1~6 alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, and 3- to 12-membered heterocyclyl; 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkyl carbonyl, C 1~6 Alkylsulfonyl, C 1~6 Alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, and 3- to 12-membered heterocyclyl are unsubstituted or substituted with hydroxyl, amino, carboxyl, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkoxy C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl)2amino, C 1~6 Alkylcarbonylamino, and C 1~6 alkylsulfonylamino; m is 0, 1, 2, or 3; R4, R5, and R6 are each independently hydrogen, halogen, hydroxy, amino, carboxy, cyano, nitro, C 1~6 Alkyl, C 2~8 Alkenyl, C 2~8 Alkynyl and halogenated C 1~6 alkyl, Preferably, at least one of X1 and X2 is N.
[0013] Some embodiments of the present invention relate to a compound of formula (II) or a pharmaceutically acceptable salt or isomer thereof: X1 is selected from N or CR4; X2 is selected from N or CR5; A is selected from 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, 3- to 12-membered heterocyclyl, aryl, and 5- to 10-membered heteroaryl; the heteroatoms of the 3- to 12-membered heterocyclyl are selected from one or any combination of O, S, and N; the C atom can be optionally oxidized to C(O); the S atom can be optionally oxidized to S(O) or S(O)2; and the heteroatoms of the 5- to 10-membered heteroaryl are selected from one or any combination of O, S, and N; R1 is hydrogen, halogen, hydroxyl, carboxyl, amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkylaminocarbonyl, (C 1~6 Alkyl)2 aminocarbonyl, C 1~6 Alkoxycarbonyl, C 1~6 Alkyl carbonyl, C 1~6 Alkyl sulfonyl, amino sulfonyl, C 1~6 The heteroatoms of the 3- to 12-membered heterocyclyl are selected from one of O, S, and N or any combination thereof, the C atom can be optionally oxidized to C(O), the S atom can be optionally oxidized to S(O) or S(O)2, the heteroatoms of the 5- to 10-membered heteroaryl are selected from one of O, S, and N or any combination thereof, the amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkylaminocarbonyl, (C 1~6 Alkyl)2 aminocarbonyl, C 1~6 Alkoxycarbonyl, C 1~6 Alkyl carbonyl, C 1~6 Alkyl sulfonyl, amino sulfonyl, C 1~6 The alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, and 3- to 12-membered cycloalkenyl are unsubstituted or substituted with hydroxyl, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl)2amino, C 1~6 optionally substituted by one or more groups selected from alkylsulfonyl, 3- to 12-membered cycloalkyl, and 3- to 12-membered heterocyclyl; R2 is halogen, cyano, hydroxyl, carboxyl, amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 alkyl)2amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, and 3- to 12-membered cycloalkenyl, wherein said amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 alkyl)2amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl are unsubstituted or substituted with halogen, cyano, hydroxyl, carboxy, amino, C 1~6 Alkyl, C 1~6 Alkoxy, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 1~6 Alkylamino, (C1~6 alkyl)2 optionally substituted by one or more groups selected from amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, aryl, and 5- to 10-membered heteroaryl; R3 is hydrogen, hydroxy, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkyl carbonyl, C 1~6 Alkyl sulfonyl, C 1~6 alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, and 3- to 12-membered heterocyclyl; 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkyl carbonyl, C 1~6 Alkyl sulfonyl, C 1~6 Alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, and 3- to 12-membered heterocyclyl are unsubstituted or substituted with hydroxyl, amino, carboxyl, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkoxy C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl)2amino, C 1~6 Alkylcarbonylamino, and C 1~6 alkylsulfonylamino; m is 0, 1, 2, or 3; R4, R5, and R6 are each independently hydrogen, halogen, hydroxy, amino, carboxy, cyano, nitro, C 1~6 Alkyl, C 2~8 Alkenyl, C 2~8 Alkynyl and halogenated C 1~6 alkyl, Preferably, at least one of X1 and X2 is N.
[0014] Some embodiments of the present invention relate to a compound of formula (II) or a pharmaceutically acceptable salt or isomer thereof: R1 is hydrogen, halogen, hydroxyl, carboxyl, amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylaminocarbonyl, (C 1~6 Alkyl)2 aminocarbonyl, C 1~6 Alkoxycarbonyl, C 1~6 Alkyl carbonyl, C 1~6 Alkyl sulfonyl, C 1~6 alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl, 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylaminocarbonyl, (C 1~6 Alkyl)2 aminocarbonyl, C 1~6 Alkoxycarbonyl, C 1~6 Alkyl carbonyl, C 1~6Alkyl sulfonyl, C 1~6 The alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, and 3- to 12-membered cycloalkenyl are unsubstituted or substituted with hydroxyl, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl)2amino, C 1~6 Alkylsulfonyl, HS(O)(=NH)-, C 1~6 optionally substituted by one or more groups selected from alkyl-S(O)(=NH)-, 3- to 12-membered cycloalkyl, and 3- to 12-membered heterocyclyl; R3 is cyano and halogenated C 1~6 alkyl.
[0015] Some embodiments of the present invention relate to a compound of formula (II) or a pharmaceutically acceptable salt or isomer thereof: X1 is N, X2 is N, A is selected from a bond, a 3- to 12-membered cycloalkyl, or a 3- to 12-membered heterocyclyl, wherein the heteroatoms of the 3- to 12-membered heterocyclyl are selected from any one of O, S, and N, or any combination thereof; R1 is hydrogen, hydroxyl, C 1~6 Alkyl, C 1~6 Alkoxy, amino, (C 1~6 Alkyl)2amino, C 1~6 alkylcarbonyl, 3- to 12-membered heterocyclyl, halogen, carboxyl, or 3- to 12-membered cycloalkyl, wherein the heteroatom of the 3- to 12-membered heterocyclyl is selected from any one of O, S, and N, or any combination thereof; 1~6 Alkyl, C 1~6 Alkoxy, amino, (C 1~6 Alkyl)2amino, C 1~6Alkylcarbonyl, 3- to 12-membered heterocyclyl, and 3- to 12-membered cycloalkyl are hydroxyl, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl)2 aminocarbonyl, C 1~6 Alkylcarbonyl, (C 1~6 Alkyl)2amino, C 1~6 optionally substituted by any one or more groups selected from alkylsulfonyl, 3- to 12-membered cycloalkyl, or 3- to 12-membered heterocyclyl; R2 is amino, C 1~6 alkylamino, 3- to 12-membered heterocyclyl or 3- to 12-membered cycloalkylamino, halogen, cyano, hydroxyl, or (C 1~6 The heteroatoms of the 3- to 12-membered heterocyclyl or 3- to 12-membered cycloalkylamino are selected from any one of O, S, and N, or any combination thereof; and the amino, C 1~6 alkylamino, 3- to 12-membered heterocyclyl, and (C 1~6 Alkyl)2amino is C 1~6 Alkyl, C 1~6 optionally substituted by any one or more groups selected from alkoxy, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, or 3- to 12-membered cycloalkenyl; R3 is cyano, C 1~6 Alkyl, aminocarbonyl, hydrogen, hydroxy, amino, halogen, or C 1~6 alkoxy, wherein C 1~6 Alkyl, aminocarbonyl, amino, and C 1~6 The alkoxy is optionally substituted with any one or more groups selected from halogen, R6 is hydrogen, halogen, hydroxy, amino, or C 1~6 alkyl, m is 0, 1, 2, or 3; p is 1, 2, or 3.
[0016] Some embodiments of the present invention relate to compounds of formula (III) or a pharmaceutically acceptable salt or isomer thereof, wherein L is —C(O)— and n is 1: [ka] X1 is selected from N or CR4; X2 is selected from N or CR5; A is selected from 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, 3- to 12-membered heterocyclyl, aryl, and 5- to 10-membered heteroaryl; the heteroatoms of the 3- to 12-membered heterocyclyl are selected from one or any combination of O, S, and N; the C atom can be optionally oxidized to C(O); the S atom can be optionally oxidized to S(O) or S(O)2; and the heteroatoms of the 5- to 10-membered heteroaryl are selected from one or any combination of O, S, and N; R1 is hydrogen, halogen, hydroxyl, carboxyl, amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkylaminocarbonyl, (C 1~6 Alkyl)2 aminocarbonyl, C 1~6 Alkoxycarbonyl, C 1~6 Alkyl carbonyl, C 1~6 Alkyl sulfonyl, amino sulfonyl, C 1~6The heteroatoms of the 3- to 12-membered heterocyclyl are selected from one of O, S, and N or any combination thereof, the C atom can be optionally oxidized to C(O), the S atom can be optionally oxidized to S(O) or S(O)2, the heteroatoms of the 5- to 10-membered heteroaryl are selected from one of O, S, and N or any combination thereof, the amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkylaminocarbonyl, (C 1~6 Alkyl)2 aminocarbonyl, C 1~6 Alkoxycarbonyl, C 1~6 Alkyl carbonyl, C 1~6 Alkyl sulfonyl, amino sulfonyl, C 1~6 The alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, and 3- to 12-membered cycloalkenyl are unsubstituted or substituted with hydroxyl, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl)2amino, C 1~6 Alkylsulfonyl, HS(O)(=NH)-, C 1~6 optionally substituted by one or more groups selected from alkyl-S(O)(=NH)-, 3- to 12-membered cycloalkyl, and 3- to 12-membered heterocyclyl; R2 is halogen, cyano, hydroxyl, carboxyl, amino, C 1~6 Alkyl, C 1~6 Alkoxy, C1~6 Alkylamino, (C 1~6 alkyl)2amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl, 3- to 12-membered heterocyclyloxy, 3- to 12-membered cycloalkylamino, and 3- to 12-membered heterocyclyl-CH2-amino, wherein said amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 alkyl)2amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl, 3- to 12-membered heterocyclyloxy, 3- to 12-membered cycloalkylamino, 3- to 12-membered heterocyclyl-CH2-amino is unsubstituted or is selected from the group consisting of halogen, cyano, hydroxyl, carboxy, amino, C 1~6 Alkyl, C 1~6 Alkoxy, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 alkyl)2 optionally substituted by one or more groups selected from amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, aryl, and 5- to 10-membered heteroaryl; R3 is hydrogen, hydroxy, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkyl carbonyl, C 1~6 Alkyl sulfonyl, C 1~6 alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, and 3- to 12-membered heterocyclyl; 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkyl carbonyl, C 1~6 Alkylsulfonyl, C 1~6 Alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, and 3- to 12-membered heterocyclyl are unsubstituted or substituted with hydroxyl, amino, carboxyl, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkoxy C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl)2amino, C 1~6 Alkylcarbonylamino, and C 1~6 alkylsulfonylamino; m is 0, 1, 2, or 3; R4, R5, and R6 are each independently hydrogen, halogen, hydroxy, amino, carboxy, cyano, nitro, C 1~6 Alkyl, C 2~8 Alkenyl, C 2~8 Alkynyl and halogenated C 1~6 alkyl, Preferably, at least one of X1 and X2 is N.
[0017] Some embodiments of the present invention relate to a compound of formula (III) or a pharmaceutically acceptable salt or isomer thereof: X1 is selected from N or CR4; X2 is selected from N or CR5; A is selected from 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, 3- to 12-membered heterocyclyl, aryl, and 5- to 10-membered heteroaryl; the heteroatoms of the 3- to 12-membered heterocyclyl are selected from one or any combination of O, S, and N; the C atom can be optionally oxidized to C(O); the S atom can be optionally oxidized to S(O) or S(O)2; and the heteroatoms of the 5- to 10-membered heteroaryl are selected from one or any combination of O, S, and N; R1 is hydrogen, halogen, hydroxyl, carboxyl, amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkylaminocarbonyl, (C 1~6 Alkyl)2 aminocarbonyl, C 1~6 Alkoxycarbonyl, C 1~6 Alkyl carbonyl, C 1~6 Alkyl sulfonyl, amino sulfonyl, C 1~6 The heteroatoms of the 3- to 12-membered heterocyclyl are selected from one of O, S, and N or any combination thereof, the C atom can be optionally oxidized to C(O), the S atom can be optionally oxidized to S(O) or S(O)2, the heteroatoms of the 5- to 10-membered heteroaryl are selected from one of O, S, and N or any combination thereof, the amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C2~8 Alkynyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkylaminocarbonyl, (C 1~6 Alkyl)2 aminocarbonyl, C 1~6 Alkoxycarbonyl, C 1~6 Alkyl carbonyl, C 1~6 Alkyl sulfonyl, amino sulfonyl, C 1~6 The alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, and 3- to 12-membered cycloalkenyl are unsubstituted or substituted with hydroxyl, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl)2amino, C 1~6 optionally substituted by one or more groups selected from alkylsulfonyl, 3- to 12-membered cycloalkyl, and 3- to 12-membered heterocyclyl; R2 is halogen, cyano, hydroxyl, carboxyl, amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 alkyl)2amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, and 3- to 12-membered cycloalkenyl, wherein said amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 alkyl)2amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl are unsubstituted or substituted with halogen, cyano, hydroxyl, carboxy, amino, C 1~6 Alkyl, C 1~6 Alkoxy, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6alkyl)2 optionally substituted by one or more groups selected from amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, aryl, and 5- to 10-membered heteroaryl; R3 is hydrogen, hydroxy, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkyl carbonyl, C 1~6 Alkylsulfonyl, C 1~6 alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, and 3- to 12-membered heterocyclyl; 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkyl carbonyl, C 1~6 Alkylsulfonyl, C 1~6 Alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, and 3- to 12-membered heterocyclyl are unsubstituted or substituted with hydroxyl, amino, carboxyl, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkoxy C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl)2amino, C 1~6 Alkylcarbonylamino, and C 1~6 alkylsulfonylamino; m is 0, 1, 2, or 3; R4, R5, and R6 are each independently hydrogen, halogen, hydroxy, amino, carboxy, cyano, nitro, C 1~6 Alkyl, C 2~8 Alkenyl, C 2~8 Alkynyl and halogenated C 1~6 alkyl, Preferably, at least one of X1 and X2 is N.
[0018] Some embodiments of the present invention relate to compounds of formula (IV) or a pharmaceutically acceptable salt or isomer thereof, wherein L is —(CH)—, p is 1, and n is 1; [ka] X1 is selected from N or CR4; X2 is selected from N or CR5; A is selected from 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, 3- to 12-membered heterocyclyl, aryl, and 5- to 10-membered heteroaryl; the heteroatoms of the 3- to 12-membered heterocyclyl are selected from one or any combination of O, S, and N; the C atom can be optionally oxidized to C(O); the S atom can be optionally oxidized to S(O) or S(O)2; and the heteroatoms of the 5- to 10-membered heteroaryl are selected from one or any combination of O, S, and N; R1 is hydrogen, halogen, hydroxyl, carboxyl, amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkylaminocarbonyl, (C 1~6 Alkyl)2 aminocarbonyl, C 1~6 Alkoxycarbonyl, C 1~6Alkyl carbonyl, C 1~6 Alkyl sulfonyl, amino sulfonyl, C 1~6 The heteroatoms of the 3- to 12-membered heterocyclyl are selected from one of O, S, and N or any combination thereof, the C atom can be optionally oxidized to C(O), the S atom can be optionally oxidized to S(O) or S(O)2, the heteroatoms of the 5- to 10-membered heteroaryl are selected from one of O, S, and N or any combination thereof, the amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkylaminocarbonyl, (C 1~6 Alkyl)2 aminocarbonyl, C 1~6 Alkoxycarbonyl, C 1~6 Alkyl carbonyl, C 1~6 Alkyl sulfonyl, amino sulfonyl, C 1~6 The alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, and 3- to 12-membered cycloalkenyl are unsubstituted or substituted with hydroxyl, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl)2amino, C 1~6 Alkylsulfonyl, HS(O)(=NH)-, C 1~6 optionally substituted by one or more groups selected from alkyl-S(O)(=NH)-, 3- to 12-membered cycloalkyl, and 3- to 12-membered heterocyclyl; R2 is halogen, cyano, hydroxyl, carboxyl, amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 alkyl)2amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl, 3- to 12-membered heterocyclyloxy, 3- to 12-membered cycloalkylamino, and 3- to 12-membered heterocyclyl-CH2-amino, wherein said amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 alkyl)2amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl, 3- to 12-membered heterocyclyloxy, 3- to 12-membered cycloalkylamino, 3- to 12-membered heterocyclyl-CH2-amino is unsubstituted or is selected from the group consisting of halogen, cyano, hydroxyl, carboxy, amino, C 1~6 Alkyl, C 1~6 Alkoxy, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 alkyl)2 optionally substituted by one or more groups selected from amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, aryl, and 5- to 10-membered heteroaryl; R3 is hydrogen, hydroxy, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkyl carbonyl, C 1~6 Alkylsulfonyl, C 1~6 alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, and 3- to 12-membered heterocyclyl; 1~6Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkyl carbonyl, C 1~6 Alkyl sulfonyl, C 1~6 Alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, and 3- to 12-membered heterocyclyl are unsubstituted or substituted with hydroxyl, amino, carboxyl, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkoxy C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl)2amino, C 1~6 Alkylcarbonylamino, and C 1~6 alkylsulfonylamino; m is 0, 1, 2, or 3; R4, R5, and R6 are each independently hydrogen, halogen, hydroxy, amino, carboxy, cyano, nitro, C 1~6 Alkyl, C 2~8 Alkenyl, C 2~8 Alkynyl and halogenated C 1~6 alkyl, Preferably, at least one of X1 and X2 is N.
[0019] Some embodiments of the present invention relate to a compound of formula (IV) or a pharmaceutically acceptable salt or isomer thereof: X1 is selected from N or CR4; X2 is selected from N or CR5; A is selected from 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, 3- to 12-membered heterocyclyl, aryl, and 5- to 10-membered heteroaryl; the heteroatoms of the 3- to 12-membered heterocyclyl are selected from one or any combination of O, S, and N; the C atom can be optionally oxidized to C(O); the S atom can be optionally oxidized to S(O) or S(O)2; and the heteroatoms of the 5- to 10-membered heteroaryl are selected from one or any combination of O, S, and N; R1 is hydrogen, halogen, hydroxyl, carboxyl, amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkylaminocarbonyl, (C 1~6 Alkyl)2 aminocarbonyl, C 1~6 Alkoxycarbonyl, C 1~6 Alkyl carbonyl, C 1~6 Alkyl sulfonyl, amino sulfonyl, C 1~6 The heteroatoms of the 3- to 12-membered heterocyclyl are selected from one of O, S, and N or any combination thereof, the C atom can be optionally oxidized to C(O), the S atom can be optionally oxidized to S(O) or S(O)2, the heteroatoms of the 5- to 10-membered heteroaryl are selected from one of O, S, and N or any combination thereof, the amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C2~8 Alkynyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkylaminocarbonyl, (C 1~6 Alkyl)2 aminocarbonyl, C 1~6 Alkoxycarbonyl, C 1~6 Alkyl carbonyl, C 1~6 Alkyl sulfonyl, amino sulfonyl, C 1~6 The alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, and 3- to 12-membered cycloalkenyl are unsubstituted or substituted with hydroxyl, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl)2amino, C 1~6 optionally substituted by one or more groups selected from alkylsulfonyl, 3- to 12-membered cycloalkyl, and 3- to 12-membered heterocyclyl; R2 is halogen, cyano, hydroxyl, carboxyl, amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 alkyl)2amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, and 3- to 12-membered cycloalkenyl, wherein said amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 alkyl)2amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl are unsubstituted or substituted with halogen, cyano, hydroxyl, carboxy, amino, C 1~6 Alkyl, C 1~6 Alkoxy, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6alkyl)2 optionally substituted by one or more groups selected from amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, aryl, and 5- to 10-membered heteroaryl; R3 is hydrogen, hydroxy, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkyl carbonyl, C 1~6 Alkyl sulfonyl, C 1~6 alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, and 3- to 12-membered heterocyclyl; 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkyl carbonyl, C 1~6 Alkyl sulfonyl, C 1~6 Alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, and 3- to 12-membered heterocyclyl are unsubstituted or substituted with hydroxyl, amino, carboxyl, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkoxy C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl)2amino, C 1~6 Alkylcarbonylamino, and C 1~6 alkylsulfonylamino; m is 0, 1, 2, or 3; R4, R5, and R6 are each independently hydrogen, halogen, hydroxy, amino, carboxy, cyano, nitro, C 1~6 Alkyl, C 2~8 Alkenyl, C 2~8 Alkynyl and halogenated C 1~6 alkyl, Preferably, at least one of X1 and X2 is N.
[0020] Some embodiments of the present invention relate to a compound of formula (I) or a pharmaceutically acceptable salt or isomer thereof: A is selected from the group consisting of 3- to 8-membered cycloalkyl, 6- to 11-membered ortho-fused cycloalkyl, 6- to 11-membered bridged cycloalkyl, 7- to 12-membered spirocycloalkyl, 3- to 8-membered monocycloalkenyl, 7- to 11-membered spirocycloalkenyl, 7- to 11-membered ortho-fused cycloalkenyl, 6- to 11-membered bridged cycloalkenyl, 3- to 8-membered heterocyclyl, 6- to 12-membered ortho-fused heterocyclyl, 6- to 12-membered spiroheterocyclyl, 6- to 12-membered bridged heterocyclyl, and 5- to 10-membered heteroaryl. The heteroatoms of the 3- to 8-membered heterocyclyl, 6- to 12-membered ortho-fused heterocyclyl, 6- to 12-membered spiroheterocyclyl, and 6- to 12-membered bridged heterocyclyl are selected from one or any combination of O, S, and N, the C atom can be optionally oxidized to C(O), and the S atom can be optionally oxidized to S(O) or S(O)2, and the heteroatoms of the 5- to 10-membered heteroaryl are selected from one or any combination of O, S, and N.
[0021] Some embodiments of the present invention relate to a compound of formula (I) or a pharmaceutically acceptable salt or isomer thereof: A is, [ka] is selected from.
[0022] Some embodiments of the present invention relate to a compound of formula (I) or a pharmaceutically acceptable salt or isomer thereof: X1 is N, X2 is CR5, L is selected from a bond or —C(O)—; A is selected from 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkyl, or 5- to 10-membered heteroaryl, and the heteroatom of the 3- to 12-membered heterocyclyl and the 5- to 10-membered heteroaryl is N; R1 is hydrogen, hydroxyl, amino, C 1~6 Alkyl or C 1~6 alkylcarbonylamino, wherein the amino, C 1~6 Alkyl or C 1~6 Alkylcarbonylamino is unsubstituted or can be HS(O)(=NH)-, C 1~6 alkyl-S(O)(=NH)-; R2 is amino, C 1~6 Alkylamino, (C 1~6 Alkyl)2amino, C 1~6 alkoxy, 3- to 12-membered heterocyclyloxy, 3- to 12-membered heterocyclyl or 3- to 12-membered cycloalkenyl, 3- to 12-membered cycloalkylamino, wherein the heteroatoms of the 3- to 12-membered heterocyclyl and 3- to 12-membered heterocyclyloxy are N, O, or any combination thereof; and the amino, C 1~6 Alkylamino, (C 1~6 Alkyl)2amino, C 1~6 The alkoxy, 3- to 12-membered heterocyclyloxy, 3- to 12-membered heterocyclyl, or 3- to 12-membered cycloalkenyl, 3- to 12-membered cycloalkylamino is unsubstituted or is selected from the group consisting of 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, aryl, C 1~6 optionally substituted with one or more groups selected from alkyl; R3 is cyano or halogenated C 1~6 alkyl, R5 and R6 are each independently hydrogen; n is 0 or 1, m is 0 or 1.
[0023] Some embodiments of the present invention relate to compounds of formula (I) or a pharmaceutically acceptable salt or isomer thereof: X1 is selected from N or CR4; X2 is selected from N or CR5; L is selected from a bond, —C(O)—, and —(CH)—; A is a bond, R1 is hydrogen, halogen, hydroxyl, carboxyl, amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkylaminocarbonyl, (C 1~6 Alkyl)2 aminocarbonyl, C 1~6 Alkoxycarbonyl, C 1~6 Alkyl carbonyl, C 1~6 Alkyl sulfonyl, amino sulfonyl, C 1~6 The heteroatoms of the 3- to 12-membered heterocyclyl are selected from one of O, S, and N or any combination thereof, the C atom can be optionally oxidized to C(O), the S atom can be optionally oxidized to S(O) or S(O)2, the heteroatoms of the 5- to 10-membered heteroaryl are selected from one of O, S, and N or any combination thereof, the amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonylamino, C1~6 Alkylaminocarbonyl, (C 1~6 Alkyl)2 aminocarbonyl, C 1~6 Alkoxycarbonyl, C 1~6 Alkyl carbonyl, C 1~6 Alkyl sulfonyl, amino sulfonyl, C 1~6 The alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, and 3- to 12-membered cycloalkenyl are unsubstituted or substituted with hydroxyl, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl)2amino, C 1~6 optionally substituted by one or more groups selected from alkylsulfonyl, 3- to 12-membered cycloalkyl, and 3- to 12-membered heterocyclyl; R2 is halogen, cyano, hydroxyl, carboxyl, amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 alkyl)2amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, and 3- to 12-membered cycloalkenyl, wherein said amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 alkyl)2amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl are unsubstituted or substituted with halogen, cyano, hydroxyl, carboxy, amino, C 1~6 Alkyl, C 1~6 Alkoxy, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 alkyl)2 optionally substituted by one or more groups selected from amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, aryl, and 5- to 10-membered heteroaryl; R3 is hydrogen, hydroxy, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkyl carbonyl, C 1~6 Alkyl sulfonyl, C 1~6 alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, and 3- to 12-membered heterocyclyl; 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkyl carbonyl, C 1~6 Alkyl sulfonyl, C 1~6 Alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, and 3- to 12-membered heterocyclyl are unsubstituted or substituted with hydroxyl, amino, carboxyl, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkoxy C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl)2amino, C 1~6 Alkylcarbonylamino, and C 1~6 alkylsulfonylamino; n is 0 or 1, m is 0, 1, 2, or 3; p is 1, 2, or 3; R4, R5, and R6 are each independently hydrogen, halogen, hydroxy, amino, carboxy, cyano, nitro, C 1~6 Alkyl, C 2~8 Alkenyl, C 2~8 Alkynyl and halogenated C 1~6 alkyl.
[0024] Some embodiments of the present invention relate to a compound of formula (I) or a pharmaceutically acceptable salt or isomer thereof: X1 is N, X2 is N, L is a bond, A is selected from 3- to 12-membered cycloalkyl or 3- to 12-membered heterocyclyl, and the heteroatom of said 3- to 12-membered heterocyclyl is N; R1 is hydrogen, hydroxyl, C 1~6 Alkyl, C 1~6 Alkoxy, amino, (C 1~6 Alkyl)2amino, C 1~6 alkylcarbonyl, or 3- to 12-membered heterocyclyl, wherein the heteroatom of the 3- to 12-membered heterocyclyl is selected from any one of N and O, or any combination thereof; 1~6 Alkyl, C 1~6 Alkoxy, amino, (C 1~6 Alkyl)2amino, C 1~6 Alkylcarbonyl and 3- to 12-membered heterocyclyl are hydroxyl, amino, C 1~6 Alkyl, (C 1~6 alkyl)2 aminocarbonyl, or C 1~6 optionally substituted by any one or more groups selected from alkylcarbonyl; R2 is amino, C 1~6 alkylamino, 3- to 12-membered heterocyclyl, or 3- to 12-membered cycloalkylamino, wherein the heteroatom of the 3- to 12-membered heterocyclyl is selected from any one of O and N, and any combination thereof; 1~6 Alkylamino, 3- to 12-membered heterocyclyl, or 3- to 12-membered cycloalkylamino is C 1~6Alkyl, C 1~6 optionally substituted by any one or more groups selected from alkoxy, 3- to 12-membered cycloalkyl, or 3- to 12-membered heterocyclyl; R3 is cyano, C 1~6 Alkyl, aminocarbonyl, hydrogen, hydroxy, amino, halogen, or C 1~6 alkoxy, wherein C 1~6 Alkyl and aminocarbonyl are optionally substituted with one or more halogens; R6 is hydrogen; n is 0, m is 0, 1, 2, or 3; p is 1, 2, or 3.
[0025] Some embodiments of the present invention relate to a compound of formula (I) or a pharmaceutically acceptable salt or isomer thereof: X1 is N, X2 is 、 CR5, L is a bond, n is 0, A is selected from 3- to 12-membered cycloalkyl or 3- to 12-membered heterocyclyl, wherein the heteroatom of said 3- to 12-membered heterocyclyl is N, and said 3- to 12-membered cycloalkyl is substituted by amino; R1 is hydrogen, R2 is amino, C 1~6 alkoxy, or 3- to 12-membered heterocyclyloxy, wherein the amino is substituted by a 3- to 12-membered heterocyclyl; R3 is cyano or halogenated C 1~6 alkyl, R5 and R6 are each independently hydrogen; m is 1.
[0026] Some embodiments of the present invention relate to a compound of formula (I) or a pharmaceutically acceptable salt or isomer thereof: X1 is selected from N or CR4; X2 is selected from N or CR5; L is selected from a bond, —C(O)—, and —(CH)—; A is selected from a bond, a 3- to 12-membered cycloalkyl, a 3- to 12-membered cycloalkenyl, a 3- to 12-membered heterocyclyl, an aryl, and a 5- to 10-membered heteroaryl; the heteroatoms of said 3- to 12-membered heterocyclyl are selected from one or any combination of O, S, and N; the C atom can be optionally oxidized to C(O); the S atom can be optionally oxidized to S(O) or S(O)2; and the heteroatoms of said 5- to 10-membered heteroaryl are selected from one or any combination of O, S, and N; R1 is hydrogen, halogen, hydroxyl, carboxyl, amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkylaminocarbonyl, (C 1~6 Alkyl)2 aminocarbonyl, C 1~6 Alkoxycarbonyl, C 1~6 Alkyl carbonyl, C 1~6 Alkyl sulfonyl, amino sulfonyl, C 1~6 The heteroatoms of the 3- to 12-membered heterocyclyl are selected from one of O, S, and N or any combination thereof, the C atom can be optionally oxidized to C(O), the S atom can be optionally oxidized to S(O) or S(O)2, the heteroatoms of the 5- to 10-membered heteroaryl are selected from one of O, S, and N or any combination thereof, the amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkylaminocarbonyl, (C 1~6 Alkyl)2 aminocarbonyl, C 1~6 Alkoxycarbonyl, C 1~6 Alkyl carbonyl, C 1~6 Alkyl sulfonyl, amino sulfonyl, C 1~6 The alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, and 3- to 12-membered cycloalkenyl are unsubstituted or substituted with hydroxyl, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl)2amino, C 1~6 Alkylsulfonyl, HS(O)(=NH)-, C 1~6 Alkyl-S(O)(=NH)-, (C 1~6 Alkyl)2 aminocarbonyl, C 1~6 optionally substituted by one or more groups selected from alkylcarbonyl, 3- to 12-membered cycloalkyl, and 3- to 12-membered heterocyclyl; R2 is halogen, cyano, hydroxyl, carboxyl, amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 alkyl)2amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl, 3- to 12-membered heterocyclyloxy, 3- to 12-membered cycloalkylamino, and 3- to 12-membered heterocyclyl-CH2-amino, wherein said amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6alkyl)2amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl, 3- to 12-membered heterocyclyloxy, 3- to 12-membered cycloalkylamino, 3- to 12-membered heterocyclyl-CH2-amino is unsubstituted or is selected from the group consisting of halogen, cyano, hydroxyl, carboxy, amino, C 1~6 Alkyl, C 1~6 Alkoxy, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 alkyl)2 optionally substituted by one or more groups selected from amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, aryl, and 5- to 10-membered heteroaryl; R3 is hydrogen, hydroxy, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkyl carbonyl, C 1~6 Alkylsulfonyl, C 1~6 alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, and 3- to 12-membered heterocyclyl; 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkyl carbonyl, C 1~6 Alkylsulfonyl, C 1~6Alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, and 3- to 12-membered heterocyclyl are unsubstituted or substituted with hydroxyl, amino, carboxyl, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkoxy C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl)2amino, C 1~6 Alkylcarbonylamino, and C 1~6 alkylsulfonylamino; n is 0 or 1, m is 0, 1, 2, or 3; p is 1, 2, or 3; R4, R5, and R6 are each independently hydrogen, halogen, hydroxy, amino, carboxy, cyano, nitro, C 1~6 Alkyl, C 2~8 Alkenyl, C 2~8 Alkynyl and halogenated C 1~6 alkyl.
[0027] The present invention also provides pharmaceutical compositions comprising a compound of Formula (I), (II), (III), or (IV) or a pharmaceutically acceptable salt or isomer thereof, and one or more second therapeutically active agents.
[0028] The present invention also provides pharmaceutical formulations comprising a compound of Formula (I), (II), (III), or (IV) or a pharmaceutically acceptable salt or isomer thereof, and one or more pharmaceutically acceptable carriers.
[0029] The present invention also provides a pharmaceutical formulation having cyclin-dependent kinase 9 inhibitory activity, comprising a compound represented by formula (I), (II), (III), or (IV) or a pharmaceutically acceptable salt or isomer thereof, and one or more pharmaceutically acceptable carriers.
[0030] The present invention also provides the use of a compound of Formula (I), (II), (III), or (IV) or a pharmaceutically acceptable salt or isomer, pharmaceutical composition, or pharmaceutical formulation in the manufacture of a medicament for the treatment or prevention of a CDK9-mediated associated disease.
[0031] In particular, the CDK9 mediated associated disease is cancer, preferably the cancer is a solid tumor or a hematological malignancy, more preferably the cancer is selected from adrenal gland tumor, melanoma, head and neck cancer, kidney cancer, bladder cancer, prostate cancer, endometrial cancer, cervical cancer, gastric cancer, colon cancer, pancreatic cancer, rectal cancer, esophageal cancer, liver cancer, lung cancer, sarcoma, breast cancer, ovarian cancer, non-Hodgkin's lymphoma, acute myeloid leukemia, acute lymphoblastic leukemia, or myeloma.
[0032] Some embodiments of the present invention relate to a compound of formula (I), (II), or a pharmaceutically acceptable salt or isomer thereof: A is selected from 3- to 12-membered cycloalkyl or 3- to 12-membered heterocyclyl, and the heteroatom of said 3- to 12-membered heterocyclyl is N.
[0033] Some embodiments of the present invention relate to a compound of formula (I), (II), or a pharmaceutically acceptable salt or isomer thereof: A is selected from 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 12-membered ortho-fused heterocyclyl, and 6- to 12-membered spiroheterocyclyl, and the heteroatom of the 3- to 12-membered heterocyclyl, 6- to 12-membered ortho-fused heterocyclyl, and 6- to 12-membered spiroheterocyclyl is N.
[0034] Some embodiments of the present invention relate to a compound of formula (I), (II), or a pharmaceutically acceptable salt or isomer thereof: A is, [ka] is selected from.
[0035] Some embodiments of the present invention relate to a compound of formula (I), (II), or a pharmaceutically acceptable salt or isomer thereof: R1 is hydrogen, hydroxyl, C 1~6 Alkyl, C 1~6 Alkoxy, amino, (C 1~6 Alkyl)2amino, C 1~6 alkylcarbonyl, or 3- to 12-membered heterocyclyl, wherein the heteroatom of the 3- to 12-membered heterocyclyl is selected from any one of N and O, or any combination thereof; 1~6 Alkyl, C 1~6 Alkoxy, amino, (C 1~6 Alkyl)2amino, C 1~6 Alkylcarbonyl and 3- to 12-membered heterocyclyl are hydroxyl, amino, C 1~6 Alkyl, (C 1~6 alkyl)2 aminocarbonyl, or C 1~6 alkylcarbonyl.
[0036] Some embodiments of the present invention relate to a compound of formula (I), (II), or a pharmaceutically acceptable salt or isomer thereof: R2 is amino, C 1~6 alkylamino, 3- to 12-membered heterocyclyl, or 3- to 12-membered cycloalkylamino, wherein the heteroatom of the 3- to 12-membered heterocyclyl is selected from one of N and O or any combination thereof; 1~6 Alkylamino, 3- to 12-membered heterocyclyl, and 3- to 12-membered cycloalkylamino are C 1~6 Alkyl, C 1~6 It is optionally substituted with any one or more groups selected from alkoxy, 3- to 12-membered cycloalkyl, or 3- to 12-membered heterocyclyl.
[0037] Some embodiments of the present invention relate to a compound of formula (I), (II), or a pharmaceutically acceptable salt or isomer thereof: R3 is cyano, C 1~6Alkyl, aminocarbonyl, hydrogen, hydroxy, amino, halogen, or C 1~6 alkoxy, wherein C 1~6 The alkyl and aminocarbonyl are optionally substituted with one or more halogens.
[0038] Some embodiments of the present invention relate to a compound of formula (I), (II), or a pharmaceutically acceptable salt or isomer thereof: R6 is hydrogen.
[0039] Some embodiments of the present invention relate to a compound of formula (I) or a pharmaceutically acceptable salt or isomer thereof: When L is a bond, n is 0, and A is selected from 3- to 12-membered cycloalkyl or 3- to 12-membered heterocyclyl, and the heteroatom of said 3- to 12-membered heterocyclyl is N, R1 and R3 are selected from the following (i) or (ii): (i) R1 is C 1~6 Alkyl, amino, or (C 1~6 alkyl)2amino, and R3 is selected from cyano, aminocarbonyl, hydroxy, or amino; C in R1 1~6 Alkyl, amino, and (C 1~6 Alkyl)2amino is a hydroxyl, amino, C 1~6 Alkyl, or (C 1~6 alkyl)2 aminocarbonyl, or C 1~6 alkylcarbonyl, and the aminocarbonyl and amino in R3 are optionally substituted with one or more groups selected from halogen; (ii) R1 is hydrogen, hydroxyl, C 1~6 Alkoxy, C 1~6 alkylcarbonyl, 3- to 12-membered heterocyclyl, halogen, carboxyl, or 3- to 12-membered cycloalkyl; R3 is selected from cyano, C 1~6 Alkyl, aminocarbonyl, hydrogen, hydroxy, amino, halogen, or C1~6 When the heteroatom of the 3- to 12-membered heterocyclyl is selected from N, O, or any combination thereof, the C 1~6 Alkoxy, C 1~6 Alkylcarbonyl, 3- to 12-membered heterocyclyl, and 3- to 12-membered cycloalkyl are hydroxyl, amino, C 1~6 Alkyl, or (C 1~6 alkyl)2 aminocarbonyl, or C 1~6 alkylcarbonyl, 1~6 Alkyl, aminocarbonyl, amino, and C 1~6 The alkoxy is optionally substituted with any one or more groups selected from halogen, When L is a bond or -(CH2)p-, A is a bond, and R1 is selected from 3- to 12-membered cycloalkyl or 3- to 12-membered heterocyclyl, and the heteroatom of the 3- to 12-membered heterocyclyl is N, R1 is selected from amino, C 1~6 Alkyl, halogenated C 1~6 Alkyl, C 1~6 Alkylamino, (C 1~6 alkyl)2amino, or C 1~6 It is not substituted with alkylsulfonyl.
[0040] Some embodiments of the present invention relate to a compound of formula (I) or a pharmaceutically acceptable salt or isomer thereof: R2 is C 1~6 alkylamino, or (C 1~6 alkyl)2amino; R3 is cyano.
[0041] Some embodiments of the present invention relate to a compound of formula (I) or a pharmaceutically acceptable salt or isomer thereof: L is a bond, n is 0, A is a 3- to 12-membered cycloalkyl; R1 is amino; R2 is C 1~6 Alkylamino or (C 1~6 alkyl)2amino; R3 is cyano; R6 is hydrogen; m is 1.
[0042] The present invention provides a compound represented by formula (I), a pharmaceutically acceptable salt or isomer thereof, however, X1 is N, X2 is N, n is 0, A is piperidinyl, and R1 is C 1~6 Alkyl sulfonyl, amino sulfonyl, or C 1~6 alkylaminosulfonyl, where m is 1, and X1 is N, X2 is N, n is 0, A is a bond, R1 is piperidinyl, m is 1, and said piperidinyl is C 1~6 The exception is when it is substituted by alkylsulfonyl.
[0043] Some embodiments of the present invention relate to compounds of formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof: X1 is selected from N or CR4; X2 is selected from N or CR5; L is selected from a bond, —C(O)—, and —(CH)—; A is a bond, R1 is hydrogen, halogen, hydroxyl, carboxyl, amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkylaminocarbonyl, (C 1~6 Alkyl)2 aminocarbonyl, C 1~6Alkoxycarbonyl, C 1~6 Alkyl carbonyl, C 1~6 Alkyl sulfonyl, amino sulfonyl, C 1~6 The heteroatoms of the 3- to 12-membered heterocyclyl are selected from one of O, S, and N or any combination thereof, the C atom can be optionally oxidized to C(O), the S atom can be optionally oxidized to S(O) or S(O)2, the heteroatoms of the 5- to 10-membered heteroaryl are selected from one of O, S, and N or any combination thereof, the amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkylaminocarbonyl, (C 1~6 Alkyl)2 aminocarbonyl, C 1~6 Alkoxycarbonyl, C 1~6 Alkyl carbonyl, C 1~6 Alkyl sulfonyl, amino sulfonyl, C 1~6 The alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, and 3- to 12-membered cycloalkenyl are unsubstituted or substituted with hydroxyl, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl)2amino, C 1~6 Alkylsulfonyl, HS(O)(=NH)-, C 1~6 optionally substituted by one or more groups selected from alkyl-S(O)(=NH)-, 3- to 12-membered cycloalkyl, and 3- to 12-membered heterocyclyl; R2 is halogen, cyano, hydroxyl, carboxyl, amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 alkyl)2amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl, 3- to 12-membered heterocyclyloxy, 3- to 12-membered cycloalkylamino, and 3- to 12-membered heterocyclyl-CH2-amino, wherein said amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 alkyl)2amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl, 3- to 12-membered heterocyclyloxy, 3- to 12-membered cycloalkylamino, 3- to 12-membered heterocyclyl-CH2-amino is unsubstituted or is selected from the group consisting of halogen, cyano, hydroxyl, carboxy, amino, C 1~6 Alkyl, C 1~6 Alkoxy, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 alkyl)2 optionally substituted by one or more groups selected from amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, aryl, and 5- to 10-membered heteroaryl; R3 is hydrogen, hydroxy, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkyl carbonyl, C 1~6 Alkyl sulfonyl, C 1~6 alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, and 3- to 12-membered heterocyclyl;1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkyl carbonyl, C 1~6 Alkyl sulfonyl, C 1~6 Alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, and 3- to 12-membered heterocyclyl are unsubstituted or substituted with hydroxyl, amino, carboxyl, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkoxy C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl)2amino, C 1~6 Alkylcarbonylamino, and C 1~6 alkylsulfonylamino; n is 0 or 1, m is 0, 1, 2, or 3; p is 1, 2, or 3; R4, R5, and R6 are each independently hydrogen, halogen, hydroxy, amino, carboxy, cyano, nitro, C 1~6 Alkyl, C 2~8 Alkenyl, C 2~8 Alkynyl and halogenated C 1~6 alkyl.
[0044] Some embodiments of the present invention relate to compounds of formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof: R1 is hydrogen, halogen, hydroxyl, carboxyl, amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkylaminocarbonyl, (C 1~6 Alkyl)2 aminocarbonyl, C 1~6 Alkoxycarbonyl, C 1~6 Alkyl carbonyl, C 1~6 Alkyl sulfonyl, amino sulfonyl, C 1~6 The heteroatoms of the 3- to 12-membered heterocyclyl are selected from one of O, S, and N or any combination thereof, the C atom can be optionally oxidized to C(O), the S atom can be optionally oxidized to S(O) or S(O)2, the heteroatoms of the 5- to 10-membered heteroaryl are selected from one of O, S, and N or any combination thereof, the amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkylaminocarbonyl, (C 1~6 Alkyl)2 aminocarbonyl, C 1~6 Alkoxycarbonyl, C 1~6 Alkyl carbonyl, C 1~6 Alkyl sulfonyl, amino sulfonyl, C 1~6 The alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, and 3- to 12-membered cycloalkenyl are unsubstituted or substituted with hydroxyl, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, halogenated C 1~6 Alkyl, halogenated C1~6 Alkoxy, C 1~6 Alkylamino, C 1~6 Alkylsulfonyl, HS(O)(=NH)-, C 1~6 It is optionally substituted with one or more groups selected from alkyl-S(O)(=NH)-, 3- to 12-membered cycloalkyl, and 3- to 12-membered heterocyclyl.
[0045] Some embodiments of the present invention relate to compounds of formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof: R3 is hydrogen, hydroxy, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkyl carbonyl, C 1~6 Alkylsulfonyl, C 1~6 alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, and 3- to 12-membered heterocyclyl; 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkyl carbonyl, C 1~6 Alkylsulfonyl, C 1~6 Alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, and 3- to 12-membered heterocyclyl are unsubstituted or substituted with amino, carboxyl, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkoxy C 1~6 Alkoxy, C1~6 Alkylamino, (C 1~6 Alkyl)2amino, C 1~6 Alkylcarbonylamino, and C 1~6 alkylsulfonylamino.
[0046] Some embodiments of the present invention relate to compounds of formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof: X1 is selected from N or CR4; X2 is selected from N or CR5; L is selected from a bond, —C(O)—, and —(CH)—; A is selected from a bond, a 3- to 12-membered cycloalkyl, and a 3- to 12-membered heterocyclyl, wherein the heteroatom of the 3- to 12-membered heterocyclyl is N; R1 is hydrogen, halogen, hydroxyl, carboxyl, amino, C 1~6 Alkyl, C 1~6 Alkylamino, C 1~6 Alkylcarbonylamino, C 1~6 Alkylaminocarbonyl, C 1~6 Alkyl carbonyl, C 1~6 alkylsulfonyl, 3- to 12-membered heterocyclyl, 1~6 Alkyl, C 1~6 Alkylamino, C 1~6 Alkylcarbonylamino, C 1~6 Alkylaminocarbonyl, C 1~6 Alkyl carbonyl, C 1~6 Alkylsulfonyl, 3- to 12-membered heterocyclyl are unsubstituted or substituted with hydroxyl, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl)2amino, C 1~6 Alkylsulfonyl, HS(O)(=NH)-, C 1~6optionally substituted by one or more groups selected from alkyl-S(O)(=NH)-, 3- to 12-membered cycloalkyl, and 3- to 12-membered heterocyclyl; R2 is amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 alkyl)2amino, 3- to 12-membered heterocyclyl, 3- to 12-membered heterocyclyloxy, 3- to 12-membered cycloalkylamino, and 3- to 12-membered heterocyclyl-CH2-amino, wherein said amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 alkyl)2amino, 3- to 12-membered heterocyclyl, 3- to 12-membered heterocyclyloxy, 3- to 12-membered cycloalkylamino, 3- to 12-membered heterocyclyl-CH2-amino are unsubstituted or substituted with halogen, cyano, hydroxyl, carboxy, amino, C 1~6 Alkyl, C 1~6 Alkoxy, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 alkyl)2 optionally substituted by one or more groups selected from amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, and aryl; R3 is hydrogen, hydroxy, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, halogenated C 1~6 Alkyl, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkyl carbonyl, C 1~6 alkylsulfonyl, 3- to 12-membered cycloalkyl, and 3- to 12-membered heterocyclyl; 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, halogenated C 1~6 Alkyl, C 2~8 Alkenyl, C1~6 Alkyl carbonyl, C 1~6 Alkylsulfonyl, 3- to 12-membered cycloalkyl, and 3- to 12-membered heterocyclyl are unsubstituted or substituted with hydroxyl, amino, carboxyl, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkoxy C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl)2amino, C 1~6 Alkylcarbonylamino, and C 1~6 alkylsulfonylamino; n is 0 or 1, m is 0, 1, 2, or 3; p is 1, 2, or 3; R4, R5, and R6 are each independently selected from hydrogen and halogen.
[0047] Some embodiments of the present invention relate to compounds of formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof: X1 is N, X2 is selected from N or CR5; L is selected from a bond or —C(O)—; A is selected from 3- to 12-membered cycloalkyl and 3- to 12-membered heterocyclyl, wherein the heteroatom of said 3- to 12-membered heterocyclyl is N; R1 is hydrogen, halogen, hydroxyl, amino, C 1~6 Alkyl, C 1~6 Alkylamino, C 1~6 alkylcarbonylamino, 1~6 Alkyl, C 1~6 Alkylamino, C 1~6 The alkylcarbonylamino may be unsubstituted or may be substituted with hydroxyl, C 1~6 Alkoxy, (C 1~6 Alkyl)2amino, HS(O)(=NH)-, C 1~6alkyl-S(O)(=NH)-; R2 is amino, C 1~6 Alkoxy, C 1~6 alkylamino, 3- to 12-membered heterocyclyloxy, 3- to 12-membered cycloalkylamino, and 3- to 12-membered heterocyclyl-CH2-amino, wherein said amino, C 1~6 alkylamino, 3- to 12-membered heterocyclyloxy, 3- to 12-membered cycloalkylamino, 3- to 12-membered heterocyclyl-CH2-amino are unsubstituted or optionally substituted by 3- to 12-membered cycloalkyl, aryl; R3 is cyano, C 1~6 alkyl, wherein C 1~6 The alkyl is unsubstituted or optionally substituted with one or more groups selected from hydroxyl, halogen; n is 0 or 1, m is 0 or 1 R4, R5, and R6 are each independently selected from hydrogen or halogen.
[0048] Some embodiments of the present invention relate to a compound of formula (II) or a pharmaceutically acceptable salt or stereoisomer thereof: R1 is hydrogen, halogen, hydroxyl, carboxyl, amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkylaminocarbonyl, (C 1~6 Alkyl)2 aminocarbonyl, C 1~6 Alkoxycarbonyl, C 1~6 Alkyl carbonyl, C 1~6 Alkyl sulfonyl, amino sulfonyl, C 1~6The heteroatoms of the 3- to 12-membered heterocyclyl are selected from one of O, S, and N or any combination thereof, the C atom can be optionally oxidized to C(O), the S atom can be optionally oxidized to S(O) or S(O)2, the heteroatoms of the 5- to 10-membered heteroaryl are selected from one of O, S, and N or any combination thereof, the amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkylaminocarbonyl, (C 1~6 Alkyl)2 aminocarbonyl, C 1~6 Alkoxycarbonyl, C 1~6 Alkyl carbonyl, C 1~6 Alkyl sulfonyl, amino sulfonyl, C 1~6 The alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, and 3- to 12-membered cycloalkenyl are unsubstituted or substituted with hydroxyl, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 1~6 Alkylamino, C 1~6 Alkylsulfonyl, HS(O)(=NH)-, C 1~6 optionally substituted by one or more groups selected from alkyl-S(O)(=NH)-, 3- to 12-membered cycloalkyl, and 3- to 12-membered heterocyclyl; R3 is hydrogen, hydroxy, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkyl carbonyl, C 1~6 Alkylsulfonyl, C 1~6 alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, and 3- to 12-membered heterocyclyl; 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkyl carbonyl, C 1~6 Alkylsulfonyl, C 1~6 Alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, and 3- to 12-membered heterocyclyl are unsubstituted or substituted with amino, carboxyl, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkoxy C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl)2amino, C 1~6 Alkylcarbonylamino, and C 1~6 alkylsulfonylamino.
[0049] Some embodiments of the present invention relate to compounds of formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof: X1 is N, X2 is CR5, L is a bond, n is 0, A is a 3- to 12-membered heterocyclyl, and the heteroatom of the 3- to 12-membered heterocyclyl is N; R1 is hydrogen, R2 is C 1~6 Alkylamino, C 1~6 alkoxy, or 3- to 12-membered cycloalkylamino; 1~6 Alkylamino, C 1~6 The alkoxy or 3- to 12-membered cycloalkylamino is unsubstituted or 1~6 optionally substituted with alkyl; R3 is cyano; R5 and R6 are each independently hydrogen; m is 1.
[0050] Some embodiments of the present invention relate to a compound of formula (II) or a pharmaceutically acceptable salt or stereoisomer thereof: R1 is hydrogen, halogen, hydroxyl, carboxyl, amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkylaminocarbonyl, (C 1~6 Alkyl)2 aminocarbonyl, C 1~6 Alkoxycarbonyl, C 1~6 Alkyl carbonyl, C 1~6 Alkyl sulfonyl, amino sulfonyl, C 1~6 The heteroatoms of the 3- to 12-membered heterocyclyl are selected from one of O, S, and N or any combination thereof, the C atom can be optionally oxidized to C(O), the S atom can be optionally oxidized to S(O) or S(O)2, the heteroatoms of the 5- to 10-membered heteroaryl are selected from one of O, S, and N or any combination thereof, the amino, C1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkylaminocarbonyl, (C 1~6 Alkyl)2 aminocarbonyl, C 1~6 Alkoxycarbonyl, C 1~6 Alkyl carbonyl, C 1~6 Alkyl sulfonyl, amino sulfonyl, C 1~6 The alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, and 3- to 12-membered cycloalkenyl are unsubstituted or substituted with hydroxyl, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 1~6 Alkylamino, C 1~6 optionally substituted by one or more groups selected from alkylsulfonyl, 3- to 12-membered cycloalkyl, and 3- to 12-membered heterocyclyl; R3 is hydrogen, hydroxy, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkyl carbonyl, C 1~6 Alkyl sulfonyl, C 1~6 alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, and 3- to 12-membered heterocyclyl; 1~6 Alkyl, C 1~6Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkyl carbonyl, C 1~6 Alkylsulfonyl, C 1~6 Alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, and 3- to 12-membered heterocyclyl are unsubstituted or substituted with amino, carboxyl, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkoxy C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl)2amino, C 1~6 Alkylcarbonylamino, and C 1~6 alkylsulfonylamino.
[0051] Some embodiments of the present invention relate to a compound of formula (II) or a pharmaceutically acceptable salt or stereoisomer thereof: R1 is hydrogen, halogen, hydroxyl, carboxyl, amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylaminocarbonyl, (C 1~6 Alkyl)2 aminocarbonyl, C 1~6 Alkoxycarbonyl, C 1~6 Alkyl carbonyl, C 1~6 Alkylsulfonyl, C 1~6alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl, 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylaminocarbonyl, (C 1~6 Alkyl)2 aminocarbonyl, C 1~6 Alkoxycarbonyl, C 1~6 Alkyl carbonyl, C 1~6 Alkylsulfonyl, C 1~6 The alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, and 3- to 12-membered cycloalkenyl are unsubstituted or substituted with hydroxyl, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl)2amino, C 1~6 optionally substituted by one or more groups selected from alkylsulfonyl, 3- to 12-membered cycloalkyl, and 3- to 12-membered heterocyclyl; R3 is cyano and halogenated C 1~6 alkyl.
[0052] Some embodiments of the present invention relate to a compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt or stereoisomer thereof: A is selected from the group consisting of 3-8 membered cycloalkyl, 6-11 membered ortho-fused cycloalkyl, 6-11 membered bridged cycloalkyl, 7-12 membered spirocycloalkyl, 3-8 membered monocycloalkenyl, 7-11 membered spirocycloalkenyl, 7-11 membered ortho-fused cycloalkenyl, 6-11 membered bridged cycloalkenyl, 3-8 membered heterocyclyl, 6-12 membered ortho-fused heterocyclyl, 6-12 membered spiroheterocyclyl, and 6-12 membered bridged heterocyclyl, wherein the heteroatoms of the 3-8 membered heterocyclyl, 6-12 membered ortho-fused heterocyclyl, 6-12 membered spiroheterocyclyl, and 6-12 membered bridged heterocyclyl are selected from one or any combination thereof, and the C atom can be optionally oxidized to C(O), and the S atom can be optionally oxidized to S(O) or S(O). The heteroatoms of the 5- to 10-membered heteroaryl are selected from one or any combination of O, S, and N.
[0053] Some embodiments of the present invention relate to a compound of formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt or stereoisomer thereof: A is, [ka] is selected from.
[0054] Some embodiments of the present invention relate to compounds of formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof: R1 is hydrogen, halogen, hydroxyl, carboxyl, amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkylaminocarbonyl, (C 1~6Alkyl)2 aminocarbonyl, C 1~6 Alkoxycarbonyl, C 1~6 Alkyl carbonyl, C 1~6 Alkyl sulfonyl, amino sulfonyl, C 1~6 The heteroatoms of the 3- to 12-membered heterocyclyl are selected from one of O, S, and N or any combination thereof, the C atom can be optionally oxidized to C(O), the S atom can be optionally oxidized to S(O) or S(O)2, the heteroatoms of the 5- to 10-membered heteroaryl are selected from one of O, S, and N or any combination thereof, the amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkylaminocarbonyl, (C 1~6 Alkyl)2 aminocarbonyl, C 1~6 Alkoxycarbonyl, C 1~6 Alkyl carbonyl, C 1~6 Alkyl sulfonyl, amino sulfonyl, C 1~6 The alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, and 3- to 12-membered cycloalkenyl are unsubstituted or substituted with hydroxyl, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 1~6 Alkylamino, C 1~6 It is optionally substituted with one or more groups selected from alkylsulfonyl, 3- to 12-membered cycloalkyl, and 3- to 12-membered heterocyclyl.
[0055] Some embodiments of the present invention relate to compounds of formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof: R3 is hydrogen, hydroxy, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkyl carbonyl, C 1~6 Alkyl sulfonyl, C 1~6 alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, and 3- to 12-membered heterocyclyl; 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkyl carbonyl, C 1~6 Alkyl sulfonyl, C 1~6 Alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, and 3- to 12-membered heterocyclyl are unsubstituted or substituted with amino, carboxyl, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkoxy C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl)2amino, C 1~6 Alkylcarbonylamino, and C 1~6 alkylsulfonylamino.
[0056] Some embodiments of the present invention relate to compounds of formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof: X1 is selected from N or CR4; X2 is selected from N or CR5; L is selected from a bond, —C(O)—, and —(CH)—; A is selected from a bond, a 3- to 12-membered cycloalkyl, and a 3- to 12-membered heterocyclyl, wherein the heteroatom of the 3- to 12-membered heterocyclyl is N; R1 is hydrogen, halogen, hydroxyl, carboxyl, amino, C 1~6 Alkyl, C 1~6 Alkylamino, C 1~6 Alkylcarbonylamino, C 1~6 Alkylaminocarbonyl, C 1~6 Alkyl carbonyl, C 1~6 alkylsulfonyl, 3- to 12-membered heterocyclyl, 1~6 Alkyl, C 1~6 Alkylamino, C 1~6 Alkylcarbonylamino, C 1~6 Alkylaminocarbonyl, C 1~6 Alkyl carbonyl, C 1~6 Alkylsulfonyl, 3- to 12-membered heterocyclyl are unsubstituted or substituted with hydroxyl, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl)2amino, C 1~6 optionally substituted by one or more groups selected from alkylsulfonyl, 3- to 12-membered cycloalkyl, and 3- to 12-membered heterocyclyl; R2 is amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 alkyl)2amino, and 3- to 12-membered heterocyclyl, wherein said amino, C 1~6Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 alkyl)2amino, 3- to 12-membered heterocyclyl is unsubstituted or substituted with halogen, cyano, hydroxyl, carboxy, amino, C 1~6 Alkyl, C 1~6 Alkoxy, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 alkyl)2 optionally substituted by one or more groups selected from amino, 3- to 12-membered cycloalkyl, and 3- to 12-membered heterocyclyl; R3 is hydrogen, hydroxy, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, halogenated C 1~6 Alkyl, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkyl carbonyl, C 1~6 alkylsulfonyl, 3- to 12-membered cycloalkyl, and 3- to 12-membered heterocyclyl; 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, halogenated C 1~6 Alkyl, C 2~8 Alkenyl, C 1~6 Alkyl carbonyl, C 1~6 Alkylsulfonyl, 3- to 12-membered cycloalkyl, and 3- to 12-membered heterocyclyl are unsubstituted or substituted with hydroxyl, amino, carboxyl, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkoxy C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl)2amino, C 1~6 Alkylcarbonylamino, and C 1~6 alkylsulfonylamino; n is 0 or 1, m is 0, 1, 2, or 3; p is 1, 2, or 3; R4, R5, and R6 are each independently selected from hydrogen and halogen.
[0057] Some embodiments of the present invention relate to compounds of formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof: X1 is N, X2 is selected from N or CR5; L is selected from a bond or —C(O)—; A is selected from 3- to 12-membered cycloalkyl and 3- to 12-membered heterocyclyl, wherein the heteroatom of said 3- to 12-membered heterocyclyl is N; R1 is hydrogen, halogen, hydroxyl, amino, C 1~6 Alkylamino, C 1~6 alkylcarbonylamino, 1~6 Alkyl, C 1~6 Alkylamino, C 1~6 The alkylcarbonylamino may be unsubstituted or may be substituted with hydroxyl, C 1~6 Alkoxy, (C 1~6 optionally substituted with one or more groups selected from: R2 is amino, C 1~6 Alkoxy, C 1~6 alkylamino, wherein the amino, C 1~6 alkylamino is unsubstituted or optionally substituted with 3- to 12-membered cycloalkyl; R3 is cyano, C 1~6 alkyl, wherein C 1~6 The alkyl is unsubstituted or optionally substituted with one or more groups selected from hydroxyl, halogen; n is 0 or 1, m is 0 or 1 R4, R5, and R6 are halogen.
[0058] In one embodiment of the present invention, the compound or a pharmaceutically acceptable salt or stereoisomer thereof is shown in Table 1: [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 1-5] [Table 1-6] [Table 1-7] [Table 1-8] [Table 1-9] [Table 1-10] [Table 1-11] [Table 1-12] [Table 1-13] [Table 1-14] [Table 1-15] [Table 1-16] [Table 1-17] [Table 1-18] [Table 1-19] [Table 1-20]
[0059] The present invention also provides pharmaceutical compositions comprising a compound of Formula (I), (II), (III), or (IV) or a pharmaceutically acceptable salt or isomer thereof and one or more second therapeutically active agents.
[0060] The present invention also provides pharmaceutical formulations comprising a compound of Formula (I), (II), (III), or (IV) or a pharmaceutically acceptable salt or isomer thereof and one or more pharmaceutically acceptable carriers.
[0061] The present invention also provides a pharmaceutical formulation having cyclin-dependent kinase 9 inhibitory activity, comprising a compound represented by formula (I), (II), (III), or (IV) or a pharmaceutically acceptable salt or isomer thereof and one or more pharmaceutically acceptable carriers.
[0062] The present invention also provides use of a compound of Formula (I), (II), (III), or (IV) or a pharmaceutically acceptable salt or isomer thereof, pharmaceutical composition, or pharmaceutical formulation in the manufacture of a medicament for treating or preventing a CDK9-mediated disease. In particular, the CDK9-mediated disease is cancer. Preferably, the cancer is a solid tumor or a hematological malignancy. More specifically, the cancer is selected from adrenal tumor, melanoma, head and neck cancer, kidney cancer, bladder cancer, prostate cancer, endometrial cancer, cervical cancer, gastric cancer, colon cancer, pancreatic cancer, rectal cancer, esophageal cancer, liver cancer, lung cancer, sarcoma, breast cancer, ovarian cancer, non-Hodgkin's lymphoma, acute myeloid leukemia, acute lymphoblastic leukemia, and myeloma.
[0063] The compounds of the present invention also show obvious inhibitory effects on CDK9, and compared with CDK1, 2, 3 and 5, the compounds of the present invention have better selectivity for CDK9, which indicates that the compounds of the present invention have better clinical application potential in the treatment of CDK9-mediated diseases and can reduce the side effects caused by the off-target of the drug. DETAILED DESCRIPTION OF THE INVENTION
[0064] As used herein, "halogen" refers to fluorine, chlorine, bromine, iodine, etc., and is preferably fluorine or chlorine.
[0065] As used herein, "halogenated" means that any hydrogen atom in a substituent can be replaced with one or more of the same or different halogen atoms. "Halogen" is defined as above.
[0066] "C" as described herein 1~6 "Alkyl" refers to a straight-chain or branched alkyl obtained by removing a hydrogen atom from a hydrocarbon moiety containing 1 to 6 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, 2-methylbutyl, neopentyl, 1-ethylpropyl, n-hexyl, isohexyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl, 1-methylpentyl, 3,3-dimethylbutyl, 2,2-dimethylbutyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,3-dimethylbutyl, 2-ethylbutyl, and 1-methyl-2-methylpropyl. 1~4 "Alkyl" refers to the above examples containing 1 to 4 carbon atoms.
[0067] "C" as described herein 2~8"Alkenyl" refers to a straight-chain, branched, or cyclic alkenyl derived by removing one hydrogen atom from an alkene moiety containing 2 to 8 carbon atoms and a carbon-carbon double bond, such as vinyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 1,3-butadienyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 1,3-pentadienyl, 1,4-pentadienyl, 1-hexenyl, and 1,4-hexadienyl.
[0068] "C" as described herein 2~8 "Alkynyl" refers to a straight-chain or branched alkynyl obtained by removing one hydrogen atom from an alkyne moiety containing 2 to 8 carbon atoms and a carbon-carbon triple bond, for example, ethynyl, propynyl, 2-butynyl, 2-pentynyl, 3-pentynyl, 4-methyl-2-pentynyl, 2-hexynyl, and 3-hexynyl.
[0069] "C" as described herein 1~6 "Alkoxy" means "C" as defined above. 1~6 A group in which "C alkyl" is attached to the parent molecule through an oxygen atom, i.e., "C 1~6 "C" refers to an alkyl-O- group, such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, n-pentyloxy, neopentyloxy, and n-hexyloxy. 1~4 "Alkoxy" refers to the above examples containing 1 to 4 carbon atoms, i.e., "C 1~4 refers to the alkyl-O- group.
[0070] "C" as described herein 1~6 alkylamino", "(C 1~6 alkyl)2amino", "C 1~6 alkylcarbonylamino", "C 1~6 alkylsulfonylamino", "C 1~6 alkylaminocarbonyl", "(C 1~6 alkyl)2 aminocarbonyl, C 1~6 Alkoxycarbonyl," "C 1~6alkylsulfonyl", "C 1~6 alkylthio", "C 1~6 alkylcarbonyl," "C 1~6 Alkoxy C 1~6 Alkoxy" and "C 1~6 "Alkylaminosulfonyl" is C 1~6 Alkyl-NH-, (C 1~6 Alkyl)(C 1~6 Alkyl)N-, C 1~6 Alkyl-C(O)-NH-, C 1~6 Alkyl-S(O)2-NH2-, C 1~6 Alkyl-NH-C(O)-, (C 1~6 Alkyl)(C 1~6 alkyl)NC(O)-, C 1~6 Alkyl-OC(O)-, C 1~6 Alkyl-S(O)2-, C 1~6 Alkyl-S-, C 1~6 Alkyl-C(O)-, C 1~6 Alkyl-O-, C 1~6 Alkyl-O- and C 1~6 alkyl-S(O)2-NH-, where "C 1~6 "Alkyl" is defined as above and is preferably "C 1~4 "Alkyl".
[0071] "C 1~6 "C" in "Alkyl-S(O)(=NH)-" 1~6 "Alkyl" is defined as above and is preferably "C 1~4 "Alkyl".
[0072] As used herein, a "polycyclic ring" refers to a polycyclic structure formed by two or more ring structures connected by ortho-fused, spiro-bonded, or bridged bonds. An ortho-fused ring refers to a polycyclic structure formed by two or more ring structures sharing two adjacent ring atoms with each other (i.e., sharing a bond). A bridged ring refers to a polycyclic structure formed by two or more ring structures sharing two non-adjacent ring atoms with each other. A spiro ring refers to a polycyclic structure formed by two or more ring structures sharing ring atoms with each other.
[0073] Unless otherwise specified, the "3- to 12-membered cycloalkenyl" described herein includes all possible monocyclic and polycyclic (including ortho, spiro, or bridged fused) cases, such as 3- to 8-membered monocyclic cycloalkenyl, 7- to 11-membered spiro cycloalkenyl, 7- to 11-membered ortho-fused cycloalkenyl, and 6- to 11-membered bridged cycloalkenyl.
[0074] The cycloalkyls described herein include all possible monocyclic and polycyclic (including ortho, spiro, or bridged fused) forms. For example, a "3- to 12-membered cycloalkyl" can be a monocyclic, bicyclic, or polycyclic cycloalkyl system (also referred to as a polycyclic ring system). Unless otherwise specified, a monocyclic ring system is a cyclic hydrocarbon group containing 3 to 8 carbon atoms. Examples of 3- to 8-membered cycloalkyls include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[1.1.1]pentyl, and the like.
[0075] Polycyclic cycloalkyls include ortho-fused cycloalkyls, bridged cycloalkyls, and spirocycloalkyls.
[0076] The ortho-fused cycloalkyl may be a 6- to 11-membered ortho-fused cycloalkyl or a 7- to 10-membered ortho-fused cycloalkyl, and representative examples include, but are not limited to, bicyclo[3.1.1]heptane, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.2]nonane, bicyclo[3.3.1]nonane, and bicyclo[4.2.1]nonane. The spirocycloalkyl may be a 7- to 12-membered spirocycloalkyl or a 7- to 11-membered spirocycloalkyl, and examples include: [ka] The bridged cycloalkyl may be a 6- to 11-membered bridged cycloalkyl or a 7- to 10-membered bridged cycloalkyl, examples of which include, but are not limited to: [ka] These include, but are not limited to:
[0077] As used herein, "heterocyclyl" refers to a 3- to 12-membered non-aromatic cyclic group in which at least one ring carbon atom is replaced with a heteroatom selected from O, S, and N, preferably 1 to 3 heteroatoms are present, and the carbon, nitrogen, and sulfur atoms are optionally oxidized.
[0078] "3- to 12-membered heterocyclyl" refers to a monocyclic heterocyclyl, bicyclic heterocyclyl, or polycyclic heterocyclyl system (also called a fused ring system), including saturated and partially saturated heterocyclyl groups, but excluding aromatic rings. Unless otherwise specified, all possible monocyclic, polycyclic (including fused in ortho, spiro, or bridged forms), saturated, and partially saturated forms are included.
[0079] The monocyclic heterocyclyl may be a 3- to 8-membered heterocyclyl, a 3- to 8-membered saturated heterocyclyl, a 3- to 6-membered heterocyclyl, a 4- to 7-membered heterocyclyl, a 5- to 7-membered heterocyclyl, a 5- to 6-membered heterocyclyl, a 5- to 6-membered oxygen-containing heterocyclyl, a 3- to 8-membered nitrogen-containing heterocyclyl, a 5- to 6-membered nitrogen-containing heterocyclyl, a 5- to 6-membered saturated heterocyclyl, and the like. Examples of "3- to 8-membered saturated heterocyclyl" include, but are not limited to, aziridinyl, oxiranyl, thiiranyl, azetidinyl, oxetanyl, thietanyl, tetrahydrofuranyl, pyrrolidinyl, tetrahydrothienyl, imidazolidinyl, pyrazolidinyl, 1,2-oxazolidinyl, 1,3-oxazolidinyl, 1,2-thiazolidinyl, 1,3-thiazolidinyl, tetrahydro-2H-pyranyl, tetrahydro-2H-thiapyranyl, piperidinyl, piperazinyl, morpholinyl, 1,4-dioxanyl, and 1,4-oxathianyl. Examples of "3 to 8-membered partially saturated heterocyclyl" include, but are not limited to, 4,5-dihydroisoxazolyl, 4,5-dihydrooxazolyl, 2,5-dihydrooxazolyl, 2,3-dihydrooxazolyl, 3,4-dihydro-2H-pyrrolyl, 2,3-dihydro-1H-pyrrolyl, 2,5-dihydro-1H-imidazolyl, 4,5-dihydro-1H-imidazolyl, 4,5-dihydro-1H-pyrazolyl, 4,5-dihydro-3H-pyrazolyl, 4,5-dihydrothiazolyl, 2,5-dihydrothiazolyl, 2H-pyranyl, 4H-pyranyl, 2H-thiapyranyl, 4H-thiapyranyl, 2,3,4,5-tetrahydropyridinyl, 1,2-isoxazinyl, 1,4-isoxazinyl, 6H-1,3-oxazinyl, and the like. Polycyclic heterocyclyls include ortho-fused heterocyclyls, spiro heterocyclyls, and bridged heterocyclyls, which may be saturated, partially saturated, or unsaturated, but are not aromatic. Polycyclic heterocyclyls may be a 5- to 6-membered monocyclic heterocyclyl ring fused to a benzene ring, a 5- to 6-membered monocyclic cycloalkyl, a 5- to 6-membered monocyclic cycloalkenyl, a 5- to 6-membered monocyclic heterocyclyl, or a 5- to 6-membered monocyclic heteroaryl.The ortho-fused heterocyclyl may be a 6- to 12-membered ortho-fused heterocyclyl, a 7- to 10-membered ortho-fused heterocyclyl, a 6- to 10-membered ortho-fused heterocyclyl, or a 6- to 12-membered saturated ortho-fused heterocyclyl, and representative examples include 3-azabicyclo[3.1.0]hexyl, 3,6-diazabicyclo[3.2.0]heptyl, 3,8-diazabicyclo[4.2.0]octyl, 3,7-diazabicyclo[4.2.0]octyl, octahydropyrrolo[3,4-c]pyrrol ... Examples of spiroheterocyclyl include, but are not limited to, octahydropyrrolo[3,4-b]pyrrolyl, octahydropyrrolo[3,4-b][1,4]oxazinyl, octahydro-1H-pyrrolo[3,4-c]pyridinyl, 2,3-dihydrobenzofuran-2-yl, 2,3-dihydrobenzofuran-3-yl, indolin-1-yl, indolin-2-yl, indolin-3-yl, 2,3-dihydrobenzothiophen-2-yl, octahydro-1H-indolyl, and octahydrobenzofuranyl. The spiroheterocyclyl may be a 6- to 12-membered spiroheterocyclyl, a 7- to 11-membered spiroheterocyclyl, or a 6- to 12-membered saturated spiroheterocyclyl, examples of which include: [ka] These include, but are not limited to:
[0080] The bridged heterocyclyl may be a 6- to 12-membered bridged heterocyclyl, a 7- to 11-membered bridged heterocyclyl, or a 6- to 12-membered saturated bridged heterocyclyl, examples of which include: [ka] These include, but are not limited to:
[0081] As used herein, the term "3- to 12-membered heterocyclyloxy" refers to a 3- to 12-membered heterocyclyl-O- group, wherein "3- to 12-membered heterocyclyl" is defined above.
[0082] As used herein, the term "3 to 12-membered cycloalkyloxy" refers to a 3 to 12-membered cycloalkyl-O- group, wherein "3 to 12-membered cycloalkyl" is defined above.
[0083] As used herein, "3- to 12-membered heterocyclyl-CH2-amino" refers to a 3- to 12-membered heterocyclyl-CH2-NH- group, wherein "3- to 12-membered heterocyclyl" is defined above.
[0084] As used herein, the term "3 to 12-membered cycloalkylamino" refers to a 3 to 12-membered cycloalkyl-NH- group, wherein "3 to 12-membered cycloalkyl" is defined above.
[0085] As used herein, "aryl" refers to a cyclic aromatic group containing 6 to 14 carbon atoms, including phenyl, naphthalene, phenanthrene, and the like.
[0086] As used herein, heteroaryl includes all possible monocyclic, polycyclic, fully aromatic, and partially aromatic ring systems. For example, "5- to 10-membered heteroaryl" refers to an aromatic ring system in which at least one ring carbon atom is replaced with a heteroatom selected from O, S, and N, preferably 1 to 3 heteroatoms. Furthermore, cases in which the carbon or sulfur atom is oxidized are also included. For example, a carbon atom is replaced with C(O) and a sulfur atom is replaced with S(O) or S(O)2. Unless otherwise specified, heteroaryl includes monocyclic and polycyclic heteroaryls. Monocyclic heteroaryl may be a 5- to 7-membered heteroaryl or a 5- to 6-membered heteroaryl, examples of which include, but are not limited to, furanyl, imidazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrazolyl, pyrrolyl, tetrazolyl, thiadiazolyl, thienyl, triazolyl, and triazinyl. In certain examples, polycyclic heteroaryl refers to a group in which a monocyclic heteroaromatic ring is fused to a phenyl, cycloalkenyl, heteroaryl, cycloalkyl, or heterocyclyl. The polycyclic heteroaryl may be an 8- to 12-membered ortho-fused heteroaryl or a 9- to 10-membered ortho-fused heteroaryl, and examples thereof include benzimidazolyl, benzofuranyl, benzothienyl, benzoxadiazolyl, benzothiadiazolyl, benzothiazolyl, cinnolinyl, 5,6-dihydroquinolin-2-yl, 5,6-dihydroisoquinolin-1-yl, furopyridinyl, indazolyl, indolyl, isoindolyl, isoquinolinyl, naphthyl, and the like. These include, but are not limited to, lysinyl, purinyl, quinolinyl, 5,6,7,8-tetrahydroquinolin-2-yl, 5,6,7,8-tetrahydroquinolinyl, 5,6,7,8-tetrahydroquinolin-4-yl, 5,6,7,8-tetrahydroisoquinolin-1-yl, thienopyridinyl, 4,5,6,7-tetrahydro[c][1,2,5]oxadiazolyl, and 6,7-dihydro[c][1,2,5]oxadiazol-4(5H)keto.
[0087] As used herein, "pharmaceutically acceptable salts" refers to pharmaceutically acceptable addition salts of acids and bases or solvates thereof. Such pharmaceutically acceptable salts include those of the following acids: hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid, sulfurous acid, formic acid, toluenesulfonic acid, methanesulfonic acid, nitric acid, benzoic acid, citric acid, tartaric acid, maleic acid, hydroiodic acid, alkanoic acid (acetic acid, HOOC-(CH)), n -COOH (n is 0 to 4), etc. Also included are salts of the following bases: sodium salts, potassium salts, calcium salts, ammonium salts, etc. Those skilled in the art are aware of a variety of pharmaceutically acceptable non-toxic addition salts.
[0088] As used herein, "isomer" refers to stereoisomers and tautomers.
[0089] Stereoisomers refer to enantiomers when atoms are asymmetric in the compound, and cis-trans isomers when double bonds or cyclic structures are present in the compound. All enantiomers, diastereomers, racemic isomers, cis-trans isomers, geometric isomers, epimers, and mixtures thereof of the compounds of formula (I) are included within the scope of the present invention.
[0090] "Tautomer" refers to a functional isomer resulting from the rapid migration of a specific atom between two positions in a molecule; tautomers are a special type of functional isomer. Examples include the tautomerization of carbonyl compounds containing α-H, specifically: [ka] "Tautomers" may be, for example, other prototropic tautomers, specifically, for example, phenol-keto tautomers, nitroso-oximino tautomers, and imine-enamine tautomers.
[0091] T, T1, and T2 are each independently selected from any group that satisfies the bonding rules of the compound.
[0092] In one embodiment of the present invention, L is preferably a bond.
[0093] In one embodiment of the present invention, A is preferably 3- to 12-membered cycloalkyl or 3- to 12-membered heterocyclyl. The 3- to 12-membered cycloalkyl of A is preferably cyclobutyl. The 3- to 12-membered heterocyclyl of A is preferably piperidinyl, azepan-3-yl, [ka] is.
[0094] In one embodiment of the present invention, R1 is preferably hydrogen, hydroxyl, C 1~6 Alkyl, C 1~6 Alkoxy, amino, (C 1~6 Alkyl)2amino, C 1~6 alkylcarbonyl, or 3- to 12-membered heterocyclyl. 1~6 Alkyl is preferably methyl, methyl substituted with amino, methyl substituted with hydroxyl, or methyl substituted with dimethylaminocarbonyl. 1~6 The alkoxy is preferably methoxy. The amino of R1 is preferably amino substituted with methyl. 1~6 The alkyl)2amino is preferably dimethylamino. 1~6 The alkylcarbonyl is preferably acetyl. The 3- to 12-membered heterocyclyl of R1 is preferably [ka] is.
[0095] In one embodiment of the present invention, R2 is preferably amino, C 1~6 The amino group of R2 is preferably amino, amino substituted with furan, amino substituted with pyran, or amino substituted with bicyclo[1.1.1]pentyl. 1~6Alkylamino is preferably ter-butylamino, isopropylamino, isopropylamino substituted with methoxy, propylamino, sec-butylamino, ethylamino, or ethylamino substituted with cyclopropyl. The 3- to 12-membered heterocyclyl of R2 is preferably piperidinyl.
[0096] In one embodiment of the present invention, R3 is preferably cyano, C 1~6 alkyl or aminocarbonyl. 1~6 Alkyl is preferably methyl, difluoromethyl, or trifluoromethyl.
[0097] In one embodiment of the present invention, R6 is preferably hydrogen.
[0098] In one embodiment of the present invention, n is preferably 0.
[0099] In one embodiment of the present invention, m is preferably 1 or 2.
[0100] "Optionally substituted by one or more groups" means optionally substituted by one group, optionally substituted by two groups, optionally substituted by three groups, optionally substituted by four groups, or optionally substituted by five groups. [Example]
[0101] List of abbreviations: LDA: lithium diisopropylamide, THF: tetrahydrofuran, EA: ethyl acetate, PE: petroleum ether, DIPEA: N,N-diisopropylethylamine, DCM: dichloromethane, DMSO: dimethyl sulfoxide, IBX: 2-iodoxybenzoic acid, DMAC: N,N-dimethylacetamide, DMF: N,N-dimethylformamide, MTBE: methyl tert-butyl ether, BINAP: (±)-2,2'-bis-(diphenylphosphino)-1,1'-dinaphthalene, TFA: trifluoroacetic acid, DAST: diethylaminosulfur trifluoride, HATU: 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate, NCS: N-chlorosuccinimide, DCE: dichloroethane, mCPBA: m-chloroperbenzoic acid, DMA: dimethylacetamide.
[0102] Example 1: Synthesis of (1S,3R)-3-acetamido-N-(7-(difluoromethyl)-5-(isopropylamino)-2,6-naphthyridin-3-yl)cyclohexane-1-carboxamide (Compound 1) [ka]
[0103] Process: [ka]
[0104] Step 1: Synthesis of 3-(difluoromethyl)-7-((diphenylmethylene)amino)-N-isopropyl-2,6-naphthyridin-1-amine [ka] 7-Chloro-3-(difluoromethyl)-N-isopropyl-2,6-naphthyridin-1-amine (1150 mg, 4.2 mmol, 1.0 equiv.), diphenylmethanimine (0.86 mL, 1.2 mmol, 1.2 equiv.), Pd(dba) (389 mg, 0.42 mmol, 0.1 equiv.), BINAP (528 mg, 0.85 mmol, 0.2 equiv.), and cesium carbonate (4148 mg, 12.7 mmol, 3.0 equiv.) were added to 1,4-dioxane (30 mL). The mixture was reacted overnight at 120 °C in a sealed tube under a nitrogen atmosphere. When no starting material remained as detected by TLC, ethyl acetate (80 mL) was added to the reaction solution, stirred for 5 minutes, and filtered. The filter cake was rinsed with ethyl acetate, and the filtrate was concentrated under reduced pressure to give the crude product, which was purified by silica gel column chromatography to give the product (1450 mg, yield: 82.1%).
[0105] Step 2: Synthesis of 3-(difluoromethyl)-N1-isopropyl-2,6-naphthyridine-1,7-diamine [ka] 3-(Difluoromethyl)-7-((diphenylmethylene)amino)-N-isopropyl-2,6-naphthyridin-1-amine (1600 mg, 3.85 mmol, 1.0 equiv.) was dissolved in THF (20 mL). 2N aqueous citric acid (10 mL) was added to the reaction solution, and the mixture was allowed to react at room temperature for 3 hours. When no starting material remained as detected by TLC, the solvent was removed under reduced pressure, and the compound was extracted with ethyl acetate (30 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the crude product, which was purified by silica gel column chromatography (DCM:MeOH = 98:2 to 95:5) to give the product (990 mg) containing some impurities.
[0106] Step 3: Synthesis of tert-butyl ((1R,3S)-3-((7-(difluoromethyl)-5-(isopropylamino)-2,6-naphthyridin-3-yl)carbamoyl)cyclohexyl)carbamate [ka] (1S,3R)-3-((tert-butoxycarbonyl)amino)cyclohexane-1-carboxylic acid (482.1 mg, 1.98 mmol, 1.0 equiv.) was dissolved in DCM (10 mL). The reaction solution was cooled to 0°C to 5°C, and 1-chloro-N,N,2-trimethylprop-1-en-1-amine (316 mg, 2.38 mmol, 1.2 equiv.) was added. The reaction mixture was allowed to react at 0°C to 5°C for 1.5 hours. A solution of 3-(difluoromethyl)-N1-isopropyl-2,6-naphthyridine-1,7-diamine (500 mg, 1.98 mmol, 1.0 equiv.) and pyridine (0.48 mL, 5.95 mmol, 3.0 equiv.) in DCM (5 mL) was added. The reaction mixture was stirred at room temperature overnight. When LCMS showed that SM was consumed, water (20 mL) was added to the reaction solution and extracted with DCM (20 mL × 3). The organic phases were combined, washed successively with brine (20 mL), and concentrated under reduced pressure to give the crude product, which was purified by silica gel column chromatography to give the product (478 mg, yield: 71.8%).
[0107] Step 4: Synthesis of (1S,3R)-3-amino-N-(7-(difluoromethyl)-5-(isopropylamino)-2,6-naphthyridin-3-yl)cyclohexane-1-carboxamide [ka] tert-Butyl ((1R,3S)-3-((7-(difluoromethyl)-5-(isopropylamino)-2,6-naphthyridin-3-yl)carbamoyl)cyclohexyl)carbamate (180 mg, 0.38 mmol, 1.0 equiv.) was dissolved in DCM (3 mL). The reaction solution was cooled in an ice-water bath, and TFA (2 mL) was added. The reaction was allowed to proceed at room temperature for 4 hours. When no starting material remained as detected by TLC, the reaction solution was concentrated under reduced pressure. The crude product was used in the next step.
[0108] Step 5: Synthesis of (1S,3R)-3-acetamido-N-(7-(difluoromethyl)-5-(isopropylamino)-2,6-naphthyridin-3-yl)cyclohexane-1-carboxamide [ka] (1S,3R)-3-amino-N-(7-(difluoromethyl)-5-(isopropylamino)-2,6-naphthyridin-3-yl)cyclohexane-1-carboxamide (143 mg, 0.38 mmol, 1.0 equiv.) was dissolved in DCM (3 mL). The reaction solution was cooled in an ice-water bath, and pyridine (0.3 mL, 3.78 mmol, 10.0 equiv.) and acetic anhydride (0.047 mL, 0.49 mmol, 1.3 equiv.) were added. The reaction was allowed to proceed at room temperature for 3 hours. When no starting material remained as detected by LC-MS, the reaction solution was poured into water (20 mL) and extracted with ethyl acetate (20 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give a crude product, which was purified by silica gel column chromatography (DCM:MeOH=98:2 to 95:5) to give the product (40 mg, yield: 26%). 1 HNMR(400MHz,DMSO)δ(ppm):10.6(s,1H),9.02(s,1H),8.64(s,1H),7.80(d,1H),7.55(d,1H),7.24(s,1H),6.78(t,1H),4.47- 4.38(m,1H),3.62-3.59(m,1H),2.71-2.63(m,1H),1.96-1.93(m,1H),1.80-1.78(m,6H),1.36-1.11(m,9H),1.12-108(m,1H). Molecular formula:C 21 H 27 F2N5O2Exact mass:419.21 LC-MS(Pos,m / z)=420.4[M+H] + .
[0109] Example 2: Synthesis of (1S,3R)-3-acetamido-N-(7-cyano-5-(isopropylamino)-2,6-naphthyridin-3-yl)cyclohexane-1-carboxamide (Compound 2) [ka]
[0110] Process: [ka]
[0111] Step 1: Synthesis of 5-bromo-2-chloroisonicotinaldehyde [ka] A solution of LDA (2 mol / L) in THF (58.5 mL, 116.93 mmol, 1.5 equiv.) was added to anhydrous THF (50 mL). The reaction solution was cooled to -70 °C under a nitrogen atmosphere, and a solution of 5-bromo-2-chloropyridine (15 g, 77.95 mmol, 1.0 equiv.) in anhydrous THF (100 mL) was added dropwise. After 1 h, the reaction was allowed to proceed at -70 °C to -65 °C for 0.5 h. DMF (18 mL, 233.85 mol, 3.0 equiv.) was added dropwise to the reaction solution. After addition, the reaction was allowed to proceed at -70 °C to -65 °C for 1 h. When no starting material remained as detected by TLC, the reaction solution was added dropwise to saturated ammonium hydroxide solution (500 mL). After stirring for 10 min, the reaction solution was dissolved in water (100 mL) and extracted with ethyl acetate (500 mL × 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the crude product, which was purified by silica gel column chromatography (EA:PE=1:40) to give the product (10.6 g, yield: 62.3%).
[0112] Step 2: Synthesis of 3-(6-chloro-4-formylpyridin-3-yl)prop-2-yn-1-yl benzoate [ka] DIPEA (16.5 g, 127.92 mmol, 3.0 equiv.), Pd(dppf)Cl2CHCl2 (2.5 g, 3.14 mmol, 0.08 equiv.), and CuI (811.3 mg, 4.26 mmol, 0.1 equiv.) were added to anhydrous THF (100 mL). The mixture was stirred under nitrogen for 10 min, and a solution of 5-bromo-2-chloroisonicotinaldehyde (9.4 g, 42.64 mmol, 1.0 equiv.) in anhydrous THF (50 mL) was added. After the addition, the mixture was cooled in an ice-water bath, and a solution of propargyl benzoate (8.2 g, 51.17 mmol, 1.2 equiv.) in anhydrous THF (50 mL) was added. After the addition, the mixture was incubated at room temperature for 22 h. When no starting material remained as detected by TLC, water (200 mL) was added to the reaction solution, stirred for 10 minutes, and filtered. The filter cake was washed with ethyl acetate, and the layers were separated. The organic phase was retained, and the aqueous phase was extracted with ethyl acetate (100 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the crude product, which was purified by silica gel column chromatography (EA:PE = 1:30 to 1:10) to give the product (5.8 g, yield: 45.6%).
[0113] Step 3: Synthesis of (E)-3-(6-chloro-4-((hydroxyimino)methyl)pyridin-3-yl)prop-2-yn-1-yl benzoate [ka] (E)-3-(6-chloro-4-((hydroxyimino)methyl)pyridin-3-yl)prop-2-yn-1-yl benzoate (5.5 g, 18.35 mmol, 1.0 equiv.) was dissolved in absolute ethanol (800 mL). Hydroxylamine hydrochloride (1.9 g, 27.53 mmol, 1.5 equiv.) and sodium acetate (2.2 g, 27.53 mmol, 1.5 equiv.) were added to the reaction solution, and the mixture was allowed to react at room temperature for 5 hours. When no starting material remained as detected by TLC, the reaction solution was concentrated under reduced pressure, water (50 mL) was added, and the mixture was extracted with ethyl acetate (50 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filter cake was concentrated under reduced pressure to give the product (5.57 g, yield: 96.5%).
[0114] Step 4: Synthesis of 3-((benzoyloxy)methyl)-7-chloro-2,6-naphthyridine 2-oxide [ka] (E)-3-(6-chloro-4-((hydroxyimino)methyl)pyridin-3-yl)prop-2-yn-1-yl benzoate (5.57 g, 17.70 mmol, 1.0 equiv.) was dissolved in DCM (80 mL). Silver trifluoromethanesulfonate (454.7 mg, 1.77 mmol, 0.1 equiv.) was added to the reaction solution, and the mixture was allowed to react at room temperature for 15 hours. When a small amount of starting material remained as detected by TLC, the reaction solution was concentrated under reduced pressure, slurried with diethyl ether (100 mL) for 0.5 hours, filtered, and the filter cake was washed with diethyl ether (50 mL) and dried to give the product (4.8 g, yield: 86.1%).
[0115] Step 5: Synthesis of (1,7-dichloro-2,6-naphthyridin-3-yl)methyl benzoate [ka] 3-((benzoyloxy)methyl)-7-chloro-2,6-naphthyridine 2-oxide (4.8 g, 15.25 mmol, 1.0 equiv.) and DIPEA (5.9 g, 45.75 mmol, 3.0 equiv.) were dissolved in DCM (100 mL). The reaction solution was cooled to 0-5 °C, and oxalyl chloride (3.87 g, 30.50 mmol, 2.0 equiv.) was added dropwise and allowed to react for 2 h. When a large amount of starting material remained as detected by TLC, the reaction solution was supplemented with DIPEA (5.9 g, 45.75 mmol, 3.0 equiv.) and oxalyl chloride (3.87 g, 30.50 mmol, 2.0 equiv.) and allowed to react for 1 h. When no starting material remained as detected by TLC, the reaction solution was added with water (100 mL), concentrated under reduced pressure, and extracted with ethyl acetate (200 mL x 2). The organic phases were combined, dried over anhydrous magnesium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the crude product, which was purified by silica gel column chromatography (EA:PE=1:30 to 1:20) to give the product (3.5 g, yield: 70%).
[0116] Step 6: Synthesis of (7-chloro-1-(isopropylamino)-2,6-naphthyridin-3-yl)methyl benzoate [ka] (1,7-Dichloro-2,6-naphthyridin-3-yl)methyl benzoate (3.5 g, 10.51 mmol, 1.0 equivalent) and isopropylamine (7.4 g, 126.12 mmol, 12.0 equivalent) were added to anhydrous THF (20 mL). The mixture was reacted in a sealed tube at 100° C. for 6 hours. When no starting material remained as detected by TLC, the reaction solution was concentrated under reduced pressure to give a pale yellow product, which was used in the next step according to theoretical amount.
[0117] Step 7: Synthesis of (7-chloro-1-(isopropylamino)-2,6-naphthyridin-3-yl)methanol [ka] (7-Chloro-1-(isopropylamino)-2,6-naphthyridin-3-yl)methyl benzoate (10.51 mmol, 1.0 equiv.) and lithium hydroxide monohydrate (1.3 g, 31.53 mmol, 3.0 equiv.) were dissolved in a mixture of THF (30 mL), methanol (15 mL), and water (15 mL), and the reaction mixture was allowed to react at room temperature for 16 h. When no starting material remained as detected by TLC, the reaction mixture was concentrated under reduced pressure, water (30 mL) was added, and the mixture was extracted with ethyl acetate (30 mL × 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the crude product, which was purified by silica gel column chromatography (EA:PE = 1:20 to 1:6) to give the product (2.48 g, 95.3% yield for two steps).
[0118] Step 8: Synthesis of 7-chloro-1-(isopropylamino)-2,6-naphthyridine-3-carbaldehyde [ka] (7-Chloro-1-(isopropylamino)-2,6-naphthyridin-3-yl)methanol (2.48 g, 9.85 mmol, 1.0 equiv.) was dissolved in DMSO (25 mL). IBX (4.1 g, 14.77 mmol, 1.5 equiv.) was added to the reaction solution and reacted at room temperature for 1 hour. When no starting material remained as detected by TLC, the reaction solution was poured into water (200 mL) and extracted with ethyl acetate (100 mL × 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the product, which was used in the next step according to theoretical amount.
[0119] Step 9: Synthesis of (Z)-7-chloro-1-(isopropylamino)-2,6-naphthyridine-3-carbaldehyde oxime [ka] 7-Chloro-1-(isopropylamino)-2,6-naphthyridine-3-carbaldehyde (9.85 mmol, 1.0 equiv.) was dissolved in absolute ethanol (25 mL). Hydroxylamine hydrochloride (1.03 g, 14.77 mmol, 1.5 equiv.) and sodium acetate (1.2 g, 14.77 mmol, 1.5 equiv.) were added to the mixture, and the mixture was allowed to react at room temperature for 16 hours. When no starting material remained as detected by TLC, the reaction solution was concentrated under reduced pressure, water (50 mL) was added, and the mixture was extracted with ethyl acetate (50 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the product (2.1 g, 80.7% yield for two steps).
[0120] Step 10: Synthesis of 7-chloro-1-(isopropylamino)-2,6-naphthyridine-3-carbonitrile [ka] (Z)-7-Chloro-1-(isopropylamino)-2,6-naphthyridine-3-carbaldehyde oxime (2.1 g, 7.93 mmol, 1.0 equiv.) was dissolved in acetic anhydride (10 mL). The reaction solution was heated to 120 °C and reacted for 15 h. When no starting material remained as detected by TLC, the reaction solution was concentrated under reduced pressure, water (20 mL) was added, and the mixture was extracted with ethyl acetate (20 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the crude product, which was purified by silica gel column chromatography (EA:PE = 1:20 to 1:15) to give the product (522 mg, yield: 27.4%).
[0121] Step 11: Synthesis of 7-((diphenylmethylene)amino)-1-(isopropylamino)-2,6-naphthyridine-3-carbonitrile [ka] 7-Chloro-1-(isopropylamino)-2,6-naphthyridine-3-carbonitrile (520 mg, 2.11 mmol, 1.0 equiv.), diphenylmethanimine (458.9 mg, 2.53 mmol, 1.2 equiv.), Pd(dba) (192.3 mg, 0.21 mmol, 0.1 equiv.), BINAP (262.8 mg, 0.42 mmol, 0.2 equiv.), and cesium carbonate (1.7 g, 5.27 mmol, 2.5 equiv.) were added to 1,4-dioxane (15 mL). The mixture was reacted in a sealed tube at 120 °C for 23 h under a nitrogen atmosphere. When no starting material remained as detected by TLC, the reaction solution was filtered, and the filtrate was concentrated under reduced pressure to give the product, which was used in the next step according to theoretical amount.
[0122] Step 12: Synthesis of 7-amino-1-(isopropylamino)-2,6-naphthyridine-3-carbonitrile [ka] 7-((diphenylmethylene)amino)-1-(isopropylamino)-2,6-naphthyridine-3-carbonitrile (2.11 mmol, 1.0 equiv.) was dissolved in THF (10 mL). Aqueous citric acid solution (mass fraction: 10%, 5 mL) was added to the reaction solution, and the mixture was allowed to react at room temperature for 23 hours. When no starting material remained as detected by TLC, water (20 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (15 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. This was purified by silica gel column chromatography (EA:PE = 1:5 to 1:1) to obtain the product (310 mg, 2-step yield: 64.6%).
[0123] Step 13: Synthesis of tert-butyl ((1R,3S)-3-((7-cyano-5-(isopropylamino)-2,6-naphthyridin-3-yl)carbamoyl)cyclohexyl)carbamate [ka] (1S,3R)-3-((tert-butoxycarbonyl)amino)cyclohexane-1-carboxylic acid (192.2 mg, 0.79 mmol, 1.05 equiv.) was dissolved in DCM (3 mL). The reaction solution was cooled to 0-5 °C, and 1-chloro-N,N,2-trimethylprop-1-en-1-amine (mass fraction: 95%, 157.5 mg, 1.12 mmol, 1.5 equiv.) was added. The reaction was allowed to proceed at 0-5 °C for 1.5 h. A solution of 7-amino-1-(isopropylamino)-2,6-naphthyridine-3-carbonitrile (170 mg, 0.75 mmol, 1.0 equiv.) and pyridine (177.9 mg, 2.25 mmol, 3.0 equiv.) in THF (3 mL) was added, and the mixture was incubated at room temperature for 19 h. When a small amount of starting material remained as detected by TLC, water (20 mL) was added to the reaction solution and extracted with ethyl acetate (20 mL × 3). The organic phases were combined, washed with water (20 mL) and brine (20 mL) successively, and concentrated under reduced pressure to give the crude product, which was purified by silica gel column chromatography (EA:PE = 1:3) to give the product (300 mg, yield: 88.4%).
[0124] Step 14: Synthesis of (1S,3R)-3-amino-N-(7-cyano-5-(isopropylamino)-2,6-naphthyridin-3-yl)cyclohexane-1-carboxamide [ka] tert-Butyl ((1R,3S)-3-((7-cyano-5-(isopropylamino)-2,6-naphthyridin-3-yl)carbamoyl)cyclohexyl)carbamate (300 mg, 0.66 mmol, 1.0 equiv.) was dissolved in DCM (10 mL). The reaction solution was cooled in an ice-water bath, and hydrogen chloride in ethanol (10 mol / L, 2 mL) was added. The reaction was allowed to proceed at room temperature for 20 hours. When no starting material remained as detected by TLC, the reaction solution was concentrated under reduced pressure, slurried with ethyl acetate (20 mL) for 10 minutes, and filtered. The filter cake was dissolved in water (50 mL) and back-extracted with ethyl acetate (30 mL × 2). The aqueous phase was retained, adjusted to pH 8 with sodium bicarbonate, and extracted with ethyl acetate (30 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the product (128 mg, yield: 54.8%).
[0125] Step 15: Synthesis of (1S,3R)-3-acetamido-N-(7-cyano-5-(isopropylamino)-2,6-naphthyridin-3-yl)cyclohexane-1-carboxamide [ka] (1S,3R)-3-amino-N-(7-cyano-5-(isopropylamino)-2,6-naphthyridin-3-yl)cyclohexane-1-carboxamide (128 mg, 0.36 mmol, 1.0 equiv.) was dissolved in DCM (3 mL). The reaction solution was cooled in an ice-water bath, and DIPEA (139.5 mg, 1.08 mmol, 3.0 equiv.) and acetic anhydride (55 mg, 0.54 mmol, 1.5 equiv.) were added. The reaction was allowed to proceed at room temperature for 3 hours. When no starting material remained as detected by LC-MS, the reaction solution was poured into water (20 mL) and extracted with ethyl acetate (20 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give a crude product, which was slurried in a mixture of diethyl ether (10 mL) and petroleum ether (10 mL), filtered, and the filter cake was dried to give the product (91.5 mg, yield: 64.4%). 1HNMR(300MHz,CD3OD)δ(ppm):8.93(s,1H),8.52(s,1H),7.50(s,1H),4.52-4.43(m,1H),3.37-3.7 2(m,1H),2.71-2.63(m,1H),2.12-2.10(m,1H),1.95(m,6H),1.55-1.47(m,3H),1.36-1.34(m,7H). Molecular formula:C 21 H 26 N6O2Exact mass:394.21 LC-MS(Pos,m / z)=395.27[M+H] + .
[0126] Example 3: Synthesis of (1S,3R)-3-acetamido-N-(6-cyano-8-(isopropylamino)pyrido[3,4-d]pyrimidin-2-yl)cyclohexane-1-carboxamide (Compound 3) [ka]
[0127] Step 1: 2-amino-8-(isopropylamino)pyrido[3,4-d]pyrimidine-6-carbonitrile [ka] 6-Chloro-N 8 Isopropylpyrido[3,4-d]pyrimidine-2,8-diamine (500 mg, 2.10 mmol, 1.0 equiv.), zinc cyanide (494 mg, 4.21 mmol, 2.0 equiv.), and tetrakis(triphenylphosphine)palladium(0) (485 mg, 0.42 mmol, 0.2 equiv.) were dissolved in DMAC (10 mL). The reaction mixture was reacted at 120 °C for 24 h under a nitrogen atmosphere. When a small amount of starting material remained as detected by LC-MS, the reaction mixture was cooled to room temperature, poured into water (20 mL), and extracted with EA (20 mL × 2). The organic phase was washed with saturated aqueous sodium chloride (15 mL × 2) and concentrated under reduced pressure to give the crude product. This was purified by silica gel column chromatography (PE:EA = 3:1) to give the product (320 mg, yield: 66.6%).
[0128] Step 2: Synthesis of tert-butyl ((1R,3S)-3-((6-cyano-8-(isopropylamino)pyrido[3,4-d]pyrimidin-2-yl)carbamoyl)cyclohexyl)carbamate [ka] 2-Amino-8-(isopropylamino)pyrido[3,4-d]pyrimidine-6-carbonitrile (160 mg, 0.71 mmol, 1.0 equiv.) and (1S,3R)-3-((tert-butoxycarbonyl)amino)cyclohexane-1-carboxylic acid (188 mg, 0.77 mmol, 1.1 equiv.) were dissolved in pyridine (3 mL). Phosphorus oxychloride (107 mg, 0.71 mmol, 1.0 equiv.) was added to the reaction solution and the mixture was allowed to react at room temperature for 23 h. When the starting material remained as detected by TLC, the reaction solution was poured into water (10 mL) and extracted with EA (15 mL × 2). The organic phase was washed with hydrochloric acid (10 mL × 3), dried, and concentrated to give the crude product, which was purified by silica gel column chromatography (PE:EA = 3:1) to give the product (160 mg, yield: 50.4%).
[0129] Step 3: Synthesis of (1S,3R)-3-amino-N-(6-cyano-8-(isopropylamino)pyrido[3,4-d]pyrimidin-2-yl)cyclohexane-1-carboxamide [ka] tert-Butyl ((1R,3S)-3-((6-cyano-8-(isopropylamino)pyrido[3,4-d]pyrimidin-2-yl)carbamoyl)cyclohexyl)carbamate (160 mg, 0.35 mmol, 1.0 equiv) was dissolved in EA (4 mL). A solution of HCl (4 mol / L, 2 mL) in 1,4-dioxane was added dropwise to the reaction solution, and the reaction was allowed to proceed at room temperature for 4 hours. After the reaction was substantially complete as detected by LC-MS, the crude product was dissolved in saturated aqueous sodium carbonate (20 mL). The aqueous phase was extracted with DCM (10 mL × 3). The organic phase was dried and concentrated to give the product (100 mg, yield: 80.2%).
[0130] Step 4: Synthesis of (1S,3R)-3-acetamido-N-(6-cyano-8-(isopropylamino)pyrido[3,4-d]pyrimidin-2-yl)cyclohexane-1-carboxamide [ka] (1S,3R)-3-amino-N-(6-cyano-8-(isopropylamino)pyrido[3,4-d]pyrimidin-2-yl)cyclohexane-1-carboxamide (100 mg, 0.28 mmol, 1.0 equiv.), DIPEA (109 mg, 0.84 mmol, 3.0 equiv.), and acetic anhydride (43 mg, 0.43 mmol, 1.5 equiv.) were dissolved in DCM (2 mL) and the reaction mixture was allowed to react at room temperature for 5 h. After completion of the reaction as detected by LC-MS, water (5 mL) was added to the reaction mixture, the aqueous phase was extracted with DCM (5 mL x 3), and the organic phase was dried and concentrated to give the crude product. The crude product was slurried with MTBE (5 mL), filtered under reduced pressure, and the filter cake was dried at 50 °C to give the product (30 mg, yield: 26.8%). 1HNMR(300MHz,DMSO-d6)δ(ppm):11.10(s,1H),9.38(s,1H),7.81-7.78(d,1H),7.65(s,1H),6.93-6.90(d,1H) ,4.29-4.22(m,1H),3.60-3.57(t,1H),2.76-2.73(d,1H),1.96-1.92(d,1H),1.77(s,6H),1.29-1.27(d,10H). Molecular formula:C 20 H 25 N7O2Exact mass:395.21 LC-MS(Pos,m / z)=396.28[M+H] + .
[0131] Example 4: Synthesis of (1S,3R)-3-acetamido-N-(6-chloro-8-(isopropylamino)pyrido[3,4-d]pyrimidin-2-yl)cyclohexane-1-carboxamide (Compound 4) [ka]
[0132] Step 1: Synthesis of methyl 3-amino-2,6-dichloroisonicotinate [ka] Methyl 3-aminoisonicotinate (105 g, 690.11 mmol, 1.0 equiv.) and N-chlorosuccinimide (193.52 g, 1449.23 mmol, 2.1 equiv.) were dissolved in DMF (500 mL), and the reaction solution was reacted at 30° C. for 22 hours. After the reaction was completed as detected by TLC, the reaction solution was poured into water (2 L), and a large amount of solid precipitated. The reaction solution was stirred for 1 hour and filtered under reduced pressure. The filter cake was dissolved in EA (2 L), dried, filtered, and the filtrate was concentrated under reduced pressure to give the product (152.54 g, yield: 100%).
[0133] Step 2: Synthesis of (3-amino-2,6-dichloropyridin-4-yl)methanol [ka] Methyl 3-amino-2,6-dichloroisonicotinate (152.54 g, 690.11 mmol, 1.0 equiv.) was dissolved in THF (1.5 L). The reaction solution was cooled to 0 °C, and lithium aluminum hydride (26.18 g, 690.11 mmol, 1.0 equiv.) was added in batches. The reaction mixture was allowed to react at 0 °C–5 °C for 40 min. After the reaction was complete as detected by TLC, an appropriate amount of water was added to the reaction mixture to quench the lithium aluminum hydride. An appropriate amount of anhydrous sodium sulfate was then added, followed by stirring for 30 min and filtration. The filtrate was concentrated under reduced pressure to give the crude product, which was slurried with (PE:EA = 5:1, 1.2 L) for 1 h, filtered, and the filter cake was dried to give the product (84 g, yield: 63%).
[0134] Step 3: Synthesis of N-((2,6-dichloro-4-(hydroxymethyl)pyridin-3-yl)carbamothioyl)benzamide [ka] (3-Amino-2,6-dichloropyridin-4-yl)methanol (84 g, 435.16 mmol, 1.0 equivalent) and benzoyl isothiocyanate (78.12 g, 478.68 mmol, 1.1 equivalent) were dissolved in THF (840 mL) and the reaction mixture was reacted for 4 hours. After the reaction was completed as detected by TLC, the reaction mixture was concentrated under reduced pressure to give the crude product, which was slurried with (PE:EA = 20:1, 1.05 L) for 0.5 hours, filtered under reduced pressure, and the filter cake was dried to give the product (151 g, yield: 97.4%).
[0135] Step 4: Synthesis of methyl (E)-N-benzoyl-N'-(2,6-dichloro-4-(hydroxymethyl)pyridin-3-yl)carbamimidothioate [ka] N-((2,6-dichloro-4-(hydroxymethyl)pyridin-3-yl)carbamothioyl)benzamide (151 g, 423.90 mmol, 1.0 equiv.), iodomethane (66.19 g, 466.29 mmol, 1.1 equiv.), and potassium carbonate (64.35 g, 466.29 mmol, 1.1 equiv.) were dissolved in THF (1.5 L), and the reaction mixture was reacted at room temperature for 12 hours. When no starting material remained as detected by LC-MS, the reaction mixture was filtered. The filtrate was concentrated under reduced pressure to give the crude product, which was slurried with MTBE (500 mL), filtered, and the filtrate was concentrated under reduced pressure to give the product (50 g, yield: 31.8%).
[0136] Step 5: Synthesis of methyl (E)-N-benzoyl-N'-(2,6-dichloro-4-formylpyridin-3-yl)carbamimidothioate [ka] Methyl (E)-N-benzoyl-N'-(2,6-dichloro-4-(hydroxymethyl)pyridin-3-yl)carbamimidothioate (50 g, 135.04 mmol, 1.0 equiv.) and IBX (37.81 g, 135.04 mmol, 1.0 equiv.) were dissolved in DMSO (250 mL), and the reaction solution was reacted at room temperature for 1 hour. After the reaction was completed as detected by TLC, the reaction solution was poured into saturated aqueous potassium carbonate (500 mL) and extracted with MTBE (500 mL x 3). The organic phases were combined, washed with water (500 mL x 2), dried, filtered, and the filtrate was concentrated under reduced pressure to give the product (40 g, yield: 80.4%).
[0137] Step 6: Synthesis of 6,8-dichloro-2-(methylthiopyrido[3,4-d]pyrimidine [ka] Methyl (E)-N-benzoyl-N'-(2,6-dichloro-4-formylpyridin-3-yl)carbamimidothioate (40 g, 108.63 mmol, 1.0 equiv.) and potassium carbonate (15.01 g, 108.63 mmol, 1.0 equiv.) were dissolved in acetonitrile (400 mL), and the reaction solution was reacted at 90 °C for 1 h. After the reaction was completed as detected by TLC, the reaction solution was concentrated under reduced pressure, water (100 mL) was added, and the mixture was extracted with ethyl acetate (100 mL × 2). The organic phase was dried and concentrated under reduced pressure to give the crude product, which was slurried with a small amount of ethyl acetate (50 mL) and filtered under reduced pressure to give the product (13.3 g, yield: 49.8%).
[0138] Step 7: Synthesis of 6-chloro-N-isopropyl-2-(methylthiopyrido[3,4-d]pyrimidin-8-amine [ka] 6,8-Dichloro-2-(methylthio)pyrido[3,4-d]pyrimidine (13.3 g, 54.04 mmol, 1.0 equiv.) and isopropylamine (15.97 g, 270.21 mmol, 5.0 equiv.) were dissolved in THF (150 mL), and the reaction solution was reacted at 35° C. for 14 hours. After the reaction was completed as detected by TLC, the reaction solution was concentrated under reduced pressure to give the crude product, which was slurried with ethyl acetate (50 mL) to give the product (11 g, yield: 75.7%).
[0139] Step 8: Synthesis of 6-chloro-N-isopropyl-2-(methylsulfonyl)pyrido[3,4-d]pyrimidin-8-amine [ka] 6-Chloro-N-isopropyl-2-(methylthio)pyrido[3,4-d]pyrimidin-8-amine (11 g, 40.92 mmol, 1.0 equiv.) was dissolved in DCM (220 mL). m-Chloroperbenzoic acid (mass fraction: 80%, 19.42 g, 90.02 mmol, 2.2 equiv.) was added to the reaction solution under ice-bath conditions. After completion of the reaction as detected by TLC, the reaction solution was poured into saturated aqueous sodium carbonate (100 mL). The aqueous phase was extracted with DCM (100 mL). The combined organic phases were dried and concentrated to give the product (10 g, yield: 81.3%).
[0140] Step 9: 6-chloro-N 8 Synthesis of -isopropylpyrido[3,4-d]pyrimidine-2,8-diamine [ka] 6-Chloro-N-isopropyl-2-(methylsulfonyl)pyrido[3,4-d]pyrimidin-8-amine (10 g, 33.25 mmol, 1.0 equivalent) was dissolved in a solution of ammonia in isopropanol (3.5 mol / L, 100 mL), and the reaction solution was reacted at 60° C. for 17.5 hours. After the reaction was completed as detected by LC-MS, the reaction solution was concentrated to give the crude product, which was purified by silica gel column chromatography (PE:EA=5:1) to give the product (6.0 g, yield: 75.9%).
[0141] Step 10: Synthesis of tert-butyl ((1R,3S)-3-((6-chloro-8-(isopropylamino)pyrido[3,4-d]pyrimidin-2-yl)carbamoyl)cyclohexyl)carbamate [ka] (1S,3R)-3-((tert-butoxycarbonyl)amino)cyclohexane-1-carboxylic acid (512 mg, 2.10 mmol, 1.0 equivalent), 1-chloro-N,N,2-trimethylprop-1-en-1-amine (365 mg, 2.73 mmol, 1.3 equivalent), and pyridine (499 mg, 6.31 mmol, 3.0 equivalent) were dissolved in DCM (10 mL), and the reaction solution was reacted in a nitrogen atmosphere at 0° C. for 0.5 hours. 8 1,4-Dimethyl-2,8-diamine (500 mg, 2.10 mmol, 1.0 equiv.) was added and the mixture was incubated at room temperature for 12 hours. When a small amount of starting material remained as detected by LC-MS, the reaction mixture was concentrated to give the crude product, which was purified by silica gel column chromatography (PE:EA = 3:1) to give the product (250 mg, yield: 25.6%).
[0142] Step 11: Synthesis of (1S,3R)-3-amino-N-(6-chloro-8-(isopropylamino)pyrido[3,4-d]pyrimidin-2-yl)cyclohexane-1-carboxamide hydrochloride [ka] tert-Butyl ((1R,3S)-3-((6-chloro-8-(isopropylamino)pyrido[3,4-d]pyrimidin-2-yl)carbamoyl)cyclohexyl)carbamate (200 mg, 0.43 mmol, 1.0 equiv.) was dissolved in EA (4 mL). A solution of HCl (4 mol / L, 2 mL) in 1,4-dioxane was added dropwise to the reaction solution, and the reaction was allowed to proceed at room temperature for 3 hours. After the reaction was substantially complete as detected by LC-MS, MTBE (4 mL) was added to the reaction solution, stirred for 10 minutes, filtered under reduced pressure, and the filter cake was dried to give the product (160 mg, yield: 92.7%).
[0143] Step 12: Synthesis of (1S,3R)-3-acetamido-N-(6-chloro-8-(isopropylamino)pyrido[3,4-d]pyrimidin-2-yl)cyclohexane-1-carboxamide [ka] (1S,3R)-3-Amino-N-(6-chloro-8-(isopropylamino)pyrido[3,4-d]pyrimidin-2-yl)cyclohexane-1-carboxamide hydrochloride (160 mg, 0.40 mmol, 1.0 equiv.) and pyridine (95 mg, 1.21 mmol, 3.0 equiv.) were dissolved in DCM (3 mL). The reaction mixture was stirred at room temperature for 5 minutes. Acetic anhydride (61 mg, 0.60 mmol, 1.5 equiv.) was added and the mixture was stirred at room temperature for 7 hours. After the reaction was complete as detected by LC-MS, the reaction mixture was concentrated to give the crude product, which was dissolved in EA (15 mL) and washed with dilute hydrochloric acid (10 mL × 2). The organic phase was dried and concentrated to give the crude product, which was slurried with MTBE (10 mL), filtered under reduced pressure, and the filter cake was dried to give the product (82 mg, yield: 50.5%). 1 HNMR(300MHz,DMSO-d6)δ(ppm):10.89(s,1H),9.27(s,1H),7.81-7.78(d,1H),7.01(s,1H),6.89-6.86(d,1 H),4.27-4.20(m,1H),3.60-3.56(m,1H),2.73(s,1H),1.95-1.91(d,1H),1.77(s,6H),1.35-1.23(m,10H). Molecular formula:C 19 H 25 ClN6O2Exact mass:404.17 LC-MS(Pos,m / z)=405.12[M+H] + .
[0144] Example 5: Synthesis of (1S,3R)-3-acetamido-N-(8-(isopropylamino)-6-(methylsulfonyl)pyrido[3,4-d]pyrimidin-2-yl)cyclohexane-1-carboxamide (Compound 5) [ka]
[0145] Process 1:N 8Synthesis of 1,2-isopropyl-6-(methylsulfonyl)pyrido[3,4-d]pyrimidine-2,8-diamine [ka] 6-Chloro-N 8 N,N'-Isopropylpyrido[3,4-d]pyrimidine-2,8-diamine (500 mg, 2.10 mmol, 1.0 equiv.), N,N'-dimethyl-1,2-cyclohexanediamine (150 mg, 1.05 mmol, 0.5 equiv.), sodium methylenesulfonate (430 mg, 4.21 mmol, 2.0 equiv.), copper iodide (200 mg, 1.05 mmol, 0.5 equiv.), and potassium phosphate (1.34 g, 6.31 mmol, 3.0 equiv.) were dissolved in DMSO (10 mL). The reaction mixture was incubated at 120 °C for 21 h under a nitrogen atmosphere. After completion of the reaction as determined by LC-MS, the reaction mixture was poured into water (50 mL), and the aqueous phase was extracted with EA (50 mL × 2). The organic phase was washed with saturated brine (50 mL × 2), dried, and concentrated to give the crude product, which was purified by silica gel column chromatography (PE:EA = 2:1) to give the product (160 mg, yield: 27.04%).
[0146] Step 2: Synthesis of tert-butyl ((1R,3S)-3-((8-(isopropylamino)-6-(methylsulfonyl)pyrido[3,4-d]pyrimidin-2-yl)carbamoyl)cyclohexyl)carbamate [ka] N 8Isopropyl-6-(methylsulfonyl)pyrido[3,4-d]pyrimidine-2,8-diamine (160 mg, 0.57 mmol, 1.0 equiv.) and (1S,3R)-3-((tert-butoxycarbonyl)amino)cyclohexane-1-carboxylic acid (152 mg, 0.62 mmol, 1.1 equiv.) were dissolved in pyridine (3 mL). Phosphorus oxychloride (436 mg, 2.84 mmol, 5.0 equiv.) was added to the reaction solution and reacted at room temperature for 0.5 h. After the reaction was completed as detected by TLC, the reaction solution was poured into hydrochloric acid (20 mL). The aqueous phase was extracted with EA (15 mL × 3). The organic phase was dried and concentrated to give the crude product. The crude product was slurried with (PE:EA = 5:1, 60 mL), filtered under reduced pressure, and the filter cake was dried at 50 °C to give the product (190 mg, yield: 65.9%).
[0147] Step 3: Synthesis of (1S,3R)-3-amino-N-(8-(isopropylamino)-6-(methylsulfonyl)pyrido[3,4-d]pyrimidin-2-yl)cyclohexane-1-carboxamide hydrochloride [ka] tert-Butyl ((1R,3S)-3-((8-(isopropylamino)-6-(methylsulfonyl)pyrido[3,4-d]pyrimidin-2-yl)carbamoyl)cyclohexyl)carbamate (180 mg, 0.36 mmol, 1.0 equiv.) was dissolved in EA (2 mL). A solution of HCl in 1,4-dioxane (4 mol / L, 2 mL) was added dropwise to the reaction solution, and the reaction was allowed to proceed at room temperature for 3 hours. After the reaction was substantially complete as detected by LC-MS, the reaction solution was filtered under reduced pressure to give the product (150 mg, yield: 95.3%).
[0148] Step 4: Synthesis of (1S,3R)-3-acetamido-N-(8-(isopropylamino)-6-(methylsulfonyl)pyrido[3,4-d]pyrimidin-2-yl)cyclohexane-1-carboxamide [ka] (1S,3R)-3-amino-N-(8-(isopropylamino)-6-(methylsulfonyl)pyrido[3,4-d]pyrimidin-2-yl)cyclohexane-1-carboxamide hydrochloride (150 mg, 0.34 mmol, 1.0 equiv.), DIPEA (131.3 mg, 1.02 mmol, 3.0 equiv.), and acetic anhydride (52 mg, 0.51 mmol, 1.5 equiv.) were dissolved in DCM (3 mL), and the reaction solution was reacted at room temperature for 1 h. After the reaction was completed as detected by LC-MS, the reaction solution was poured into water (5 mL) and extracted with DCM (10 mL × 2). The organic phase was dried and concentrated to give the crude product, which was slurried with EA (3 mL), filtered under reduced pressure, and the filter cake was dried to give the product (50 mg, yield: 32.9%). 1 HNMR(300MHz,DMSO-d6)δ(ppm):11.08(s,1H),9.55(s,1H),7.82-7.80(d,1H),6.69(s,1H),7.01-6.98(d,1H),4.34 -4.25(m,1H),3.61-3.59(t,1H),3.23(s,3H),2.78-2.75(d,1H),1.96-1.94(d1H),1.78(s,6H),1.33-1.31(d,10H). Molecular formula:C 20 H 28 N6O4S Exact mass:448.19 LC-MS(Pos,m / z)=449.08[M+H] + .
[0149] Example 6: Synthesis of (S)-1-acetyl-N-(6-cyano-8-(isopropylamino)pyrido[3,4-d]pyrimidin-2-yl)piperidine-3-carboxamide (Compound 6) [ka]
[0150] Step 1: tert-butyl (S)-3-((6-cyano-8-(isopropylamino)pyrido[3,4-d]pyrimidin-2-yl)carbamoyl)piperidine-1-carboxylate [ka] (S)-1-(tert-Butoxycarbonyl)piperidine-3-carboxylic acid (177 mg, 0.77 mmol, 1.0 equiv.), 1-chloro-N,N,2-trimethylprop-1-en-1-amine (140 mg, 1.05 mmol, 1.5 equiv.), and pyridine (166 mg, 2.10 mmol, 3.0 equiv.) were dissolved in DCM (4 mL) and the reaction mixture was incubated at 0 °C for 1.5 h. 2-Amino-8-(isopropylamino)pyrido[3,4-d]pyrimidine-6-carbonitrile (1600 mg, 0.7 mmol, 1.0 equiv.) was added to the reaction mixture and incubated at room temperature for 16 h. After completion of the reaction as detected by TLC, the reaction mixture was concentrated to give the crude product, which was purified by silica gel column chromatography (PE:EA = 3:1) to give the product (160 mg, yield: 51.9%).
[0151] Step 2: Synthesis of (S)—N-(6-cyano-8-(isopropylamino)pyrido[3,4-d]pyrimidin-2-yl)piperidine-3-carboxamide hydrochloride [ka] tert-Butyl (S)-3-((6-cyano-8-(isopropylamino)pyrido[3,4-d]pyrimidin-2-yl)carbamoyl)piperidine-1-carboxylate (160 mg, 0.36 mmol, 1.0 equiv.) was dissolved in EA (2 mL). A solution of HCl (4 mol / L, 2 mL) in 1,4-dioxane was added dropwise to the reaction solution, and the reaction was carried out at room temperature for 15 hours. After the reaction was substantially complete as detected by LC-MS, the reaction solution was filtered under reduced pressure to give the product (136 mg, yield: 100%).
[0152] Step 3: Synthesis of (S)-1-acetyl-N-(6-cyano-8-(isopropylamino)pyrido[3,4-d]pyrimidin-2-yl)piperidine-3-carboxamide [ka] (S)—N-(6-cyano-8-(isopropylamino)pyrido[3,4-d]pyrimidin-2-yl)piperidine-3-carboxamide hydrochloride (136 mg, 0.36 mmol, 1.0 equiv.), DIPEA (140 mg, 1.09 mmol, 3.0 equiv.), and acetic anhydride (55 mg, 0.54 mmol, 1.5 equiv.) were dissolved in DCM (3 mL) and the reaction mixture was allowed to react at room temperature for 3 hours. After completion of the reaction as detected by LC-MS, the reaction mixture was concentrated under reduced pressure to give the crude product, which was purified by silica gel column chromatography (DCM:MeOH=50:1) to give the product (30 mg, yield: 21.7%). 1 HNMR(300MHz,DMSO-d6)δ(ppm):11.27-11.24(d,1H),9.42-9.41(d,1H),7. 68-7.67(d,1H),7.93-7.90(d,1H),6.93-6.90(d,1H),4.45-4.24(m,2H),3 .96-3.77(m,1H),3.23-3.16(t,1H),3.08-2.86(m,1H),2.74-2.73(d,1H), 2.71-2.60(m,1H),2.05-2.02(d,4H),1.74-1.63(m,2H),1.29-1.27(d,6H). Molecular formula:C 19 H 23 N7O2Exact mass:381.19 LC-MS(Pos,m / z)=382.15[M+H] + .
[0153] Example 7: Synthesis of (1S,3R)-3-acetamido-N-(6-(difluoromethyl)-8-(isopropylamino)pyrido[3,4-d]pyrimidin-2-yl)cyclohexane-1-carboxamide (Compound 7) [ka]
[0154] Step 1: Synthesis of 2-amino-8-(isopropylamino)pyrido[3,4-d]pyrimidine-6-carbaldehyde [ka] N 8 Isopropyl-6-vinylpyrido[3,4-d]pyrimidine-2,8-diamine (900 mg, 3.93 mmol, 1.0 equiv.), sodium periodate (2.52 g, 11.78 mmol, 3.0 equiv.), and potassium osmate dihydrate (144 mg, 0.39 mmol, 0.1 equiv.) were dissolved in HO (4 mL) and THF (9 mL). The reaction solution was reacted at room temperature for 18 h. After completion of the reaction as detected by LC-MS, the reaction solution was poured into water (20 mL) and extracted with EA (20 mL × 3). The organic phase was dried and concentrated to give the crude product, which was purified by silica gel column chromatography (PE:EA = 5:1) to give the product (200 mg, yield: 22.0%).
[0155] Step 2: 6-(difluoromethyl)-N 8 Synthesis of -isopropylpyrido[3,4-d]pyrimidine-2,8-diamine [ka] 2-Amino-8-(isopropylamino)pyrido[3,4-d]pyrimidine-6-carbaldehyde (200 mg, 0.86 mmol, 1.0 equivalent) and bis(2-methoxyethyl)aminosulfur trifluoride (951 mg, 4.30 mmol, 5.0 equivalent) were dissolved in DCM (9 mL), and the reaction solution was reacted at 40° C. for 17 hours. The reaction solution was concentrated under reduced pressure to give the crude product, which was purified by silica gel column chromatography (PE:EA=6:1) to give the product (40 mg, yield: 18.2%).
[0156] Step 3: Synthesis of tert-butyl ((1R,3S)-3-((6-(difluoromethyl)-8-(isopropylamino)pyrido[3,4-d]pyrimidin-2-yl)carbamoyl)cyclohexyl)carbamate [ka] 6-(Difluoromethyl)-N 8
[0111] -Isopropylpyrido[3,4-d]pyrimidine-2,8-diamine (40 mg, 0.16 mmol, 1.0 equiv.) and (1S,3R)-3-((tert-butoxycarbonyl)amino)cyclohexane-1-carboxylic acid (42 mg, 0.17 mmol, 1.1 equiv.) were dissolved in pyridine (1 mL). Phosphorus oxychloride (121 mg, 0.79 mmol, 5.0 equiv.) was added to the reaction solution and reacted at room temperature for 10 min. After the reaction was completed as detected by TLC, the reaction solution was poured into water (3 mL) and extracted with EA (5 mL × 2). The organic phase was dried and concentrated to give the crude product, which was purified by preparative thin-layer chromatography (PE:EA = 2:1) to give the product (20 mg, yield: 26.4%).
[0157] Step 4: Synthesis of (1S,3R)-3-amino-N-(6-(difluoromethyl)-8-(isopropylamino)pyrido[3,4-d]pyrimidin-2-yl)cyclohexane-1-carboxamide hydrochloride [ka] tert-Butyl ((1R,3S)-3-((6-(difluoromethyl)-8-(isopropylamino)pyrido[3,4-d]pyrimidin-2-yl)carbamoyl)cyclohexyl)carbamate (20 mg, 0.04 mmol, 1.0 equiv.) was dissolved in EA (1 mL). A solution of HCl (4 mol / L, 0.5 mL) in 1,4-dioxane was added dropwise to the reaction solution, and the reaction was carried out at room temperature for 18 hours. After the reaction was substantially complete as detected by LC-MS, the reaction solution was filtered under reduced pressure to give the product (16 mg, yield: 100%).
[0158] Step 5: Synthesis of (1S,3R)-3-acetamido-N-(6-(difluoromethyl)-8-(isopropylamino)pyrido[3,4-d]pyrimidin-2-yl)cyclohexane-1-carboxamide [ka] (1S,3R)-3-amino-N-(6-(difluoromethyl)-8-(isopropylamino)pyrido[3,4-d]pyrimidin-2-yl)cyclohexane-1-carboxamide hydrochloride (16 mg, 0.038 mmol, 1.0 equiv.), DIPEA (15.5 mg, 0.12 mmol, 3.0 equiv.), and acetic anhydride (6 mg, 0.058 mmol, 1.5 equiv.) were dissolved in DCM (1 mL), and the reaction solution was reacted at room temperature for 20 min. After the reaction was completed as detected by TLC, the reaction solution was poured into water (3 mL) and extracted with EA (5 mL × 2). The organic phase was dried and concentrated to give the crude product, which was slurried with MTBE (1 mL) and purified to give the product (4 mg, yield: 25.0%). 1 HNMR(300MHz,DMSO-d6)δ(ppm):10.97(s,1H),9.44(s,1H),7.82-7.79(d,1H),7.27(s,1H),7.02(s,0.3H),6.84(s,0.5H),6.79-6.76 (d,1H),6.66(s,0.3H),4.36-4.25(m,1H),3.61-3.59(t,1H),2.77-2.73(d,1H),1.93-1.91(d,3H),1.78(s,4H),1.33-1.24(d,10H). Molecular formula:C 20 H 26 F2N6O2Exact mass:420.21 LC-MS(Pos,m / z)=421.14[M+H] + .
[0159] Example 8: Synthesis of (1S,3R)-3-acetamido-N-(8-(isopropylamino)-6-methylpyrido[3,4-d]pyrimidin-2-yl)cyclohexane-1-carboxamide (Compound 8) [ka]
[0160] Process 1:N 8 Synthesis of 1,2-isopropyl-6-methylpyrido[3,4-d]pyrimidine-2,8-diamine [ka] 6-Chloro-N 8 Isopropylpyrido[3,4-d]pyrimidine-2,8-diamine (500 mg, 2.10 mmol, 1.0 equiv.), 50% trimethylboroxine (2.11 g, 8.41 mmol, 4.0 equiv.), cesium carbonate (1.37 g, 4.21 mmol, 2.0 equiv.), and [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (307 mg, 0.42 mmol, 0.2 equiv.) were dissolved in HO (2 mL) and 1,4-dioxane (10 mL). The reaction mixture was incubated at 100 °C for 16 h under a nitrogen atmosphere. After completion of the reaction as determined by LC-MS, the reaction mixture was poured into water (20 mL) and extracted with EA (30 mL × 2). The organic phase was dried and concentrated to give the crude product, which was purified by silica gel column chromatography (PE:EA=3:1) to give the product (300 mg, yield: 65.6%).
[0161] Step 2: Synthesis of tert-butyl ((1R,3S)-3-((8-(isopropylamino)-6-methylpyrido[3,4-d]pyrimidin-2-yl)carbamoyl)cyclohexyl)carbamate [ka] N 8 1-Isopropyl-6-methylpyrido[3,4-d]pyrimidine-2,8-diamine (300 mg, 1.38 mmol, 1.0 equiv.) and (1S,3R)-3-((tert-butoxycarbonyl)amino)cyclohexane-1-carboxylic acid (370 mg, 1.52 mmol, 1.1 equiv.) were dissolved in pyridine (5 mL). Phosphorus oxychloride (1.06 g, 6.90 mmol, 5.0 equiv.) was added to the reaction solution and reacted at room temperature for 0.5 h. After completion of the reaction as detected by TLC, the reaction solution was poured into hydrochloric acid (20 mL) and extracted with EA (15 mL × 3). The organic phase was dried and concentrated to give the crude product, which was purified by silica gel column chromatography (PE:EA = 3:1) to give the product (80 mg, yield: 13.1%).
[0162] Step 3: Synthesis of (1S,3R)-3-amino-N-(8-(isopropylamino)-6-methylpyrido[3,4-d]pyrimidin-2-yl)cyclohexane-1-carboxamide hydrochloride [ka] tert-Butyl ((1R,3S)-3-((8-(isopropylamino)-6-methylpyrido[3,4-d]pyrimidin-2-yl)carbamoyl)cyclohexyl)carbamate (80 mg, 0.18 mmol, 1.0 equiv.) was dissolved in EA (1 mL). A solution of HCl (4 mol / L, 0.5 mL) in 1,4-dioxane was added dropwise to the reaction solution, and the reaction was carried out at room temperature for 19 hours. After the reaction was substantially complete as detected by LC-MS, the reaction solution was filtered under reduced pressure to give the product (68 mg, yield: 100%).
[0163] Step 4: Synthesis of (1S,3R)-3-acetamido-N-(8-(isopropylamino)-6-methylpyrido[3,4-d]pyrimidin-2-yl)cyclohexane-1-carboxamide [ka] (1S,3R)-3-amino-N-(8-(isopropylamino)-6-methylpyrido[3,4-d]pyrimidin-2-yl)cyclohexane-1-carboxamide hydrochloride (68 mg, 0.18 mmol, 1.0 equiv.), DIPEA (69 mg, 0.54 mmol, 3.0 equiv.), and acetic anhydride (28 mg, 0.27 mmol, 1.5 equiv.) were dissolved in DCM (2 mL) and the reaction mixture was allowed to react at room temperature for 20 min. After completion of the reaction as detected by LC-MS, the reaction mixture was concentrated under reduced pressure to give the crude product, which was purified by silica gel column chromatography (MeOH:DCM = 1:20) and slurried with MTBE (2 mL) to give the product (14 mg, yield: 20.3%). 1HNMR(300MHz,DMSO-d6)δ(ppm):10.77(s,1H),9.23(s,1H),7.82-7.79(d,1H),6.76(s,1H),6.53-6.50(d,1H),4. 35-4.26(d,1H),3.60-3.58(d,1H),2.73(s,1H),2.40(s,1H),1.95-1.91(d,1H),1.78(s,6H),1.28-1.26(d,10H). Molecular formula:C 20 H 28 N6O2Exact mass:384.23 LC-MS(Pos,m / z)=385.15[M+H] + .
[0164] Example 9: Synthesis of (1S,3R)-3-acetamido-N-(6-ethyl-8-(isopropylamino)pyrido[3,4-d]pyrimidin-2-yl)cyclohexane-1-carboxamide (Compound 9) [ka]
[0165] Step 1: 6-Ethyl-N 8 Synthesis of -isopropylpyrido[3,4-d]pyrimidine-2,8-diamine [ka] N 8 Isopropyl-6-vinylpyrido[3,4-d]pyrimidine-2,8-diamine (200 mg, 0.87 mmol, 1.0 equiv.) and 10% palladium on carbon (40 mg) were added to MeOH (5 mL), and the reaction solution was reacted under a hydrogen atmosphere for 3 hours. After the reaction was complete as detected by TLC, the reaction solution was filtered, and the filtrate was concentrated under reduced pressure to give the product (201 mg, yield: 100%).
[0166] Step 2: Synthesis of tert-butyl ((1R,3S)-3-((6-ethyl-8-(isopropylamino)pyrido[3,4-d]pyrimidin-2-yl)carbamoyl)cyclohexyl)carbamate [ka] 6-Ethyl-N 8
[0044] -Isopropylpyrido[3,4-d]pyrimidine-2,8-diamine (201 mg, 0.87 mmol, 1.0 equiv.) and (1S,3R)-3-((tert-butoxycarbonyl)amino)cyclohexane-1-carboxylic acid (234 mg, 0.96 mmol, 1.1 equiv.) were dissolved in pyridine (4 mL). Phosphorus oxychloride (667 mg, 4.35 mmol, 5.0 equiv.) was added to the reaction solution and reacted at room temperature for 20 min. After the reaction was completed as detected by TLC, the reaction solution was poured into hydrochloric acid (20 mL), and the aqueous phase was extracted with EA (20 mL × 2). The organic phase was dried and concentrated to give the crude product, which was slurried with MTBE (10 mL), filtered under reduced pressure, and the filter cake was dried to give the product (200 mg, yield: 50.3%).
[0167] Step 3: Synthesis of (1S,3R)-3-amino-N-(6-ethyl-8-(isopropylamino)pyrido[3,4-d]pyrimidin-2-yl)cyclohexane-1-carboxamide hydrochloride [ka] tert-Butyl ((1R,3S)-3-((6-ethyl-8-(isopropylamino)pyrido[3,4-d]pyrimidin-2-yl)carbamoyl)cyclohexyl)carbamate (200 mg, 0.44 mmol, 1.0 equiv.) was dissolved in EA (4 mL), and a solution of hydrogen chloride in 1,4-dioxane (4 mol / L, 2 mL) was added dropwise to the reaction solution, followed by reaction at room temperature for 17 hours. After the reaction was substantially complete as detected by LC-MS, the reaction solution was filtered under reduced pressure to give the product (172 mg, yield: 100%).
[0168] Step 4: Synthesis of (1S,3R)-3-acetamido-N-(6-ethyl-8-(isopropylamino)pyrido[3,4-d]pyrimidin-2-yl)cyclohexane-1-carboxamide [ka] (1S,3R)-3-amino-N-(6-ethyl-8-(isopropylamino)pyrido[3,4-d]pyrimidin-2-yl)cyclohexane-1-carboxamide hydrochloride (172 mg, 0.44 mmol, 1.0 equiv.), DIPEA (170 mg, 1.32 mmol, 3.0 equiv.), and acetic anhydride (67 mg, 0.66 mmol, 1.5 equiv.) were dissolved in DCM (4 mL), and the reaction solution was reacted at room temperature for 20 minutes. After the reaction was complete as detected by LC-MS, the reaction solution was concentrated under reduced pressure to give the crude product, which was slurried with EA (10 mL) and filtered under reduced pressure. The filter cake was dried to give the product (40 mg, yield: 17.4%). 1 HNMR(300MHz,DMSO-d6)δ(ppm):10.76(s,1H),9.25(s,1H),7.82-7.79(d,1H),6.77(s,1H),6.51-6.48(d,1H),4.34-4. 27(m,1H),3.61-3.58(t,1H),2.74-2.63(m,3H),1.96-1.91(d,1H),1.78(s,6H),1.29-1.23(m,12H),1.11-1.08(t,1H). Molecular formula:C 21 H 30 N6O2Exact mass:398.24 LC-MS(Pos,m / z)=399.16[M+H] + .
[0169] Example 10: Synthesis of (1S,3R)-3-acetamido-N-(8-(isopropylamino)-6-vinylpyrido[3,4-d]pyrimidin-2-yl)cyclohexane-1-carboxamide (Compound 10) [ka]
[0170] Process 1:N 8 Synthesis of 1,2-isopropyl-6-vinylpyrido[3,4-d]pyrimidine-2,8-diamine [ka] 6-Chloro-N 8 Isopropylpyrido[3,4-d]pyrimidine-2,8-diamine (2.0 g, 8.41 mmol, 1.0 equiv.), potassium vinylfluoroborate (2.25 g, 16.83 mmol, 2.0 equiv.), cesium carbonate (5.48 g, 16.83 mmol, 2.0 equiv.), and [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (614 mg, 0.84 mmol, 0.1 equiv.) were dissolved in HO (5 mL) and dioxane (25 mL). The reaction mixture was incubated at 100 °C for 21 h under a nitrogen atmosphere. After completion of the reaction as determined by LC-MS, the reaction mixture was poured into water (20 mL) and extracted with EA (30 mL × 2). The organic phase was dried and concentrated to give the crude product, which was purified by silica gel column chromatography (PE:EA=5:1) to give the product (1.2 g, yield: 62.1%).
[0171] Step 2: Synthesis of tert-butyl ((1R,3S)-3-((8-(isopropylamino)-6-vinylpyrido[3,4-d]pyrimidin-2-yl)carbamoyl)cyclohexyl)carbamate [ka] N 8 Isopropyl-6-vinylpyrido[3,4-d]pyrimidine-2,8-diamine (300 mg, 1.31 mmol, 1.0 equiv.) and (1S,3R)-3-((tert-butoxycarbonyl)amino)cyclohexane-1-carboxylic acid (350 mg, 1.44 mmol, 1.1 equiv.) were dissolved in pyridine (3 mL). Phosphorus oxychloride (1.0 g, 6.54 mmol, 5.0 equiv.) was added to the reaction solution and reacted at room temperature for 0.5 h. After the reaction was completed as detected by TLC, the reaction solution was poured into hydrochloric acid (20 mL) and extracted with EA (15 mL × 3). The organic phase was dried and concentrated to give the crude product, which was slurried with (PE:EA = 5:1, 12 mL), filtered under reduced pressure, and the filter cake was dried to give the product (350 mg, yield: 58.8%).
[0172] Step 3: Synthesis of (1S,3R)-3-amino-N-(8-(isopropylamino)-6-vinylpyrido[3,4-d]pyrimidin-2-yl)cyclohexane-1-carboxamide hydrochloride [ka] tert-Butyl ((1R,3S)-3-((8-(isopropylamino)-6-vinylpyrido[3,4-d]pyrimidin-2-yl)carbamoyl)cyclohexyl)carbamate (350 mg, 0.77 mmol, 1.0 equiv.) was dissolved in EA (5 mL). A solution of HCl (4 mol / L, 3 mL) in 1,4-dioxane was added dropwise to the reaction solution, and the reaction was carried out at room temperature for 18 hours. After the reaction was substantially complete as detected by LC-MS, the reaction solution was filtered under reduced pressure to give the product (300 mg, yield: 100%).
[0173] Step 4: Synthesis of (1S,3R)-3-acetamido-N-(8-(isopropylamino)-6-vinylpyrido[3,4-d]pyrimidin-2-yl)cyclohexane-1-carboxamide [ka] (1S,3R)-3-amino-N-(8-(isopropylamino)-6-vinylpyrido[3,4-d]pyrimidin-2-yl)cyclohexane-1-carboxamide hydrochloride (300 mg, 0.76 mmol, 1.0 equiv.), DIPEA (298 mg, 2.13 mmol, 3.0 equiv.), and acetic anhydride (117 mg, 1.15 mmol, 1.5 equiv.) were dissolved in DCM (5 mL) and reacted at room temperature for 2.5 h. After completion of the reaction as detected by LC-MS, the reaction solution was concentrated under reduced pressure to give the crude product, which was purified by silica gel column chromatography (MeOH:DCM = 1:50) to give the product (120 mg, yield: 39.4%). 1HNMR(300MHz,DMSO-d6)δ(ppm):10.84(s,1H),9.28(s,1H),7.82-7.80(d,1H),6.91(s,1H),6.80-6.71(m,1H),6.59-6.56(d,1H),6.27- 6.21(d,1H),5.39-5.36(d,1H),4.37-4.25(d,1H),3.58(s,1H),2.75(s,1H),1.96(s,1H),1.78(s,6H),1.32-1.30(d,9H),1.11(s,1H). Molecular formula:C 21 H 28 N6O2Exact mass:396.23 LC-MS(Pos,m / z)=397.18[M+H] + .
[0174] Example 11: Synthesis of (1S,3R)-3-acetamido-N-(8-(isopropylamino)-6-(methylamino)pyrido[3,4-d]pyrimidin-2-yl)cyclohexane-1-carboxamide (Compound 11) [ka]
[0175] Step 1: tert-butyl (8-(isopropylamino)-2-(methylthiopyrido[3,4-d]pyrimidin-6-yl)(methyl)carbamate [ka] 6-Chloro-N-isopropyl-2-(methylthio)pyrido[3,4-d]pyrimidin-8-amine (1.5 g, 5.58 mmol, 1.0 equiv.), tert-butyl methylcarbamate (1.10 g, 8.37 mmol, 1.5 equiv.), 2-di-tert-butylphosphino-2',4',6'-triisopropylbiphenyl (476 mg, 1.12 mmol, 0.2 equiv.), cesium carbonate (3.64 g, 11.16 mmol, 2.0 equiv.), and allylpalladium chloride dimer (204 mg, 0.56 mmol, 0.1 equiv.) were dispersed in dioxane (20 mL), and the reaction solution was reacted at 80 °C for 4.5 h under a nitrogen atmosphere. After the reaction was completed as detected by TLC, the reaction solution was concentrated under reduced pressure to obtain the crude product, which was purified by silica gel column chromatography (PE:EA=30:1) to obtain the product (1.3 g, yield: 64.3%).
[0176] Step 2: Synthesis of tert-butyl (8-(isopropylamino)-2-(methylsulfinyl)pyrido[3,4-d]pyrimidin-6-yl)(methyl)carbamate [ka] tert-Butyl (8-(isopropylamino)-2-(methylthio)pyrido[3,4-d]pyrimidin-6-yl)(methyl)carbamate (1.3 g, 3.57 mmol, 1.0 equiv.) was dissolved in DCM (200 mL), and m-chloroperbenzoic acid (mass fraction: 80%, 771 mg, 3.57 mmol, 1.0 equiv.) was added to the reaction solution. After completion of the reaction as detected by TLC, the reaction solution was poured into saturated aqueous potassium carbonate (20 mL), and the layers were separated. The aqueous phase was extracted with DCM (20 mL × 2). The combined organic phases were dried and concentrated to give the product (1.1 g, yield: 81.4%).
[0177] Step 3: Synthesis of tert-butyl (2-amino-8-(isopropylamino)pyrido[3,4-d]pyrimidin-6-yl)(methyl)carbamate [ka] tert-Butyl (8-(isopropylamino)-2-(methylsulfinyl)pyrido[3,4-d]pyrimidin-6-yl)(methyl)carbamate (1.1 g, 2.90 mmol, 1.0 equiv.) was dissolved in a solution of amine in isopropanol (3.5 mol / L, 20 mL), and the reaction solution was reacted at 150° C. for 15 hours. After the reaction was completed as detected by TLC, the reaction solution was concentrated under reduced pressure to obtain the crude product, which was purified by silica gel column chromatography (PE:EA=4:1) to obtain the product (500 mg, yield: 51.9%).
[0178] Step 4: Synthesis of tert-butyl (2-((1S,3R)-3-acetamidocyclohexane-1-carboxamido)-8-(isopropylamino)pyrido[3,4-d]pyrimidin-6-yl)(methyl)carbamate [ka] tert-Butyl (2-amino-8-(isopropylamino)pyrido[3,4-d]pyrimidin-6-yl)(methyl)carbamate (300 mg, 0.90 mmol, 1.0 equiv.) and (1S,3R)-3-acetamidocyclohexane-1-carboxylic acid (183 mg, 0.99 mmol, 1.1 equiv.) were dissolved in pyridine (3 mL). Phosphorus oxychloride (414 mg, 2.70 mmol, 3.0 equiv.) was added to the reaction solution and reacted at room temperature for 5 minutes. When the reaction was complete and starting materials remained as detected by TLC, the reaction solution was poured into EA (20 mL) and washed with aqueous citric acid (30 mL × 3) and saturated aqueous sodium bicarbonate (30 mL). The organic phase was dried and concentrated to give the crude product, which was purified by silica gel column chromatography (MeOH:DCM = 1:40) to give the product (130 mg, yield: 28.9%).
[0179] Step 5: Synthesis of tert-butyl (2-((1S,3R)-3-acetamidocyclohexane-1-carboxamido)-8-(isopropylamino)pyrido[3,4-d]pyrimidin-6-yl)(methyl)carbamate [ka] tert-Butyl (2-((1S,3R)-3-acetamidocyclohexane-1-carboxamido)-8-(isopropylamino)pyrido[3,4-d]pyrimidin-6-yl)(methyl)carbamate (120 mg, 0.24 mmol, 1.0 equiv.) and 2,6-dimethylpyridine (386 mg, 3.60 mmol, 15 equiv.) were dissolved in DCM (2 mL). The reaction solution was cooled to 5° C., and trimethylsilyl trifluoromethanesulfonate (533 mg, 2.40 mmol, 10 equiv.) was added and reacted for 20 minutes. After the reaction was completed as detected by TLC, the reaction solution was poured into water (10 mL) and extracted with DCM (10 mL × 3). The organic phase was washed with saturated aqueous sodium bicarbonate solution (10 mL), dried, and concentrated to give the crude product, which was slurried with MTBE (10 mL) for 1 hour, filtered under reduced pressure, and the filter cake was dried to give the product (56 mg, yield: 58.3%). 1 HNMR(300MHz,DMSO-d6)δ(ppm):10.40(s,1H),8.96(s,1H),7.79-7.76(d,1H),6.42-6.40(d,1H),6.20-6.18(d,1H),5.65(s,1H) ,4.27-4.20(m,1H),3.58-3.55(t,1H),2.74-2.72(d,3H),2.65-2.62(d,1H),1.91-1.87(d,1H),1.79(s,6H),1.25-1.23(d,10H). Molecular formula:C 20 H 29 N7O2Exact mass:399.24 LC-MS(Pos,m / z)=400.46[M+H] + .
[0180] Example 12: Synthesis of (1S,3R)-3-acetamido-N-(8-(isopropylamino)-6-methoxypyrido[3,4-d]pyrimidin-2-yl)cyclohexane-1-carboxamide (Compound 12) [ka]
[0181] Step 1: Synthesis of (1S,3R)-3-aminocyclohexane-1-carboxylic acid hydrochloride [ka] (1S,3R)-3-((tert-butoxycarbonyl)amino)cyclohexane-1-carboxylic acid (2.0 g, 8.22 mmol, 1.0 equiv.) was dissolved in EA (20 mL). A solution of hydrogen chloride in 1,4-dioxane (4 mol / L, 10 mL) was added to the reaction solution, and the mixture was allowed to react at room temperature for 17 hours. The reaction solution was filtered under reduced pressure to give the product (1.476 g, yield: 100%).
[0182] Step 2: Synthesis of (1S,3R)-3-acetamidocyclohexane-1-carboxylic acid [ka] (1S,3R)-3-((tert-Butoxycarbonyl)amino)cyclohexane-1-carboxylic acid (1.476 g, 8.22 mmol, 1.0 equiv.) and triethylamine (2.49 g, 24.65 mmol, 3.0 equiv.) were dissolved in DCM (20 mL) and isopropanol (2 mL). Acetic anhydride (1.26 mg, 12.32 mmol, 1.5 equiv.) was added to the reaction solution and the reaction was allowed to proceed at room temperature for 16 min. After the reaction was complete as detected by LC-MS, the reaction solution was concentrated under reduced pressure to give the crude product, which was dissolved in water (20 mL) and adjusted to pH 1 with hydrochloric acid. The aqueous phase was extracted with EA (20 mL × 3). The organic phase was dried and concentrated to give the crude product, which was slurried with (PE:MTBE=1:1, 30 mL), filtered under reduced pressure, and the filter cake was dried to give the product (1.3 g, yield: 85.56%).
[0183] Step 3: Synthesis of N-isopropyl-6-methoxy-2-(methylthiopyrido[3,4-d]pyrimidin-8-amine [ka] 6-Chloro-N-isopropyl-2-(methylthio)pyrido[3,4-d]pyrimidin-8-amine (1.5 g, 5.58 mmol, 1.0 equiv.), 2-di-tert-butylphosphino-2',4',6'-triisopropylbiphenyl (476 mg, 1.12 mmol, 0.2 equiv.), cesium carbonate (3.64 g, 11.16 mmol, 2.0 equiv.), and allylpalladium chloride dimer (205 mg, 0.56 mmol, 0.1 equiv.) were dispersed in methanol (5 mL) and 1,4-dioxane (15 mL), and the reaction solution was reacted at 80°C for 0.5 hours under a nitrogen atmosphere. After the reaction was completed as detected by TLC, the reaction solution was concentrated under reduced pressure to obtain the crude product, which was purified by silica gel column chromatography (PE:EA=20:1) to obtain the product (1.2 g, yield: 81.6%).
[0184] Step 4: Synthesis of N-isopropyl-6-methoxy-2-(methylsulfinyl)pyrido[3,4-d]pyrimidin-8-amine [ka] 8-(Isopropylamino)-2-(methylthio)pyrido[3,4-d]pyrimidine-6-carbonitrile (1.2 g, 4.54 mmol, 1.0 equiv.) was dissolved in DCM (200 mL), and m-chloroperbenzoic acid (mass fraction: 80%, 979 mg, 4.54 mmol, 1.0 equiv.) was added to the reaction solution. After the reaction was complete as detected by TLC, the reaction solution was poured into saturated aqueous sodium carbonate (20 mL) and extracted with DCM (15 mL x 2). The organic phase was dried and concentrated to give the crude product, which was purified by silica gel column chromatography (MeOH:DCM = 1:80) to give the product (1.0 g, yield: 78.7%).
[0185] Process 5:N 8 Synthesis of 1,2-isopropyl-6-methoxypyrido[3,4-d]pyrimidine-2,8-diamine [ka] N-isopropyl-6-methoxy-2-(methylsulfinyl)pyrido[3,4-d]pyrimidin-8-amine (1.0 g, 3.56 mmol, 1.0 equiv.) was dissolved in a solution of amine in isopropanol (3.5 mol / L, 20 mL), and the reaction solution was reacted at 150° C. for 17 hours. After the reaction was completed as detected by TLC, the reaction solution was cooled to room temperature and concentrated under reduced pressure to obtain the crude product, which was purified by silica gel column chromatography (PE:EA=3:1) to obtain the product (200 mg, yield: 24.0%).
[0186] Step 6: Synthesis of (1S,3R)-3-acetamido-N-(8-(isopropylamino)-6-methoxypyrido[3,4-d]pyrimidin-2-yl)cyclohexane-1-carboxamide [ka] N 8 1-Isopropyl-6-methoxypyrido[3,4-d]pyrimidine-2,8-diamine (100 mg, 0.42 mmol, 1.0 equiv.) and (1S,3R)-3-acetamidocyclohexane-1-carboxylic acid (85 mg, 0.46 mmol, 1.1 equiv.) were dissolved in pyridine (2 mL). Phosphorus oxychloride (193 mg, 1.26 mmol, 3.0 equiv.) was added to the reaction solution and the mixture was allowed to react at room temperature for 5 min. When the product was detected by TLC, the reaction solution was poured into EA (20 mL). The EA phase was washed with aqueous citric acid (20 mL × 3) and saturated aqueous sodium bicarbonate (20 mL). The organic phase was dried and concentrated to give the crude product, which was slurried with EA (3 mL) and filtered under reduced pressure to give the product (20 mg, yield: 11.9%). 1 HNMR(300MHz,DMSO-d6)δ(ppm):10.63(s,1H),9.18(s,1H),7.79-7.77(d,1H),6.71-6.68(d,1H),6.21(s,1H), 4.26-4.22(t,1H),3.83(s,3H),3.58(s,2H),2.70(s,1H),1.93-1.89(d,1H),1.77(s,5H),1.29-1.27(d,10H). Molecular formula:C 20 H 28 N6O3Exact mass:400.22 LC-MS(Pos,m / z)=401.20[M+H] + .
[0187] Example 13: Synthesis of (1S,3R)-3-acetamido-N-(7-ethynyl-5-(isopropylamino)-2,6-naphthyridin-3-yl)cyclohexane-1-carboxamide (Compound 13) [ka]
[0188] Process: [ka]
[0189] Step 1: Synthesis of 7-((diphenylmethylene)amino)-1-(isopropylamino)-2,6-naphthyridine-3-carbaldehyde [ka] 7-Chloro-1-(isopropylamino)-2,6-naphthyridine-3-carbaldehyde (249.7 mg, 1 mmol, 1.0 equiv.), diphenylmethanimine (217.5 mg, 1.2 mmol, 1.2 equiv.), Pd(dba) (91.5 mg, 0.1 mmol, 0.1 equiv.), BINAP (124.5 mg, 0.2 mmol, 0.2 equiv.), and cesium carbonate (814.5 mg, 5.27 mmol, 2.5 equiv.) were added to 1,4-dioxane (10 mL). The mixture was reacted in a sealed tube under a nitrogen atmosphere at 120 °C for 18 h. When no raw materials remained as detected by TLC, ethyl acetate (20 mL) was added to the reaction solution, stirred for 5 minutes, and filtered. The filter cake was washed with ethyl acetate, and the filtrate was concentrated under reduced pressure to obtain the crude product, which was purified by silica gel column chromatography (EA:PE = 1:20 to 1:6) to obtain the product (340 mg, yield: 86.1%).
[0190] Step 2: Synthesis of 7-amino-1-(isopropylamino)-2,6-naphthyridine-3-carbaldehyde [ka] 7-((Diphenylmethylene)amino)-1-(isopropylamino)-2,6-naphthyridine-3-carbaldehyde (340 mg, 0.86 mmol, 1.0 equiv.) was dissolved in THF (5 mL). Aqueous citric acid solution (mass fraction: 10%, 5 mL) was added to the reaction solution, and the mixture was allowed to react at room temperature for 17 hours. When no starting material remained as detected by TLC, saturated aqueous sodium carbonate solution (20 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (30 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. This was purified by silica gel column chromatography (EA:PE = 1:10 to 1:1) to obtain the product (123 mg, yield: 62.1%).
[0191] Step 3: Synthesis of (1S,3R)-3-acetamido-N-(7-formyl-5-(isopropylamino)-2,6-naphthyridin-3-yl)cyclohexane-1-carboxamide [ka] (1S,3R)-3-Acetamidocyclohexane-1-carboxylic acid (101.8 mg, 0.55 mmol, 1.1 equiv.) was dissolved in DCM (5 mL). The reaction solution was cooled to 0-5 °C in an ice-water bath, and 1-chloro-N,N,2-trimethylprop-1-en-1-amine (mass fraction: 95%, 105.4 mg, 0.75 mmol, 1.5 equiv.) was added. The reaction was allowed to proceed at 0-5 °C for 1.5 h. A solution of 7-amino-1-(isopropylamino)-2,6-naphthyridine-3-carbaldehyde (115 mg, 0.50 mmol, 1.0 equiv.) and pyridine (118.6 mg, 1.50 mmol, 3.0 equiv.) in THF (10 mL) was added, and the mixture was incubated at room temperature for 17 h. When a small amount of starting material remained as detected by TLC, saturated aqueous sodium carbonate (20 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (20 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the product (150 mg, yield: 75.5%).
[0192] Step 4: Synthesis of (1S,3R)-3-acetamido-N-(7-ethynyl-5-(isopropylamino)-2,6-naphthyridin-3-yl)cyclohexane-1-carboxamide [ka] (1S,3R)-3-Acetamido-N-(7-formyl-5-(isopropylamino)-2,6-naphthyridin-3-yl)cyclohexane-1-carboxamide (150 mg, 0.37 mmol, 1.0 equiv.), dimethyl (1-diazo-2-oxopropyl)phosphonate (107.6 mg, 0.56 mmol, 1.5 equiv.), and potassium carbonate (153.2 mg, 1.11 mmol, 3.0 equiv.) were dissolved in methanol (5 mL) and the reaction mixture was incubated at room temperature for 2 h. When no starting material remained as detected by TLC, saturated aqueous sodium carbonate (20 mL) was added to the reaction mixture and extracted with ethyl acetate (30 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the crude product, which was purified by preparative thin-layer chromatography (MeOH:DCM=1:20) to give the product (41 mg, yield: 28.2%). 1 HNMR(400MHz,CD3OD)δ(ppm):8.83(s,1H),8.44(s,1H),7.19(s,1H),4.52-4.46(m,1H),3.80-3.75(m,1H ),3.50(m,1H),2.69-2.63(m,1H),2.13-2.10(m,1H),1.95(s,3H),1.54-1.48(m,4H),1.35-1.31(m,9H). Molecular formula:C 22 H 27 N5O2Exact mass:393.22 LC-MS(Pos,m / z)=394.27[M+H] + .
[0193] Example 14: Synthesis of (1S,3R)-3-acetamido-N-(7-(2-hydroxyethyl)-5-(isopropylamino)-2,6-naphthyridin-3-yl)cyclohexane-1-carboxamide (Compound 14) [ka]
[0194] Process: [ka]
[0195] Step 1: Synthesis of (E)-7-chloro-N-isopropyl-3-(2-methoxyvinyl)-2,6-naphthyridin-1-amine [ka] (Methoxymethyl)triphenylphosphonium (4.9 g, 14.4 mmol, 3.0 equiv.) was added to anhydrous THF (30 mL). The reaction solution was cooled to 0 °C in an ice-water bath under a nitrogen atmosphere, and a solution of potassium tert-butoxide (1.6 g, 14.4 mmol, 3.0 equiv.) in anhydrous THF (5 mL) was added dropwise. After the addition, the reaction was allowed to proceed at 0 °C–5 °C for 40 min. 7-Chloro-1-(isopropylamino)-2,6-naphthyridine-3-carbaldehyde (1.2 g, 4.8 mmol, 1.0 equiv.) in anhydrous THF (10 mL) was added dropwise and the mixture was incubated at room temperature for 48 h. When the starting material remained as detected by TLC, water (30 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (50 mL × 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the crude product, which was purified by silica gel column chromatography (EA:PE = 1:50 to 1:30) to give the product (710 mg, yield: 54.6%).
[0196] Step 2: Synthesis of 2-(7-chloro-1-(isopropylamino)-2,6-naphthyridin-3-yl)acetaldehyde [ka] (E)-7-Chloro-N-isopropyl-3-(2-methoxyvinyl)-2,6-naphthyridin-1-amine (710 mg, 2.56 mmol, 1.0 equiv.) was dissolved in THF (12 mL). Aqueous hydrochloric acid (4 mol / L, 3 mL) was added to the reaction solution, which was then heated to 80°C and reacted for 1 hour. When no starting material remained as detected by TLC, the reaction solution was concentrated under reduced pressure, water (20 mL) was added, the pH was adjusted to approximately 8 with sodium carbonate, and the mixture was extracted with ethyl acetate (20 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the product, which was used in the next step according to theoretical amount.
[0197] Step 3: Synthesis of 2-(7-chloro-1-(isopropylamino)-2,6-naphthyridin-3-yl)ethanol [ka] 2-(7-Chloro-1-(isopropylamino)-2,6-naphthyridin-3-yl)acetaldehyde (2.56 mmol, 1.0 equiv.) was dissolved in absolute ethanol (10 mL). Sodium triacetoxyborohydride (968.4 mg, 25.6 mmol, 10 equiv.) was added to the reaction solution, and the mixture was allowed to react at room temperature for 0.5 hours. When no starting material remained as detected by TLC, the reaction solution was concentrated under reduced pressure, water (10 mL) was added, and the mixture was extracted with ethyl acetate (20 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the crude product, which was purified by silica gel column chromatography (EA:PE = 1:10-1:3) to give the product (353 mg, 2-step yield: 54.6%).
[0198] Step 4: Synthesis of 2-(7-((diphenylmethylene)amino)-1-(isopropylamino)-2,6-naphthyridin-3-yl)ethan-1-ol [ka] 2-(7-Chloro-1-(isopropylamino)-2,6-naphthyridin-3-yl)ethanol (350 mg, 1.32 mmol, 1.0 equiv.), diphenylmethanimine (286.3 mg, 1.58 mmol, 1.2 equiv.), Pd(dba) (119 mg, 0.13 mmol, 0.1 equiv.), BINAP (161.9 mg, 0.26 mmol, 0.2 equiv.), and cesium carbonate (1.1 g, 3.3 mmol, 2.5 equiv.) were added to 1,4-dioxane (15 mL). The mixture was reacted in a sealed tube under a nitrogen atmosphere at 120 °C for 16 h. When no starting material remained as detected by TLC, ethyl acetate (20 mL) was added to the reaction solution, stirred for 20 minutes, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product, which was purified by silica gel column chromatography (EA:PE = 1:10 to 1:3) to obtain the product (457 mg, yield: 84.3%).
[0199] Step 5: Synthesis of 2-(7-amino-1-(isopropylamino)-2,6-naphthyridin-3-yl)ethan-1-ol [ka] 2-(7-((diphenylmethylene)amino)-1-(isopropylamino)-2,6-naphthyridin-3-yl)ethan-1-ol (457 mg, 1.11 mmol, 1.0 equiv.) was dissolved in THF (10 mL). A citric acid solution (mass fraction: 10%, 10 mL) was added to the reaction solution, and the mixture was allowed to react at room temperature for 1 hour. When no starting material remained as detected by TLC, water (10 mL) was added to the reaction solution, the pH was adjusted to approximately 8 with sodium carbonate, and the mixture was extracted with ethyl acetate (20 mL × 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was slurried with methyl tert-butyl ether (5 mL) for 5 minutes, filtered, and the filter cake was dried to obtain the product (191 mg, yield: 69.8%).
[0200] Step 6: 3-(2-((tert-butyldimethylsilyl)oxy)ethyl)-N 1Synthesis of 1,7-isopropyl-2,6-naphthyridine-1,7-diamine [ka] 2-(7-Amino-1-(isopropylamino)-2,6-naphthyridin-3-yl)ethanol (190 mg, 0.77 mmol, 1.0 equiv.) was dissolved in DCM (5 mL). Imidazole (157.3 mg, 2.31 mmol, 3.0 equiv.) and tert-butyldimethylsilyl chloride (173.3 mg, 1.15 mmol, 1.5 equiv.) were added to the reaction solution, and the mixture was allowed to react at room temperature for 15 hours. When approximately 50% of the starting material remained as detected by TLC, the reaction solution was concentrated under reduced pressure, water (20 mL) was added, and the mixture was extracted with ethyl acetate (20 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the crude product, which was purified by preparative thin-layer chromatography (MeOH:DCM = 1:20) to give the product (110 mg, yield: 39.6%).
[0201] Step 7: Synthesis of (1S,3R)-3-acetamido-N-(7-(2-((tert-butyldimethylsilyl)oxy)ethyl)-5-(isopropylamino)-2,6-naphthyridin-3-yl)cyclohexane-1-carboxamide [ka] (1S,3R)-3-acetamidocyclohexane-1-carboxylic acid (66.7 mg, 0.36 mmol, 1.2 equivalents) was dissolved in DCM (3 mL). The reaction solution was cooled to 0-5 °C in an ice-water bath, and 1-chloro-N,N,2-trimethylprop-1-en-1-amine (mass fraction: 95%, 63.3 mg, 0.45 mmol, 1.5 equivalents) was added. The reaction was allowed to proceed at 0-5 °C for 1.5 hours. 3-(2-((tert-butyldimethylsilyl)oxy)ethyl)-N,N,N-tetrahydrofuran (2 mL) was added. 1A solution of 1,7-isopropyl-2,6-naphthyridine-1,7-diamine (110 mg, 0.30 mmol, 1.0 equiv.) and pyridine (71.2 mg, 0.90 mmol, 3.0 equiv.) was added and incubated at room temperature for 18 hours. When 16% of the starting material remained as detected by LC-MS, water (20 mL) was added to the reaction solution, the pH was adjusted to approximately 8 with sodium carbonate, and the mixture was extracted with ethyl acetate (20 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the crude product, which was purified by preparative thin-layer chromatography (MeOH:DCM = 1:20) to give the product (48 mg, yield: 30.3%).
[0202] Step 8: Synthesis of (1S,3R)-3-acetamido-N-(7-(2-hydroxyethyl)-5-(isopropylamino)-2,6-naphthyridin-3-yl)cyclohexane-1-carboxamide [ka] (1S,3R)-3-acetamido-N-(7-(2-((tert-butyldimethylsilyl)oxy)ethyl)-5-(isopropylamino)-2,6-naphthyridin-3-yl)cyclohexane-1-carboxamide (48 mg, 0.09 mmol, 1.0 equiv.) was dissolved in THF (2 mL). A solution of tetra-n-butylammonium fluoride (1 mol / L) in THF (0.18 mL, 0.18 mmol, 2.0 equiv.) was added to the reaction solution and reacted at room temperature for 2 hours. When no starting material remained as detected by TLC, water (10 mL) was added to the reaction solution and extracted with DCM (10 mL × 4). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the crude product, which was purified by preparative thin-layer chromatography (MeOH:DCM = 1:10) to give the product (27 mg, yield: 72.5%). 1HNMR(400MHz,CD3OD)δ(ppm):8.79(s,1H),8.39(s,1H),6.83(s,1H),4.44-4.00(m,1H),3.98-3.81(m,2H),3.79-3.75(m,1H),3.28-3.24(m,2H), 2.95-2.92(m,2H),2.68-2.62(m,1H),2.13-2.10(m,1H),2.00(s,3H),1. 70-1.66(m,1H),1.55-1.49(m,2H),1.47-1.41(m,2H),1.40-1.36(m,6H). Molecular formula:C 22 H 31 N5O2Exact mass:413.24 LC-MS(Pos,m / z)=414.33[M+H] + .
[0203] Example 15: Synthesis of (1S,3R)-3-acetamido-N-(5-(tert-butylamino)-7-cyano-2,6-naphthyridin-3-yl)cyclohexane-1-carboxamide (Compound 15) [ka]
[0204] Step 1: Synthesis of (1S,3R)-3-acetamido-N-(5-(tert-butylamino)-7-cyano-2,6-naphthyridin-3-yl)cyclohexane-1-carboxamide [ka] (1S,3R)-3-acetamido-N-(7-cyano-5-(methylsulfonyl)-2,6-naphthyridin-3-yl)cyclohexane-1-carboxamide (80 mg, 0.19 mmol, 1.0 equiv.) and tert-butylamine (69 mg, 0.95 mmol, 5.0 equiv.) were dissolved in THF (3 mL), and the reaction solution was reacted at 80° C. for 20 hours. After the reaction was completed as detected by TLC, the reaction solution was concentrated under reduced pressure to give the crude product, which was slurried with DCM (2 mL) and filtered under reduced pressure. The filter cake was dried at 50° C. to give the product (25 mg, yield: 31.6%). 1 HNMR(300MHz,DMSO-d6)δ(ppm):10.83(s,1H),9.01(s,1H),8.67(s,1H),7.83-7.81(d,1H),7.70(s,1H),7. 06(s,1H),3.62-3.59(d,1H),2.68(s,1H),1.96-1.92(d,1H),1.79(s,6H),1.52(s,9H),1.34-1.25(m,4H). Molecular formula:C 22 H 28 N6O2Exact mass:408.23 LC-MS(Pos,m / z)=409.22[M+H] + .
[0205] Example 16: Synthesis of (1S,3R)-3-acetamido-N-(7-cyano-5-(cyclopropylamino)-2,6-naphthyridin-3-yl)cyclohexane-1-carboxamide (Compound 16) [ka]
[0206] Step 1: Synthesis of (1S,3R)-3-acetamido-N-(7-cyano-5-(cyclopropylamino)-2,6-naphthyridin-3-yl)cyclohexane-1-carboxamide [ka] (1S,3R)-3-Acetamido-N-(7-cyano-5-(methylsulfonyl)-2,6-naphthyridin-3-yl)cyclohexane-1-carboxamide (80 mg, 0.19 mmol, 1.0 equiv.) and cyclopropylamine (54 mg, 0.95 mmol, 5.0 equiv.) were dissolved in THF (2 mL), and the reaction solution was reacted at 40 °C for 2 h. After the reaction was completed as detected by LC-MS, the reaction mixture was poured into water (5 mL) and extracted with EA (10 mL × 3). The organic phase was dried and concentrated to give the crude product. The crude product was slurried with (MTBE:EA = 1:1), filtered under reduced pressure, and the filter cake was dried at 50 °C to give the product (30 mg, yield: 40.5%). 1 HNMR(300MHz,DMSO-d6)δ(ppm):10.83(s,1H),9.04(s,1H),8.65(s,1H),8.26(s,1H),7.84-7.81(d,1H),7.74(s,1H),3.6(s, 1H),2.93-2.92(d,1H),2.70-2.67(d,1H),1.95-1.92(d,1H),1.79(s,6H),1.33-1.24(t,4H),0.79-0.78(d,2H),0.65(s,2H). Molecular formula:C 21 H 24 N6O2Exact mass:392.20 LC-MS(Pos,m / z)=393.17[M+H] + .
[0207] Example 17: Synthesis of (1S,3R)-3-acetamido-N-(7-cyano-5-((1-methylcyclopropyl)amino)-2,6-naphthyridin-3-yl)cyclohexane-1-carboxamide (Compound 17) [ka]
[0208] Process: [ka] (1S,3R)-3-Acetamido-N-(7-cyano-5-(methylsulfonyl)-2,6-naphthyridin-3-yl)cyclohexane-1-carboxamide (100 mg, 0.24 mmol, 1.0 equiv.) was dissolved in THF (3 mL). DIPEA (248 mg, 1.92 mmol, 8.0 equiv.) and 1-methylcyclopropan-1-amine hydrochloride (129 mg, 1.2 mmol, 5.0 equiv.) were added to the reaction solution, and the mixture was reacted in a sealed tube at 100 °C for 16 h. When no starting material remained as detected by LC-MS, water (20 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (20 mL x 3). The organic phases were combined, washed with hydrochloric acid solution (0.1 mol / L, 30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the crude product, which was purified by preparative thin-layer chromatography (MeOH:DCM=1:20) to give the product (11 mg, yield: 11.2%). 1 HNMR(400MHz,MeOD)δ(ppm):8.95(s,1H),8.49(s,1H),7.57(s,1H),3.80-3.74(m,1H),2.69-2.64 (m,1H),2.12-2.09(m,1H),1.95(m,4H),1.54(m,4H),1.31(m,5H),0.92-0.88(m,2H),0.80(m,2H). Molecular formula:C 22 H 26 N6O2Exact mass:406.21 LC-MS(Pos,m / z)=407.39[M+H] + .
[0209] Example 18: Synthesis of (1S,3R)-3-acetamido-N-(7-cyano-5-((1,5-dihydroxypentan-3-yl)amino)-2,6-naphthyridin-3-yl)cyclohexane-1-carboxamide (Compound 18) [ka]
[0210] Step 1: Synthesis of dimethyl 3-(benzylamino)pentanedioate [ka] Dimethyl (E)-pent-2-enedioate (2.0 g, 12.64 mmol, 1.0 equivalent) and benzylamine (1.42 g, 13.27 mmol, 1.05 equivalent) were dissolved in methanol (200 mL), and the reaction solution was reacted at 65° C. for 17 hours. When the product was detected by LC-MS, the reaction solution was concentrated under reduced pressure to obtain the crude product, which was purified by silica gel column chromatography (PE:EA=2:1) to obtain the product (2.5 g, yield: 74.6%).
[0211] Step 2: Synthesis of 3-(benzylamino)pentane-1,5-diol [ka] Dimethyl 3-(benzylamino)pentanedioate (2.5 g, 9.42 mmol, 1.0 equiv.) was dissolved in THF (50 mL), and lithium aluminum hydride (714 mg, 18.84 mmol, 2.0 equiv.) was added in batches at room temperature. The mixture was allowed to react for 10 minutes. Water (714 mg), 15% aqueous NaOH (714 mg), and water (2.142 g) were added sequentially to the reaction solution. An appropriate amount of anhydrous sodium sulfate was added, and the mixture was stirred for 30 minutes. The mixture was filtered under reduced pressure, and the filtrate was concentrated under reduced pressure to give the product (1.97 g, 100% yield).
[0212] Step 3: Synthesis of 3-aminopentane-1,5-diol [ka] 3-(Benzylamino)pentane-1,5-diol (1.97 g, 9.42 mmol, 1.0 equiv.) and 20% Pd(OH) (200 mg) were dissolved in methanol (20 mL), and the reaction solution was reacted under a hydrogen atmosphere for 16 hours. The reaction solution was filtered, and the filtrate was concentrated under reduced pressure to give the product (1.0 g, yield: 89.2%).
[0213] Step 4: Synthesis of (1S,3R)-3-acetamido-N-(7-cyano-5-((1,5-dihydroxypentan-3-yl)amino)-2,6-naphthyridin-3-yl)cyclohexane-1-carboxamide [ka] (1S,3R)-3-acetamido-N-(7-cyano-5-(methylsulfonyl)-2,6-naphthyridin-3-yl)cyclohexane-1-carboxamide (80 mg, 0.19 mmol, 1.0 equiv.), 3-aminopentane-1,5-diol (226 mg, 1.90 mmol, 10 equiv.), and DIPEA (74 mg, 0.57 mmol, 3.0 equiv.) were dissolved in THF (2 mL), and the reaction solution was reacted at 30 °C for 17 h. When the product was detected by LC-MS, the reaction solution was poured into water (5 mL) and extracted with EA (5 mL × 4). The organic phase was dried and concentrated to give the crude product, which was purified by preparative thin-layer chromatography (MeOH:DCM = 1:10) to give the product (20 mg, yield: 23.2%). 1 HNMR(300MHz,DMSO-d6)δ(ppm):10.84(s,1H),9.02(s,1H),8.68(s,1H),7.86-7.82(m,2H),7.65(s,1H),4 .50-4.46(m,1H),3.48-3.46(d,5H),2.74-2.68(d,1H),2.02-1.93(m,3H),1.79(s,9h),1.34-1.30(d,4H). Molecular formula:C 23 H 30 N6O4Exact mass:454.23 LC-MS(Pos,m / z)=455.32[M+H] + .
[0214] Example 19: Synthesis of (1S,3R)-3-acetamido-N-(7-cyano-5-((R)-3-hydroxypyrrolidin-1-yl)-2,6-naphthyridin-3-yl)cyclohexane-1-carboxamide (Compound 19) [ka]
[0215] Step 1: Synthesis of (1S,3R)-3-acetamido-N-(7-cyano-5-((R)-3-hydroxypyrrolidin-1-yl)-2,6-naphthyridin-3-yl)cyclohexane-1-carboxamide [ka] (1S,3R)-3-acetamido-N-(7-cyano-5-(methylsulfonyl)-2,6-naphthyridin-3-yl)cyclohexane-1-carboxamide (80 mg, 0.19 mmol, 1.0 equiv.), (R)-pyrrolidin-3-ol (24 mg, 0.28 mmol, 1.5 equiv.), and DIPEA (74 mg, 0.57 mmol, 3.0 equiv.) were dissolved in THF (3 mL), and the reaction solution was reacted at room temperature for 2 hours. When the product was detected by TLC and no starting material remained, the reaction solution was concentrated under reduced pressure to give the crude product, which was slurried with DCM (3 mL) and filtered under reduced pressure. The filter cake was dried at 50 °C to give the product (20 mg, yield: 25%). 1 HNMR(300MHz,DMSO-d6)δ(ppm):10.92(s,1H),9.11-9.05(d,2H),7.81-7.76(t,2H),5.09(s,1H),4.44(s,1H),4. 01-3.97(t,2H),3.83-3.78(t,1H),3.36-3.58(m,2H),2.68(s,1H),2.05(s,3H),1.79(s,6H),1.34-1.24(m,4H). Molecular formula:C 22 H 26 N6O3Exact mass:422.21 LC-MS(Pos,m / z)=423.22[M+H] + .
[0216] Example 20: Synthesis of (1S,3R)-3-acetamido-N-(5-((R)-3-aminopyrrolidin-1-yl)-7-cyano-2,6-naphthyridin-3-yl)cyclohexane-1-carboxamide (Compound 20) [ka]
[0217] Step 1: Synthesis of tert-butyl ((R)-1-(7-((1S,3R)-3-acetamidocyclohexane-1-carboxamido)-3-cyano-2,6-naphthyridin-1-yl)pyrrolidin-3-yl)carbamate [ka] (1S,3R)-3-acetamido-N-(7-cyano-5-(methylsulfonyl)-2,6-naphthyridin-3-yl)cyclohexane-1-carboxamide (180 mg, 0.43 mmol, 1.0 equiv.), tert-butyl (R)-pyrrolidin-3-ylcarbamate (119 mg, 0.64 mmol, 1.5 equiv.), and DIPEA (167 mg, 1.29 mmol, 3.0 equiv.) were dissolved in THF (5 mL), and the reaction solution was reacted at 40° C. for 2 hours. After the reaction was completed as detected by LC-MS, the reaction solution was concentrated under reduced pressure to give the crude product, which was slurried with EA (5 mL) and filtered under reduced pressure. The filter cake was dried to give the product (100 mg, yield: 44.6%).
[0218] Step 2: Synthesis of (1S,3R)-3-acetamido-N-(5-((R)-3-aminopyrrolidin-1-yl)-7-cyano-2,6-naphthyridin-3-yl)cyclohexane-1-carboxamide [ka] tert-Butyl ((R)-1-(7-((1S,3R)-3-acetamidocyclohexane-1-carboxamido)-3-cyano-2,6-naphthyridin-1-yl)pyrrolidin-3-yl)carbamate (100 mg, 0.19 mmol, 1.0 equiv) was dissolved in EA (2 mL). A solution of hydrogen chloride in 1,4-dioxane (4 mol / L, 1 mL) was added dropwise to the reaction solution, and the reaction was allowed to proceed at room temperature for 17 hours. The mixture was then filtered under reduced pressure. The filter cake was dissolved in water (3 mL) and the pH was adjusted to 9 by adding saturated aqueous sodium bicarbonate solution with stirring. A white solid precipitated. The mixture was filtered under reduced pressure and dried at 60° C. to give the product (20 mg, yield: 25%). 1 HNMR(300MHz,DMSO-d6)δ(ppm):10.90(s,1H),9.11-9.04(d,2H),7.81-7.74(t,2H),3.95(s, 2H), 3.60-3.54(d,2H),2.74-2.67(d,2H),2.04-1.92(m,4H),1.79(s,6H),1.33-1.25(t,6H). Molecular formula:C 22 H 27 N7O2Exact mass:421.22 LC-MS(Pos,m / z)=422.20[M+H] + .
[0219] Example 21: Synthesis of (1S,3R)-3-acetamido-N-(7-cyano-5-morpholino-2,6-naphthyridin-3-yl)cyclohexane-1-carboxamide (Compound 21) [ka]
[0220] Step 1: Synthesis of 2-chloro-5-(3,3-diethoxyprop-1-yn-1-yl)isonicotinaldehyde [ka] 5-Bromo-2-chloroisonicotinaldehyde (30 g, 136.08 mmol, 1.0 equivalent), cuprous iodide (2.59 g, 13.6 mmol, 0.1 equivalent), bis(triphenylphosphine)palladium(II) chloride (7.64 g, 10.89 mmol, 0.08 equivalent), and DIPEA (52.76 g, 408.24 mmol, 3.0 equivalent) were dispersed in THF (300 mL), the reaction solution was cooled to 0 ° C to 5 ° C, and reacted for 30 minutes, after which 3,3-diethoxyprop-1-yne (20.93 g, 163.30 mmol, 1.2 equivalent) was added dropwise, and the reaction was continued at 0 ° C to 5 ° C for 20 hours. After the reaction was completed as detected by TLC, the reaction solution was poured into water (300 mL) and extracted with EA (300 mL × 2). The organic phase was dried and concentrated to give the crude product, which was purified by silica gel column chromatography (PE:EA = 20:1) to give the product (23 g, yield: 63.1%).
[0221] Step 2: Synthesis of (E)-2-chloro-5-(3,3-diethoxyprop-1-yn-1-yl)isonicotinaldehyde oxime [ka] 2-Chloro-5-(3,3-diethoxyprop-1-yn-1-yl)isonicotinaldehyde (23 g, 85.91 mmol, 1.0 equiv.), sodium acetate (10.6 g, 128.86 mmol, 1.5 equiv.), and hydroxylamine hydrochloride (8.95 g, 128.86 mmol, 1.5 equiv.) were dispersed in ethanol (230 mL), and the reaction solution was reacted at room temperature for 1 hour. After the reaction was completed as detected by TLC, the reaction solution was concentrated under reduced pressure to obtain the crude product. The crude product was added to water (100 mL) and extracted with water (100 mL x 2). The organic phase was dried and concentrated to obtain the product (24.29 g, yield: 100%).
[0222] Step 3: Synthesis of 7-chloro-3-(diethoxymethyl)-2,6-naphthyridine 2-oxide [ka] (E)-2-Chloro-5-(3,3-diethoxyprop-1-yn-1-yl)isonicotinaldehyde oxime (24.29 g, 85.91 mmol, 1.0 equiv.) was dissolved in DCM (250 mL). Silver trifluoromethanesulfonate (2.21 g, 8.6 mmol, 0.1 equiv.) was added to the reaction solution and the mixture was allowed to react at room temperature for 16 hours. After completion of the reaction as detected by TLC, the reaction solution was filtered, and the filtrate was used directly in the next step.
[0223] Step 4: Synthesis of 1,7-dichloro-3-(diethoxymethyl)-2,6-naphthyridine [ka] DIPEA (33.31 g, 257.73 mmol, 3.0 equiv.) was added to the solution of 1,7-dichloro-3-(diethoxymethyl)-2,6-naphthyridine (85.91 mmol, 1.0 equiv.) obtained in the previous step, and oxalyl chloride (16.1 g, 126.86 mmol, 1.5 equiv.) was added dropwise at room temperature and allowed to react for 20 min. After completion of the reaction as detected by TLC, the reaction solution was concentrated under reduced pressure to give the crude product, which was purified by silica gel column chromatography (PE:EA = 10:1) to give the product (12.4 g, yield: 47.9%).
[0224] Step 5: Synthesis of 7-chloro-3-(diethoxymethyl)-1-(methylthio-2,6-naphthyridine [ka] 1,7-Dichloro-3-(diethoxymethyl)-2,6-naphthyridine (12 g, 39.84 mmol, 1.0 equiv.) was dissolved in THF (150 mL). A 20% aqueous solution of sodium thiomethoxide (15.36 g, 43.82 mmol, 1.0 equiv.) was added to the reaction solution, and the mixture was allowed to react for 16 hours. After completion of the reaction as detected by TLC, the reaction solution was used in the next step without further treatment.
[0225] Step 6: Synthesis of 7-chloro-1-(methylthio)-2,6-naphthyridine-3-carbaldehyde [ka] Water (20 mL) and TFA (20 mL) were added to 7-chloro-1-(methylthio)-2,6-naphthyridine-3-carbaldehyde (12.46 g, 39.84 mmol, 1.0 equivalent) obtained in the previous step, and the mixture was allowed to react at room temperature for 3 hours. After the reaction was completed as detected by TLC, the reaction solution was concentrated under reduced pressure to a residue of 80 mL, which was then filtered, and the filter cake was dried to obtain the product (10 g, yield: 100%).
[0226] Step 7: Synthesis of (E)-7-chloro-1-(methylthio-2,6-naphthyridine-3-carbaldehyde oxime [ka] 7-Chloro-1-(methylthio)-2,6-naphthyridine-3-carbaldehyde (10 g, 41.89 mmol, 1.0 equiv.), sodium acetate (5.2 g, 64.34 mmol, 1.5 equiv.), and hydroxylamine hydrochloride (4.47 g, 64.34 mmol, 1.5 equiv.) were dispersed in ethanol (200 mL), and the reaction solution was reacted at room temperature for 1 hour. After the reaction was completed as detected by TLC, the reaction solution was concentrated under reduced pressure to give the crude product, which was then slurried with water (100 mL), filtered under reduced pressure, and the filter cake was dried to give the product (10.62 g, 100% yield).
[0227] Step 8: Synthesis of 7-chloro-1-(methylthio)-2,6-naphthyridine-3-carbonitrile [ka] (E)-7-Chloro-1-(methylthio)-2,6-naphthyridine-3-carbaldehyde oxime (10.62 g, 41.89 mmol, 1.0 equivalent) was dissolved in acetic anhydride (200 mL), and the reaction solution was reacted at 120° C. for 143 hours. After the reaction was completed as detected by LC-MS, the reaction solution was concentrated under reduced pressure to give the crude product, which was slurried with (PE:MTBE=1:1, 150 mL), filtered under reduced pressure, and the filter cake was dried to give the product (6.1 g, yield: 61.8%).
[0228] Step 9: Synthesis of 7-((diphenylmethylene)amino)-1-(methylthio-2,6-naphthyridine-3-carbonitrile [ka] 7-Chloro-1-(methylthio)-2,6-naphthyridine-3-carbonitrile (3 g, 12.73 mmol, 1.0 equiv.), diphenylmethanimine (2.77 g, 15.27 mmol, 1.2 equiv.), Pd(dba) (1.16 g, 1.27 mmol, 0.1 equiv.), BINAP (1.58 g, 2.54 mmol, 0.2 equiv.), and cesium carbonate (8.30 g, 25.46 mmol, 2.0 equiv.) were dispersed in 1,4-dioxane (60 mL). The mixture was reacted at 100 °C for 19 h under a nitrogen atmosphere. After completion of the reaction as detected by TLC, the reaction solution was concentrated under reduced pressure to give the crude product, which was purified by silica gel column chromatography (PE:EA = 10:1) to give the product (3.2 g, yield: 66.1%).
[0229] Step 10: Synthesis of 7-amino-1-(methylthio)-2,6-naphthyridine-3-carbonitrile [ka] 7-((diphenylmethylene)amino)-1-(methylthio)-2,6-naphthyridine-3-carbonitrile (3.2 g, 8.41 mmol, 1.0 equiv.) and citric acid (4.85 g, 25.23 mmol, 3.0 equiv.) were dissolved in a mixture of THF (32 mL) and HO (16 mL), and the reaction mixture was reacted at room temperature for 40 minutes. After the reaction was completed as detected by TLC, the reaction mixture was concentrated under reduced pressure to give the crude product, which was then slurried in water (30 mL) and filtered under reduced pressure. The filter cake was slurried in (PE:EA = 5:1, 60 mL) and filtered under reduced pressure. The resulting filter cake was dried to give the product (1.7 g, yield: 93.4%).
[0230] Step 11: Synthesis of (1S,3R)-3-acetamido-N-(7-cyano-5-(methylthio-2,6-naphthyridin-3-yl)cyclohexane-1-carboxamide [ka] 7-Amino-1-(methylthio)-2,6-naphthyridine-3-carbonitrile (1.7 g, 7.86 mmol, 1.0 equiv.) and (1S,3R)-3-acetamidocyclohexane-1-carboxylic acid (2.18 g, 11.79 mmol, 1.5 equiv.) were dissolved in pyridine (20 mL). Phosphorus oxychloride (3.62 g, 23.58 mmol, 3.0 equiv.) was added to the reaction solution and the mixture was allowed to react at room temperature for 10 min. After completion of the reaction as detected by TLC, the reaction solution was poured into ice water (50 mL) and extracted with EA (30 mL × 3). The organic phase was concentrated under reduced pressure to give the crude product, which was purified by silica gel column chromatography (MeOH:DCM = 1:50) to give the product (1.4 g, yield: 46.5%).
[0231] Step 12: Synthesis of (1S,3R)-3-acetamido-N-(7-cyano-5-(methylsulfonyl)-2,6-naphthyridin-3-yl)cyclohexane-1-carboxamide [ka] (1S,3R)-3-acetamido-N-(7-cyano-5-(methylthio)-2,6-naphthyridin-3-yl)cyclohexane-1-carboxamide (1.4 g, 0.40 mmol, 1.0 equiv.) was dissolved in DCM (30 mL). m-Chloroperbenzoic acid (mass fraction: 80%, 1.65 g, 7.66 mmol, 2.1 equiv.) was added to the reaction solution and reacted at room temperature for 0.5 h. After the reaction was completed as detected by TLC, the reaction solution was poured into water (20 mL), an appropriate amount of potassium carbonate was added, and the mixture was extracted with DCM (20 mL × 3). The organic phase was dried and concentrated to give the crude product, which was slurried with MTBE (20 mL), filtered under reduced pressure, and the filter cake was dried to give the product (1.36 g, yield: 90%).
[0232] Step 13: Synthesis of (1S,3R)-3-acetamido-N-(7-cyano-5-morpholino-2,6-naphthyridin-3-yl)cyclohexane-1-carboxamide [ka] (1S,3R)-3-Acetamido-N-(7-cyano-5-(methylsulfonyl)-2,6-naphthyridin-3-yl)cyclohexane-1-carboxamide (80 mg, 0.19 mmol, 1.0 equiv.) and morpholine (50 mg, 0.57 mmol, 3.0 equiv.) were dissolved in THF (2 mL), and the reaction solution was reacted at 40 °C for 19 h. After the reaction was completed as detected by LC-MS, the reaction solution was poured into water (5 mL) and extracted with EA (5 mL × 3). The organic phase was dried and concentrated to give the crude product, which was purified by preparative thin-layer chromatography (MeOH:DCM = 1:15) to give the product (25 mg, yield: 31.2%). 1 HNMR(300MHz,DMSO-d6)δ(ppm):11.03(s,1H),9.22(s,1H),8.72(s,1H),8.18(s,1H),7.82-7.79(d,1H),3.85 (s,4H),3.59-3.58(d,1H),3.46(s,4H),2.73-2.69(d,1H),1.95-1.92(d,1H),1.79(s,6H),1.40-1.25(m,4H). Molecular formula:C 22 H 26 N6O3Exact mass:422.21 LC-MS(Pos,m / z)=423.21[M+H] + .
[0233] Example 22: Synthesis of (1S,3R)-3-acetamido-N-(7-cyano-5-((R)-3-hydroxy-3-methylpyrrolidin-1-yl)-2,6-naphthyridin-3-yl)cyclohexane-1-carboxamide (Compound 22) [ka]
[0234] Process: [ka] (1S,3R)-3-acetamido-N-(7-cyano-5-(methylsulfonyl)-2,6-naphthyridin-3-yl)cyclohexane-1-carboxamide (200 mg, 0.48 mmol, 1.0 equiv.) was dissolved in THF (3 mL). DIPEA (248 mg, 1.92 mmol, 4.0 equiv.) and (R)-3-methylpyrrolidin-3-ol (97.3 mg, 0.48 mmol, 1.0 equiv.) were added to the reaction solution, and the mixture was allowed to react at room temperature for 16 hours. When no starting material remained as detected by LC-MS, the reaction solution was cooled to room temperature, water (20 mL) was added, and the mixture was extracted with ethyl acetate (20 mL x 3). The organic phases were combined, washed with hydrochloric acid solution (0.1 mol / L, 30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give a crude material, which was purified by preparative thin-layer chromatography (MeOH:DCM=1:20) to give a crude product (150 mg). The crude product was dissolved in water (10 mL) and extracted with ethyl acetate (10 mL). The organic phase was dried over anhydrous magnesium sulfate, filtered, and the filtrate was concentrated under reduced pressure, slurried with a mixture of ethyl acetate and methyl tert-butyl ether (5 mL) at 1:10, filtered, and the filter cake was dried to give the product (42 mg, yield: 20%). 1HNMR(400MHz,DMSO)δ(ppm):10.92(s,1H),9.08-9.05(s,2H),7.83-7.80(s,1H),7.75(s,1H),4.92(s,1H),4.11-4.02(m,1H),3 .84-3.74(m,2H),3.67-3.58(m,2H),2.68(m,1H),1.96-1.93(m,3H),1.79(s,6H),1.39(m,3H),1.36-1.31(m,3H),1.11(m,1H). Molecular formula:C 23 H 28 N6O3Exact mass:436.22 LC-MS(Pos,m / z)=436.52[M+H] + .
[0235] Example 23: Synthesis of (1S,3R)-3-acetamido-N-(7-cyano-5-(4,4-difluoropiperidin-1-yl)-2,6-naphthyridin-3-yl)cyclohexane-1-carboxamide (Compound 23) [ka]
[0236] Process: [ka]
[0237] Step 1: Synthesis of (7-chloro-1-(4,4-difluoropiperidin-1-yl)-2,6-naphthyridin-3-yl)methyl acetate [ka] (1,7-Dichloro-2,6-naphthyridin-3-yl)methyl acetate (2.0 g, 7.38 mmol, 1.0 equiv.), 4,4-difluoropiperidine (2.68 g, 22.14 mmol, 3.0 equiv.), and DIPEA (2.86 g, 22.14 mmol, 3.0 equiv.) were dissolved in anhydrous THF (20 mL), and the reaction solution was reacted in a sealed tube at 100 °C for 4 h. When no starting material remained as detected by TLC, the reaction solution was concentrated under reduced pressure, water (30 mL) was added, and the mixture was extracted with ethyl acetate (30 mL × 2). The organic phases were combined, washed with hydrochloric acid solution (0.5 mol / L, 50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the product, which was used in the next step according to theoretical amount.
[0238] Step 2: Synthesis of (7-chloro-1-(4,4-difluoropiperidin-1-yl)-2,6-naphthyridin-3-yl)methanol [ka] (7-Chloro-1-(4,4-difluoropiperidin-1-yl)-2,6-naphthyridin-3-yl)methyl acetate (7.38 mmol, 1.0 equiv.) and lithium hydroxide monohydrate (928.7 mg, 22.14 mmol, 3.0 equiv.) were dissolved in a mixture of THF (20 mL), methanol (10 mL), and water (10 mL), and the reaction mixture was allowed to react at room temperature for 16 hours. When no starting material remained as detected by TLC, the reaction mixture was concentrated under reduced pressure, water (20 mL) was added, and the mixture was extracted with ethyl acetate (20 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated. The filtrate was concentrated under reduced pressure to give the product (2.2 g, yield: 95.6%).
[0239] Step 3: Synthesis of 7-chloro-1-(4,4-difluoropiperidin-1-yl)-2,6-naphthyridine-3-carbaldehyde [ka] (7-Chloro-1-(4,4-difluoropiperidin-1-yl)-2,6-naphthyridin-3-yl)methanol (2.2 g, 7.0 mmol, 1.0 equiv.) was dissolved in DMSO (30 mL). IBX (2.9 g, 10.5 mmol, 1.5 equiv.) was added to the reaction solution and reacted at room temperature for 2 hours. When no starting material remained as detected by TLC, the reaction solution was poured into water (200 mL), filtered, and the filter cake was retained and slurried with 2-methyltetrahydrofuran (50 mL × 2) and filtered. The organic phases were combined, and the filtrate was extracted with ethyl acetate (50 mL × 2). The combined organic phase was washed with saturated aqueous sodium carbonate (100 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the product (2.1 g, yield: 96.3%).
[0240] Step 4: Synthesis of 7-chloro-1-(4,4-difluoropiperidin-1-yl)-2,6-naphthyridine-3-carbonitrile [ka] 7-Chloro-1-(4,4-difluoropiperidin-1-yl)-2,6-naphthyridine-3-carbaldehyde (1 g, 3.2 mmol, 1.0 equiv.) was dissolved in THF (30 mL). Aqueous ammonia (mass fraction: 28%, 30 mL) and iodine (974.6 mg, 3.84 mmol, 1.2 equiv.) were added to the reaction solution, and the mixture was allowed to react at room temperature for 18 hours. When no starting material remained as detected by TLC, water (30 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (50 mL x 2). The combined organic phases were washed with aqueous sodium thiosulfate (mass fraction: 10%, 50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the crude product, which was purified by silica gel column chromatography (EA:PE = 1:10 to 1:5) to give the product (970 mg, yield: 98.2%).
[0241] Step 5: Synthesis of 1-(4,4-difluoropiperidin-1-yl)-7-((diphenylmethylene)amino)-2,6-naphthyridine-3-carbonitrile [ka] 7-Chloro-1-(4,4-difluoropiperidin-1-yl)-2,6-naphthyridine-3-carbonitrile (600 mg, 1.94 mmol, 1.0 equiv.), diphenylmethanimine (422.3 mg, 2.33 mmol, 1.2 equiv.), Pd(dba) (177.6 mg, 0.19 mmol, 0.1 equiv.), BINAP (236.6 mg, 0.38 mmol, 0.2 equiv.), and cesium carbonate (1.58 g, 4.85 mmol, 2.5 equiv.) were added to 1,4-dioxane (30 mL). The mixture was reacted in a sealed tube at 120 °C for 18 h under a nitrogen atmosphere. When no starting material remained as detected by TLC, water (50 mL) was added to the reaction solution and extracted with ethyl acetate (50 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the crude product, which was purified by silica gel column chromatography (EA:PE=1:15 to 1:10) to give the product (546 mg, yield: 62%).
[0242] Step 6: Synthesis of 7-amino-1-(4,4-difluoropiperidin-1-yl)-2,6-naphthyridine-3-carbonitrile [ka] 1-(4,4-Difluoropiperidin-1-yl)-7-((diphenylmethylene)amino)-2,6-naphthyridine-3-carbonitrile (546 mg, 1.20 mmol, 1.0 equiv.) was dissolved in THF (10 mL). A citric acid solution (mass fraction: 10%, 10 mL) was added to the reaction solution, and the mixture was allowed to react at room temperature for 1 hour. When no starting material remained as detected by TLC, water (30 mL) was added to the reaction solution, the pH was adjusted to approximately 8 with sodium carbonate, and the mixture was extracted with ethyl acetate (30 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product, which was purified by silica gel column chromatography (EA:PE = 1:5 - EA = 100%) to obtain the product (268 mg, yield: 77.2%).
[0243] Step 7: Synthesis of (1S,3R)-3-acetamido-N-(7-cyano-5-(4,4-difluoropiperidin-1-yl)-2,6-naphthyridin-3-yl)cyclohexane-1-carboxamide [ka] 7-Amino-1-(4,4-difluoropiperidin-1-yl)-2,6-naphthyridine-3-carbonitrile (268 mg, 0.93 mmol, 1.0 equiv.) and (1S,3R)-3-acetamidocyclohexane-1-carboxylic acid (254.4 mg, 1.39 mmol, 1.5 equiv.) were dissolved in pyridine (3 mL). Phosphorus oxychloride (213.1 mg, 1.39 mmol, 1.5 equiv.) was added dropwise to the reaction solution and the mixture was allowed to react at room temperature for 1 hour. When no starting material remained as detected by TLC, water (30 mL) was added to the reaction solution and the mixture was extracted with ethyl acetate (30 mL x 3). The organic phases were combined, washed successively with hydrochloric acid solution (0.2 mol / L, 50 mL × 2) and aqueous sodium carbonate solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the crude product, which was purified by preparative thin-layer chromatography (MeOH:DCM = 1:20) to give the product (175 mg, yield: 41.2%). 1 HNMR(300MHz,CD3OD)δ(ppm):9.12(s,1H),8.78(s,1H),7.96(s,1H),3.81-3.76(m,1H),3.69-3.67(m,4H), 2.71-2.65(m,1H),2.32-2.25(m,4H),2.13-2.10(m,1H),1.95(m,5H),1.53-1.44(m,3H),1.36-1.33(m,2H). Molecular formula:C 23 H 26 F2N6O2Exact mass:456.21 LC-MS(Pos,m / z)=457.50[M+H] + .
[0244] Example 24: Synthesis of (S)-1-acetyl-N-(7-cyano-5-(isopropylamino)-2,6-naphthyridin-3-yl)piperidine-3-carboxamide (Compound 24) [ka]
[0245] Step 1: Synthesis of tert-butyl (S)-3-((7-cyano-5-(isopropylamino)-2,6-naphthyridin-3-yl)carbamoyl)piperidine-1-carboxylate [ka] (S)-1-(tert-butoxycarbonyl)piperidine-3-carboxylic acid (110 mg, 0.48 mmol, 1.1 equiv.) was dissolved in DCM (3 mL). The reaction solution was cooled to 0-5 °C in an ice-water bath, and 1-chloro-N,N,2-trimethylprop-1-en-1-amine (mass fraction: 95%, 92.5 mg, 0.66 mmol, 1.5 equiv.) was added. The reaction was allowed to proceed at 0-5 °C for 1.5 h. A solution of 7-amino-1-(isopropylamino)-2,6-naphthyridine-3-carbonitrile (100 mg, 0.44 mmol, 1.0 equiv.) and pyridine (104.3 mg, 1.32 mmol, 3.0 equiv.) in THF (3 mL) was added, and the mixture was incubated at room temperature for 22 h. When no starting material remained as detected by TLC, water (20 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (20 mL × 2). The combined organic phases were washed with water (20 mL) and concentrated under reduced pressure to give the crude product, which was purified by silica gel column chromatography (EA:PE = 1:3) to give the product (120 mg, yield: 62.2%).
[0246] Step 2: Synthesis of (S)—N-(7-cyano-5-(isopropylamino)-2,6-naphthyridin-3-yl)piperidine-3-carboxamide [ka] tert-Butyl (S)-3-((7-cyano-5-(isopropylamino)-2,6-naphthyridin-3-yl)carbamoyl)piperidine-1-carboxylate (120 mg, 0.27 mmol, 1.0 equiv.) was dissolved in DCM (4 mL). A solution of hydrogen chloride (4 mol / L) in dioxane (2 mL) was added dropwise to the reaction solution, and the mixture was allowed to react at room temperature for 21 hours. When no starting material remained as detected by TLC, the reaction solution was concentrated under reduced pressure, water (20 mL) was added, and back-extracted with ethyl acetate (20 mL × 2). The aqueous phase was retained, adjusted to pH 8 with sodium bicarbonate, and extracted with ethyl acetate (20 mL × 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the product (68 mg, yield: 74.4%).
[0247] Step 3: Synthesis of (S)-1-acetyl-N-(7-cyano-5-(isopropylamino)-2,6-naphthyridin-3-yl)piperidine-3-carboxamide [ka] (S)—N-(7-cyano-5-(isopropylamino)-2,6-naphthyridin-3-yl)piperidine-3-carboxamide (68 mg, 0.20 mmol, 1.0 equiv.) was dissolved in DCM (3 mL). DIPEA (77.5 mg, 0.60 mmol, 3.0 equiv.) and acetic anhydride (30.7 mg, 0.30 mmol, 1.5 equiv.) were added to the reaction solution, and the mixture was allowed to react at room temperature for 3 hours. When no starting material remained as detected by TLC, the reaction solution was poured into water (20 mL) and extracted with ethyl acetate (20 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give the crude product, which was purified by preparative thin-layer chromatography (MeOH:DCM = 1:20) to give the product (45 mg, yield: 59.2%). 1HNMR(300MHz,CD3OD)δ(ppm):8.94(s,1H),8.54(s,1H),7.51(s,1H),4.42-4.25(m,2H),4.05-3.89(m,1H),3.56-3.48(m ,1H),3.28-3.19(m,1H),3.08-2.92(m,1H),2.83-2.63(m,1H),2.19-2.16(m,4H),1.94-1.82(m,2H),1.38-1.35(m,6H). Molecular formula:C 20 H 24 N6O2Exact mass:380.20 LC-MS(Pos,m / z)=381.25[M+H] + .
[0248] Example 25: Synthesis of (1S,3S)-3-acetamido-N-(7-cyano-5-(isopropylamino)-2,6-naphthyridin-3-yl)cyclohexane-1-carboxamide (Compound 25) [ka]
[0249] Step: Synthesis of (1S,3S)-3-acetamido-N-(7-cyano-5-(isopropylamino)-2,6-naphthyridin-3-yl)cyclohexane-1-carboxamide [ka] (1S,3S)-3-Acetamido-N-(7-cyano-5-(isopropylamino)-2,6-naphthyridin-3-yl)cyclohexane-1-carboxamide (73 mg, 0.21 mmol, 1.0 equiv.) was dissolved in DCM (3 mL). DIPEA (81.3 mg, 0.63 mmol, 3.0 equiv.) and acetic anhydride (32 mg, 0.31 mmol, 1.5 equiv.) were added to the reaction solution and reacted at room temperature for 1 hour. When no starting material remained as detected by TLC, water (20 mL) was added to the reaction solution and extracted with ethyl acetate (20 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give the crude product, which was purified by preparative thin-layer chromatography (MeOH:DCM = 1:20) to give the product (68 mg, yield: 82.1%). 1 HNMR(400MHz,CD3OD)δ(ppm):8.97(s,1H),8.64(s,1H),7.58(s,1H),4.50-4.43(m,1H),4.25-4.2 4(m,1H),2.89-2.87(m,1H),2.00(m,4H),1.90-1.71(m,6H),1.63-1.60(m,1H),1.39-1.37(m,6H). Molecular formula:C 21 H 26 N6O2Exact mass:394.21 LC-MS(Pos,m / z)=395.18[M+H] + .
[0250] Example 26: Synthesis of (1S,3R)-3-amino-N-(7-cyano-5-(isopropylamino)-2,6-naphthyridin-3-yl)cyclohexane-1-carboxamide (Compound 26) [ka]
[0251] Step 1: Synthesis of tert-butyl ((1R,3S)-3-((7-cyano-5-(isopropylamino)-2,6-naphthyridin-3-yl)carbamoyl)cyclohexyl)carbamate [ka] 7-Amino-1-(isopropylamino)-2,6-naphthyridine-3-carbonitrile (120 mg, 0.53 mmol, 1.0 equiv.) and (1S,3R)-3-((tert-butoxycarbonyl)amino)cyclohexane-1-carboxylic acid (128.9 mg, 0.53 mmol, 1.0 equiv.) were dissolved in pyridine (1 mL). Phosphorus oxychloride (162.4 mg, 1.06 mmol, 2 equiv.) was added to the reaction solution and the mixture was allowed to react at room temperature for 0.5 to 1 h. When no starting material remained as detected by TLC, water (20 mL) was added to the reaction solution and the mixture was extracted with ethyl acetate (20 mL x 3). The organic phases were combined, washed with hydrochloric acid (1 mol / L, 30 mL × 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the crude product, which was purified by silica gel column chromatography (EA:PE = 1:10 to 1:2) to give the product (115 mg, yield: 47.9%).
[0252] Step 2: Synthesis of (1S,3R)-3-amino-N-(7-cyano-5-(isopropylamino)-2,6-naphthyridin-3-yl)cyclohexane-1-carboxamide [ka] tert-Butyl ((1R,3S)-3-((7-cyano-5-(isopropylamino)-2,6-naphthyridin-3-yl)carbamoyl)cyclohexyl)carbamate (115 mg, 0.25 mmol, 1.0 equiv.) was dissolved in DCM (6 mL). A solution of hydrogen chloride (4 mol / L) in dioxane (4 mL) was added dropwise to the reaction solution, and the reaction was allowed to proceed at room temperature for 18 hours. When no starting material remained as detected by LC-MS, the reaction solution was filtered, and the filter cake was dissolved in water (5 mL) and lyophilized to give the product (86 mg, yield: 88.4%). 1HNMR(400MHz,CD3OD)δ(ppm):9.07(s,1H),8.80(s,1H),7.78(s,1H),4.46-4.40(m,1H),3.33-3.24(m,1H),2.7 9-2.73(m,1H),2.28-2.25(m,1H),2.12-2.02(m,4H),1.78-1.53(m,1H),1.51-1.43(m,2H),1.41-1.40(m,6H). Molecular formula:C 19 H 25 N6ClO Exact mass:388.18 LC-MS(Pos,m / z)=353.17[M+H] + .
[0253] Example 27: Synthesis of (1S,3S)-3-amino-N-(7-cyano-5-(isopropylamino)-2,6-naphthyridin-3-yl)cyclohexane-1-carboxamide (Compound 27) [ka]
[0254] Step 1: Synthesis of tert-butyl ((1S,3S)-3-((7-cyano-5-(isopropylamino)-2,6-naphthyridin-3-yl)carbamoyl)cyclohexyl)carbamate [ka] (1S,3S)-3-((tert-butoxycarbonyl)amino)cyclohexane-1-carboxylic acid (267.6 mg, 1.10 mmol, 1.05 equiv.) was dissolved in DCM (5 mL). The reaction solution was cooled to 0-5 °C in an ice-water bath, and 1-chloro-N,N,2-trimethylprop-1-en-1-amine (mass fraction: 95%, 220.8 mg, 1.57 mmol, 1.5 equiv.) was added. The reaction was allowed to proceed at 0-5 °C for 1.5 h. A solution of 7-amino-1-(isopropylamino)-2,6-naphthyridine-3-carbonitrile (240 mg, 1.05 mmol, 1.0 equiv.) and pyridine (249.1 mg, 3.15 mmol, 3.0 equiv.) in THF (10 mL) was added, and the mixture was incubated at room temperature for 18 h. The supernatant was poured into water (20 mL) and extracted with ethyl acetate (20 mL × 2). The organic phases were combined, washed with hydrochloric acid solution (1 mol / L, 20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the crude product, which was purified by silica gel column chromatography (EA:PE = 1:5 to 1:2) to give the product (269 mg, yield: 56.6%).
[0255] Step 2: Synthesis of (1S,3S)-3-amino-N-(7-cyano-5-(isopropylamino)-2,6-naphthyridin-3-yl)cyclohexane-1-carboxamide [ka] tert-Butyl ((1S,3S)-3-((7-cyano-5-(isopropylamino)-2,6-naphthyridin-3-yl)carbamoyl)cyclohexyl)carbamate (269 mg, 0.59 mmol, 1.0 equiv.) was dissolved in DCM (8 mL). A solution of hydrogen chloride (4 mol / L) in dioxane (4 mL) was added dropwise to the reaction solution, and the mixture was allowed to react at room temperature for 3 hours. When no starting material remained as detected by LC-MS, the reaction solution was filtered, and a portion of the filter cake (68 mg) was dissolved in water (10 mL), adjusted to pH 8 with sodium bicarbonate, and extracted with ethyl acetate (20 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the crude product, which was purified by preparative thin-layer chromatography (MeOH:DCM = 1:20) to give the product (31 mg, yield: 30.9%). 1 HNMR(400MHz,CD3OD)δ(ppm):8.94(s,1H),8.54(s,1H),7.51(s,1H),4.52-4.46(m,1H),3.51-3.46(m,1H),3.0 0-2.96(m,1H),2.12-2.11(m,1H),1.87-1.82(m,2H),1.76-1.72(m,3H),1.52-1.47(m,2H),1.37-1.35(m,6H). Molecular formula:C 19 H 24 N6O Exact mass:352.20 LC-MS(Pos,m / z)=353.17[M+H] + .
[0256] Example 28: Synthesis of 7-(((1S,3S)-3-aminocyclopentyl)amino)-1-(isopropylamino)-2,6-naphthyridine-3-carbonitrile (Compound 28) [ka]
[0257] Process: [ka]
[0258] Step 1: Synthesis of 7-chloro-1-(isopropylamino)-2,6-naphthyridine-3-carbonitrile [ka] 7-Chloro-1-(isopropylamino)-2,6-naphthyridine-3-carbaldehyde (2.5 g, 10 mmol, 1.0 equiv.) was dissolved in THF (50 mL). Aqueous ammonia (mass fraction: 28%, 50 mL) and iodine (2.54 g, 10 mmol, 1.0 equiv.) were added to the reaction solution, and the mixture was allowed to react at room temperature for 4 hours. When no starting material remained as detected by TLC, water (100 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (100 mL x 4). The combined organic phases were washed with aqueous sodium thiosulfate (mass fraction: 10%, 200 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the crude product. This was purified by silica gel column chromatography (EA:PE = 1:10 to 1:5) to give the product (1.8 g, yield: 73.2%).
[0259] Step 2: Synthesis of tert-butyl ((1S,3S)-3-((6-cyano-8-(isopropylamino)pyrido[3,4-d]pyrimidin-2-yl)amino)cyclopentyl)carbamate [ka] 7-Chloro-1-(isopropylamino)-2,6-naphthyridine-3-carbonitrile (100 mg, 0.41 mmol, 1.0 equiv.), tert-butyl ((1S,3S)-3-aminocyclopentyl)carbamate (98.1 mg, 0.49 mmol, 1.2 equiv.), Pd(dba) (36.6 mg, 0.04 mmol, 0.1 equiv.), BINAP (49.8 mg, 0.08 mmol, 0.2 equiv.), and cesium carbonate (335.6 mg, 1.03 mmol, 2.5 equiv.) were added to 1,4-dioxane (6 mL). The mixture was reacted in a sealed tube under a nitrogen atmosphere at 120 °C for 22 h. When no raw materials remained as detected by TLC, the reaction solution was filtered, and the filtrate was concentrated under reduced pressure to obtain a crude product, which was purified by silica gel column chromatography (MeOH:DCM = 1:150 to 1:100) to obtain the product (86 mg, yield: 50.9%).
[0260] Step 3: Synthesis of 7-(((1S,3S)-3-aminocyclopentyl)amino)-1-(isopropylamino)-2,6-naphthyridine-3-carbonitrile [ka] tert-Butyl ((1S,3S)-3-((6-cyano-8-(isopropylamino)pyrido[3,4-d]pyrimidin-2-yl)amino)cyclopentyl)carbamate (85 mg, 0.20 mmol, 1.0 equiv.) was dissolved in DCM (4 mL). A solution of hydrogen chloride (4 mol / L) in dioxane (3 mL) was added dropwise to the reaction solution, and the reaction was allowed to proceed at room temperature for 4 hours. When no starting material remained as detected by LC-MS, the reaction solution was filtered, and the filter cake was dissolved in water (10 mL) and back-extracted with ethyl acetate (5 mL × 2). The aqueous phase was retained, adjusted to pH 8 with sodium bicarbonate, and extracted with ethyl acetate (10 mL × 4). The organic phases were combined, dried over anhydrous magnesium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give a crude product, which was dissolved in methanol (2 mL), added with hydrogen chloride ethanol solution (10 mol / L, 0.1 mL), stirred for 5 minutes, added with water (10 mL), and lyophilized to give the product (42.5 mg, yield: 61.3%). 1 HNMR(300MHz,CD3OD)δ(ppm):8.83(s,1H),7.73(s,1H),7.68(s,1H),4.68-4.65(m,1H),4.44-4.37(m ,1H),3.90-3.87(m,1H),2.44-2.35(m,2H),2.31-2.24(m,2H),2.21-2.16(m,2H),1.85-1.83(m,6H). Molecular formula:C 17 H 23 N6Cl Exact mass:346.17 LC-MS(Pos,m / z)=311.17[M+H] + .
[0261] Example 29: Synthesis of 7-(((1S,3R)-3-aminocyclopentyl)amino)-1-(isopropylamino)-2,6-naphthyridine-3-carbonitrile (Compound 29) [ka]
[0262] Step 1: Synthesis of tert-butyl ((1R,3S)-3-((7-cyano-5-(isopropylamino)-2,6-naphthyridin-3-yl)amino)cyclopentyl)carbamate [ka] 7-Chloro-1-(isopropylamino)-2,6-naphthyridine-3-carbonitrile (130 mg, 0.53 mmol, 1.0 equiv.), tert-butyl ((1R,3S)-3-aminocyclopentyl)carbamate (128.2 mg, 0.64 mmol, 1.2 equiv.), Pd(dba) (73.2 mg, 0.08 mmol, 0.15 equiv.), BINAP (99.6 mg, 0.16 mmol, 0.3 equiv.), and cesium carbonate (433.3 mg, 1.33 mmol, 2.5 equiv.) were added to 1,4-dioxane (10 mL). The mixture was reacted in a sealed tube under a nitrogen atmosphere at 120 °C for 17 h. When no starting material remained as detected by TLC, the obtained crude material was purified by silica gel column chromatography (MeOH:DCM=1:100) to give a crude product (145 mg), which was then purified by preparative thin layer chromatography (MeOH:DCM=1:20) to give the product (86 mg, yield: 39.5%).
[0263] Step 2: Synthesis of 7-(((1S,3R)-3-aminocyclopentyl)amino)-1-(isopropylamino)-2,6-naphthyridine-3-carbonitrile [ka] tert-Butyl ((1R,3S)-3-((7-cyano-5-(isopropylamino)-2,6-naphthyridin-3-yl)amino)cyclopentyl)carbamate (86 mg, 0.21 mmol, 1.0 equiv.) was dissolved in DCM (4 mL). A solution of hydrogen chloride (4 mol / L) in dioxane (4 mL) was added dropwise to the reaction solution, and the reaction was allowed to proceed at room temperature for 2 hours. When no starting material remained as detected by LC-MS, water (10 mL) was added to the reaction solution, and the mixture was back-extracted with ethyl acetate (10 mL × 3). The aqueous phase was retained, adjusted to pH 8 with sodium bicarbonate, and extracted with dichloromethane (10 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the crude product, which was purified by preparative thin-layer chromatography (MeOH:DCM=1:20) to give the product (27 mg, yield: 41.4%). 1 HNMR(400MHz,CD3OD)δ(ppm):8.67(s,1H),7.37(s,1H),6.93(s,1H),4.48-4.45(m,1H),4.33-4.23(m,1H),3.5 8-3.54(m,1H),2.67-2.58(m,1H),2.23-2.06(m,1H),1.81-1.73(m,2H),1.53-1.45(m,2H),1.35-1.33(m,6H). Molecular formula:C 17 H 22 N6Exact mass:310.19 LC-MS(Pos,m / z)=311.27[M+H] + .
[0264] Example 30: Synthesis of 7-(((1R,3R)-3-aminocyclopentyl)amino)-1-(isopropylamino)-2,6-naphthyridine-3-carbonitrile (Compound 30) [ka]
[0265] Step 1: Synthesis of tert-butyl ((1R,3R)-3-((7-cyano-5-(isopropylamino)-2,6-naphthyridin-3-yl)amino)cyclopentyl)carbamate [ka] 7-Chloro-1-(isopropylamino)-2,6-naphthyridine-3-carbonitrile (150 mg, 0.61 mmol, 1.0 equiv.), tert-butyl ((1R,3R)-3-aminocyclopentyl)carbamate (146.2 mg, 0.73 mmol, 1.2 equiv.), Pd(dba) (82.4 mg, 0.09 mmol, 0.15 equiv.), BINAP (112 mg, 0.18 mmol, 0.3 equiv.), and cesium carbonate (498.5 mg, 1.53 mmol, 2.5 equiv.) were added to 1,4-dioxane (10 mL). The mixture was reacted in a sealed tube under a nitrogen atmosphere at 120 °C for 17 h. When no starting material remained as detected by TLC, the obtained crude material was purified by silica gel column chromatography (MeOH:DCM=1:100) to give a crude product (215 mg), which was then purified by preparative thin layer chromatography (MeOH:DCM=1:20) to give the product (88 mg, yield: 35.1%).
[0266] Step 2: Synthesis of 7-(((1R,3R)-3-aminocyclopentyl)amino)-1-(isopropylamino)-2,6-naphthyridine-3-carbonitrile [ka] tert-Butyl ((1R,3R)-3-((7-cyano-5-(isopropylamino)-2,6-naphthyridin-3-yl)amino)cyclopentyl)carbamate (88 mg, 0.21 mmol, 1.0 equiv.) was dissolved in DCM (3 mL). Hydrogen chloride ethanol solution (10 mol / L, 3 mL) was added dropwise to the reaction solution, and the mixture was allowed to react at room temperature for 2 hours. When no starting material remained as detected by LC-MS, water (10 mL) was added to the reaction solution, and the mixture was back-extracted with ethyl acetate (10 mL × 3). The aqueous phase was retained, adjusted to pH 8 with sodium bicarbonate, and extracted with dichloromethane (10 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the crude product, which was purified by preparative thin-layer chromatography (MeOH:DCM = 1:10) to give the product (34 mg, yield: 52.1%). 1HNMR(400MHz,CD3OD)δ(ppm):8.68(s,1H),7.37(s,1H),6.90(s,1H),4.47-4.42(m,2H),3.7 7-3.72(m,1H),2.39-2.28(m,2H),2.10-2.06(m,2H),1.74-1.63(m,2H),1.35-1.33(m,6H). Molecular formula:C 17 H 22 N6Exact mass:310.19 LC-MS(Pos,m / z)=311.37[M+H] + .
[0267] Example 31: Synthesis of (S)-1-(isopropylamino)-7-(pyrrolidin-3-ylamino)-2,6-naphthyridine-3-carbonitrile (Compound 31) [ka]
[0268] Step 1: Synthesis of tert-butyl (S)-3-((7-cyano-5-(isopropylamino)-2,6-naphthyridin-3-yl)amino)pyrrolidine-1-carboxylate [ka] 7-Chloro-1-(isopropylamino)-2,6-naphthyridine-3-carbonitrile (150 mg, 0.61 mmol, 1.0 equiv.), tert-butyl (S)-3-aminopyrrolidine-1-carboxylate (136 mg, 0.73 mmol, 1.2 equiv.), Pd(dba) (82.4 mg, 0.09 mmol, 0.15 equiv.), BINAP (112 mg, 0.18 mmol, 0.3 equiv.), and cesium carbonate (498.5 mg, 1.53 mmol, 2.5 equiv.) were added to 1,4-dioxane (10 mL). The mixture was reacted in a sealed tube under a nitrogen atmosphere at 120 °C for 17 h. When no starting material remained as detected by TLC, the obtained crude material was purified by silica gel column chromatography (MeOH:DCM=1:100) to give a crude product (146 mg), which was then purified by preparative thin layer chromatography (MeOH:DCM=1:30) to give the product (83 mg, yield: 34.3%).
[0269] Step 2: Synthesis of (S)-1-(isopropylamino)-7-(pyrrolidin-3-ylamino)-2,6-naphthyridine-3-carbonitrile [ka] tert-Butyl (S)-3-((7-cyano-5-(isopropylamino)-2,6-naphthyridin-3-yl)amino)pyrrolidine-1-carboxylate (83 mg, 0.21 mmol, 1.0 equiv.) was dissolved in DCM (3 mL). Hydrogen chloride in ethanol (10 mol / L, 3 mL) was added dropwise to the reaction solution, and the mixture was allowed to react at room temperature for 1 hour. When no starting material remained as detected by LC-MS, water (10 mL) was added to the reaction solution, and the mixture was back-extracted with ethyl acetate (10 mL × 2). The aqueous phase was retained, the pH was adjusted to approximately 8-9 with sodium bicarbonate, and the mixture was extracted with dichloromethane (10 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the crude product, which was purified by preparative thin-layer chromatography (MeOH:DCM = 1:10) to give the product (18 mg, yield: 28.9%). 1HNMR(400MHz,DMSO+D2O)δ(ppm):8.67(s,1H),7.44(s,1H),6.86(s,1H),4.31-4.21(m,2H),2 .20-2.14(m,1H),1.93-1.86(m,2H),1.69-1.60(m,1H),1.51-1.35(m,2H),1.22-1.20(m,6H). Molecular formula:C 16 H 20 N6Exact mass:296.17 LC-MS(Pos,m / z)=297.22[M+H] + .
[0270] Example 32: Synthesis of 1-(isopropylamino)-7-(((1S,3R)-3-(methylamino)cyclopentyl)amino)-2,6-naphthyridine-3-carbonitrile (Compound 32) [ka]
[0271] Process: [ka]
[0272] Step 1: Synthesis of tert-butyl ((1R,3S)-3-(tritylamino)cyclopentyl)carbamate [ka] tert-Butyl ((1R,3S)-3-aminocyclopentyl)carbamate (550 mg, 2.75 mmol, 1.0 equiv.), triphenylchloromethane (1.15 g, 4.13 mmol, 1.5 equiv.), and triethylamine (556.5 mg, 5.5 mmol, 2.0 equiv.) were dissolved in DCM (20 mL) and the reaction mixture was allowed to react at room temperature for 3 h. When no starting material remained as detected by TLC, water (30 mL) was added to the reaction mixture and extracted with ethyl acetate (30 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give the crude product, which was purified by silica gel column chromatography (EA:PE = 1:20 to 1:15) to give the product (1.16 g, yield: 96.6%).
[0273] Process 2: (1R,3S)-N 1 -methyl-N 3 Synthesis of -tritylcyclopentane-1,3-diamine [ka] tert-Butyl ((1R,3S)-3-(tritylamino)cyclopentyl)carbamate (1.1 g, 2.48 mmol, 1.0 equiv.) was dissolved in anhydrous THF (25 mL). Lithium aluminum hydride (376.5 mg, 9.92 mmol, 4.0 equiv.) was added in batches to the reaction solution, which was then heated to reflux for 1 h. When no starting material remained as detected by TLC, water (376.5 mg) was added to the reaction solution and stirred for 2 min. Sodium hydroxide solution (10% by mass, 376.5 mg) was added and stirred for 2 min. Water (1.1 g) was then added and stirred for 5 min. Ethyl acetate (50 mL) was added, the mixture was dried over anhydrous magnesium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the product (884.1 mg, 100% yield).
[0274] Step 3: Synthesis of tert-butyl methyl ((1R,3S)-3-(tritylamino)cyclopentyl)carbamate [ka] (1R,3S)-N1 -methyl-N 3 Tritylcyclopentane-1,3-diamine (880 mg, 2.47 mmol, 1.0 equiv.) was dissolved in DCM (10 mL). Triethylamine (499.9 mg, 4.94 mmol, 2.0 equiv.) and di-tert-butyl dicarbonate (646 mg, 2.96 mmol, 1.2 equiv.) were added to the reaction solution and reacted at room temperature for 15 h. When no starting material remained as detected by TLC, water (20 mL) was added to the reaction solution and extracted with ethyl acetate (30 mL x 2). The combined organic phase was washed sequentially with aqueous citric acid (5% by mass, 30 mL) and water (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the product (1.1 g, 100% yield).
[0275] Step 4: Synthesis of tert-butyl ((1R,3S)-3-aminocyclopentyl)(methyl)carbamate [ka] tert-Butyl methyl ((1R,3S)-3-(tritylamino)cyclopentyl)carbamate (1.1 g, 2.47 mmol, 1.0 equiv.) was dissolved in 1% (v / v) TFA / DCM (50 mL), and the reaction solution was reacted at room temperature for 18 h. When a new spot was detected by TLC, water (20 mL) was added to the reaction solution, and the pH was adjusted to approximately 9 with sodium hydroxide. The layers were separated, the organic phase was retained, and the aqueous phase was extracted with DCM (30 mL). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the crude product, which was purified by silica gel column chromatography (MeOH:DCM = 1:20) to give the product (234 mg, yield: 44.2%).
[0276] Step 5: Synthesis of tert-butyl ((1R,3S)-3-((7-cyano-5-(isopropylamino)-2,6-naphthyridin-3-yl)amino)cyclopentyl)(methyl)carbamate [ka] 7-Chloro-1-(isopropylamino)-2,6-naphthyridine-3-carbonitrile (200 mg, 0.81 mmol, 1.0 equiv.), tert-butyl ((1R,3S)-3-aminocyclopentyl)(methyl)carbamate (225 mg, 1.05 mmol, 1.2 equiv.), Pd(dba) (109.9 mg, 0.12 mmol, 0.15 equiv.), BINAP (149.4 mg, 0.24 mmol, 0.3 equiv.), and cesium carbonate (658.1 mg, 2.02 mmol, 2.5 equiv.) were added to 1,4-dioxane (20 mL). The mixture was reacted in a sealed tube under a nitrogen atmosphere at 100 °C for 15 h. When no starting material remained as detected by TLC, water (30 mL) was added to the reaction solution and extracted with ethyl acetate (30 mL × 2). The organic phases were combined, washed with hydrochloric acid solution (0.2 mol / L, 30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the crude product, which was purified by preparative thin-layer chromatography (EA:PE = 1:2) to give the product (163 mg, yield: 47.4%).
[0277] Step 6: Synthesis of 1-(isopropylamino)-7-(((1S,3R)-3-(methylamino)cyclopentyl)amino)-2,6-naphthyridine-3-carbonitrile [ka] tert-Butyl ((1R,3S)-3-((7-cyano-5-(isopropylamino)-2,6-naphthyridin-3-yl)amino)cyclopentyl)(methyl)carbamate (163 mg, 0.38 mmol, 1.0 equiv.) was dissolved in DCM (3 mL). Hydrogen chloride ethanol solution (10 mol / L, 3 mL) was added dropwise to the reaction solution, and the mixture was allowed to react at room temperature for 1 hour. When no starting material remained as detected by TLC, water (20 mL) was added to the reaction solution, and the mixture was back-extracted with DCM (20 mL × 2). The aqueous phase was retained, the pH was adjusted to approximately 8 with sodium bicarbonate, and the mixture was extracted with DCM (30 mL × 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the crude product, which was purified by preparative thin-layer chromatography (MeOH:DCM = 1:10) to give the product (90 mg, yield: 72.9%). 1 HNMR(400MHz,CD3OD)δ(ppm):8.86(s,1H),7.36(s,1H),6.94(s,1H),4.49-4.43(m,1H),4.29-4.25(m,1H),3.46-3.4 3(m,1H),2.70-2.63(m,1H),2.61(s,3H),2.14-2.12(m,2H),1.86-1.79(m,2H),1.61-1.53(m,1H),1.35-1.33(m,6H). Molecular formula:C 18 H 24 N6Exact mass:324.21 LC-MS(Pos,m / z)=325.35[M+H] + .
[0278] Example 33: Synthesis of 7-(((1S,3S)-3-hydroxycyclopentyl)amino)-1-(isopropylamino)-2,6-naphthyridine-3-carbonitrile (Compound 33) [ka]
[0279] Process: [ka] 7-Chloro-1-(isopropylamino)-2,6-naphthyridine-3-carbonitrile (150 mg, 0.61 mmol, 1.0 equiv.), (1S,3S)-3-aminocyclopentan-1-ol hydrochloride (100.5 mg, 0.73 mmol, 1.2 equiv.), Pd(dba) (82.4 mg, 0.09 mmol, 0.15 equiv.), BINAP (112 mg, 0.18 mmol, 0.3 equiv.), and cesium carbonate (697.2 mg, 2.14 mmol, 3.5 equiv.) were added to 1,4-dioxane (10 mL). The mixture was reacted in a sealed tube under a nitrogen atmosphere at 120 °C for 18 h. When no starting material remained as detected by TLC, the obtained crude material was purified by silica gel column chromatography (MeOH:DCM=1:100) to give a crude product (150 mg), which was then purified twice by preparative thin layer chromatography (MeOH:DCM=1:20) to give the product (34 mg, yield: 17.9%). 1 HNMR(400MHz,DMSO)δ(ppm):8.70(s,1H),7.47(s,1H),7.40-7.37(d,1H),7.09-7.07(d,1H),6.93(s,1H),4.61-4.60(m ,1H),4.39-4.25(m,3H),2.27-2.18(m,1H),2.17-1.88(m,2H),1.75-1.67(m,1H),1.54-1.38(m,2H),1.27-1.25(m,6H). Molecular formula:C 17 H 21 N5O Exact mass:311.17 LC-MS(Pos,m / z)=312.27[M+H] + .
[0280] Example 34: Synthesis of 7-(((1S,3S)-3-aminocyclopentyl)amino)-1-(tert-butylamino)-2,6-naphthyridine-3-carbonitrile (Compound 34) [ka]
[0281] Step 1: Synthesis of 1-(tert-butylamino)-7-chloro-2,6-naphthyridine-3-carbonitrile [ka] 7-Chloro-1-(methylsulfonyl)-2,6-naphthyridine-3-carbonitrile (400 mg, 1.49 mmol, 1.0 equiv.) and tert-butylamine (545 mg, 7.45 mmol, 5.0 equiv.) were dissolved in THF (10 mL), and the reaction solution was reacted at 80 °C for 3 h. After the reaction was completed as detected by TLC, the reaction solution was poured into water (10 mL) and extracted with EA (10 mL × 3). The organic phase was dried and concentrated to give the product (360 mg, yield: 92.7%).
[0282] Step 2: Synthesis of tert-butyl ((1S,3S)-3-((5-(tert-butylamino)-7-cyano-2,6-naphthyridin-3-yl)amino)cyclopentyl)carbamate [ka] 1-(tert-butylamino)-7-chloro-2,6-naphthyridine-3-carbonitrile (180 mg, 0.69 mmol, 1.0 equiv.), tert-butyl ((1S,3S)-3-aminocyclopentyl)carbamate (166 mg, 0.83 mmol, 1.2 equiv.), Pd(dba) (63 mg, 0.069 mmol, 0.1 equiv.), BINAP (86 mg, 0.138 mmol, 0.2 equiv.), and cesium carbonate (450 mg, 1.38 mmol, 2.0 equiv.) were dispersed in 1,4-dioxane (5 mL), and the reaction solution was reacted at 100 °C for 22 hours under a nitrogen atmosphere. After the reaction was completed as detected by TLC, the reaction solution was concentrated under reduced pressure to obtain the crude product, which was purified by silica gel column chromatography (PE:EA=2:1) to obtain the product (70 mg, yield: 23.9%).
[0283] Step 3: Synthesis of 7-(((1S,3S)-3-aminocyclopentyl)amino)-1-(tert-butylamino)-2,6-naphthyridine-3-carbonitrile [ka] tert-Butyl ((1S,3S)-3-((5-(tert-butylamino)-7-cyano-2,6-naphthyridin-3-yl)amino)cyclopentyl)carbamate (70 mg, 0.16 mmol, 1.0 equiv.) was dissolved in EA (2 mL). A solution of hydrogen chloride (4 mol / L, 1 mL) in 1,4-dioxane was added dropwise to the reaction solution and reacted at room temperature for 20 hours. After the reaction was substantially complete as detected by LC-MS, the reaction solution was poured into water (5 mL) and separated. The aqueous phase was retained, adjusted to pH 9 with sodium carbonate, and extracted with (MeOH:DCM=1:10, 10 mL × 4). The organic phase was dried and concentrated to give the crude product, which was purified by preparative thin-layer chromatography (MeOH:DCM=1:5) to give the product (40 mg, yield: 76.9%). 1 HNMR(400MHz,MeOD)δ(ppm):8.69(s,1H),7.39(s,1H),6.86(s,1H),4.56-4.53(t,1H),3 .83-3.80(t,1H),2.37-2.34(t,2H),2.16-2.12(m,2H),1.76-1.73(m,2H),1.58(s,9H). Molecular formula:C 18 H 24 N6Exact mass:324.21 LC-MS(Pos,m / z)=325.36[M+H] + .
[0284] Example 35: Synthesis of 1-(tert-butylamino)-7-(((1S,3S)-3-hydroxycyclopentyl)amino)-2,6-naphthyridine-3-carbonitrile (Compound 35) [ka]
[0285] Process: [ka] 1-(tert-Butylamino)-7-chloro-2,6-naphthyridine-3-carbonitrile (130 mg, 0.50 mmol, 1.0 equiv.), (1S,3S)-3-aminocyclopentan-1-ol hydrochloride (103.2 mg, 0.75 mmol, 1.5 equiv.), Pd(dba) (68.7 mg, 0.075 mmol, 0.15 equiv.), BINAP (93.4 mg, 0.15 mmol, 0.3 equiv.), and cesium carbonate (570.2 mg, 1.75 mmol, 3.5 equiv.) were added to 1,4-dioxane (15 mL). The mixture was reacted in a sealed tube at 120 °C for 17 h under a nitrogen atmosphere. When no starting material remained as detected by TLC, water (20 mL) was added to the reaction solution and extracted with ethyl acetate (30 mL x 3). The organic phases were combined, washed with hydrochloric acid solution (0.2 mol / L, 50 mL), dried over anhydrous sodium sulfate, and filtered to obtain a crude material. The crude material was purified by silica gel column chromatography (EA:PE=1:5 to EA=100%) to obtain a crude product (87 mg). The crude product was purified by preparative thin-layer chromatography (MeOH:DCM=1:20) to obtain the product (52 mg, yield: 31.9%). 1 HNMR(400MHz,MeOD)δ(ppm):8.65(s,1H),7.37(s,1H),6.83(s,1H),4.46-4.40(m,2H),2.39-2.30 (m,1H),2.18-2.08(m,2H),1.82-1.75(m,1H),1.71-1.67(m,1H),1.58(m,9H),1.32-1.31(m,1H). Molecular formula:C 18 H 23 N5O Exact mass:325.19 LC-MS(Pos,m / z)=326.34[M+H] + .
[0286] Example 36: Synthesis of 7-(((1S,3R)-3-hydroxycyclopentyl)amino)-1-(isopropylamino)-2,6-naphthyridine-3-carbonitrile (Compound 36) [ka]
[0287] Process: [ka] 7-Chloro-1-(isopropylamino)-2,6-naphthyridine-3-carbonitrile (100 mg, 0.40 mmol, 1.0 equiv.), (1R,3S)-3-aminocyclopentan-1-ol hydrochloride (66 mg, 0.48 mmol, 1.2 equiv.), Pd(dba) (55 mg, 0.06 mmol, 0.15 equiv.), BINAP (74.7 mg, 0.12 mmol, 0.3 equiv.), and cesium carbonate (456.1 mg, 1.4 mmol, 3.5 equiv.) were added to 1,4-dioxane (10 mL). The mixture was reacted in a sealed tube at 120 °C for 17 h under a nitrogen atmosphere. When no starting material remained as detected by TLC, water (20 mL) was added to the reaction solution and extracted with DCM (20 mL x 3). The organic phases were combined, washed with hydrochloric acid solution (0.1 mol / L, 30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the crude product, which was purified by preparative thin-layer chromatography (MeOH:DCM=1:20) to give the product (13 mg, yield: 10.4%). 1 HNMR(400MHz,MeOD)δ(ppm):8.64(s,1H),7.36(s,1H),6.94(s,1H),4.48-4.44(m,1H),4.38-4.36(m,1H),4.29-4.24(m ,1H),2.24-2.35(m,1H),2.20-2.21(m,1H),1.94-1.89(m,1H),1.85-1.78(m,2H),1.66-1.60(m,1H),1.35-1.33(m,6H). Molecular formula:C 17 H 21 N5O Exact mass:311.17 LC-MS(Pos,m / z)=312.27[M+H] + .
[0288] Example 37: Synthesis of 7-(((3S,5S)-5-(hydroxymethyl)pyrrolidin-3-yl)amino)-1-(isopropylamino)-2,6-naphthyridine-3-carbonitrile (Compound 37) [ka]
[0289] Step 1: Synthesis of tert-butyl (2S,4S)-4-((7-cyano-5-(isopropylamino)-2,6-naphthyridin-3-yl)amino)-2-(hydroxymethyl)pyrrolidine-1-carboxylate [ka] 7-Chloro-1-(isopropylamino)-2,6-naphthyridine-3-carbonitrile (150 mg, 0.61 mmol, 1.0 equiv.), tert-butyl (2S,4S)-4-amino-2-(hydroxymethyl)pyrrolidine-1-carboxylate hydrochloride (308.3 mg, 1.22 mmol, 1.2 equiv.), Pd(dba) (82.4 mg, 0.09 mmol, 0.15 equiv.), BINAP (112 mg, 0.18 mmol, 0.3 equiv.), and cesium carbonate (697.2 mg, 2.14 mmol, 3.5 equiv.) were added to 1,4-dioxane (10 mL). The mixture was reacted in a sealed tube under a nitrogen atmosphere at 120 °C for 15 h. When no starting material remained as detected by TLC, water (20 mL) was added to the reaction solution and extracted with ethyl acetate (20 mL × 3). The organic phases were combined, washed with hydrochloric acid solution (0.1 mol / L, 30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the crude product, which was purified by preparative thin-layer chromatography (MeOH:DCM = 1:20) to give the product (151 mg, yield: 58%).
[0290] Step 2: Synthesis of 7-(((3S,5S)-5-(hydroxymethyl)pyrrolidin-3-yl)amino)-1-(isopropylamino)-2,6-naphthyridine-3-carbonitrile [ka] tert-Butyl (2S,4S)-4-((7-cyano-5-(isopropylamino)-2,6-naphthyridin-3-yl)amino)-2-(hydroxymethyl)pyrrolidine-1-carboxylate (150 mg, 0.35 mmol, 1.0 equiv.) was dissolved in DCM (3 mL). Hydrogen chloride in ethanol (10 mol / L, 3 mL) was added dropwise to the reaction solution, and the mixture was allowed to react at room temperature for 2 hours. When no starting material remained as detected by TLC, water (20 mL) was added to the reaction solution, and the mixture was back-extracted with DCM (20 mL × 2). The aqueous phase was retained, adjusted to pH 8 with sodium carbonate, and extracted with ethyl acetate (20 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the crude product, which was purified by preparative thin-layer chromatography (MeOH:DCM = 1:10) to give the product (33 mg, yield: 28.9%). 1 HNMR(400MHz,CD3OD)δ(ppm):8.75(s,1H),7.40(s,1H),7.04(s,1H),4.71-4.68(m,1H),4.47-4.44(m,1H),3.96-3.87(m ,2H),3.82-3.77(m,1H),3.71-3.66(m,1H),2.68-2.61(m,1H),2.02-1.94(m,1H),1.51-1.45(m,1H),1.35-1.33(m,6H). Molecular formula:C 17 H 22 N6O Exact mass:326.19 LC-MS(Pos,m / z)=327.29[M+H] + .
[0291] Example 38: Synthesis of (S)-1-(isopropylamino)-7-(piperidin-3-ylamino)-2,6-naphthyridine-3-carbonitrile (Compound 38) [ka]
[0292] Step 1: Synthesis of tert-butyl (S)-3-((7-cyano-5-(isopropylamino)-2,6-naphthyridin-3-yl)amino)piperidine-1-carboxylate: [ka] 7-Chloro-1-(isopropylamino)-2,6-naphthyridine-3-carbonitrile (150 mg, 0.61 mmol, 1.0 equiv.), tert-butyl (S)-3-aminopiperidine-1-carboxylate (146.2 mg, 0.73 mmol, 1.2 equiv.), Pd(dba) (82.4 mg, 0.09 mmol, 0.15 equiv.), BINAP (112 mg, 0.18 mmol, 0.3 equiv.), and cesium carbonate (498.5 mg, 1.53 mmol, 2.5 equiv.) were added to 1,4-dioxane (10 mL). The mixture was reacted in a sealed tube at 120 °C for 18 h under a nitrogen atmosphere. When no starting material remained as detected by TLC, water (20 mL) was added to the reaction solution and extracted with ethyl acetate (20 mL x 3). The organic phases were combined, washed with hydrochloric acid solution (0.2 mol / L, 20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the crude product, which was purified by silica gel column chromatography (EA:PE=1:10 to 1:2) to give the product (128 mg, yield: 51.1%).
[0293] Step 2: Synthesis of (S)-1-(isopropylamino)-7-(piperidin-3-ylamino)-2,6-naphthyridine-3-carbonitrile [ka] tert-Butyl (S)-3-((7-cyano-5-(isopropylamino)-2,6-naphthyridin-3-yl)amino)piperidine-1-carboxylate (128 mg, 0.31 mmol, 1.0 equiv.) was dissolved in DCM (3 mL). Hydrogen chloride ethanol solution (10 mol / L, 3 mL) was added dropwise to the reaction solution, and the mixture was allowed to react at room temperature for 3 hours. When no starting material remained as detected by TLC, water (20 mL) was added to the reaction solution, the pH was adjusted to approximately 8 with sodium carbonate, and the mixture was extracted with DCM (20 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the crude product, which was purified by preparative thin-layer chromatography (MeOH:DCM = 1:20) to give the product (61 mg, yield: 63.4%). 1 HNMR(400MHz,CD3OD)δ(ppm):8.68(s,1H),7.36(s,1H),6.93(s,1H),4.47-4.42(m,1H),3.97-3.92(m,1H),3.08-3.04(m,1H),2.7 6-2.70(m,1H),2.65-2.59(m,1H),2.15-2.11(m,1H),1.93-1.88(m,1H),1.76-1.70(m,1H),1.64-1.58(m,1H),1.35-1.33(m,7H). Molecular formula:C 17 H 22 N6Exact mass:310.19 LC-MS(Pos,m / z)=311.17[M+H] + .
[0294] Example 39: Synthesis of (R)-1-(isopropylamino)-7-(piperidin-3-ylamino)-2,6-naphthyridine-3-carbonitrile (Compound 39) [ka]
[0295] Step 1: Synthesis of tert-butyl (R)-3-((7-cyano-5-(isopropylamino)-2,6-naphthyridin-3-yl)amino)piperidine-1-carboxylate [ka] 7-Chloro-1-(isopropylamino)-2,6-naphthyridine-3-carbonitrile (150 mg, 0.61 mmol, 1.0 equiv.), tert-butyl (R)-3-aminopiperidine-1-carboxylate (184.3 mg, 0.92 mmol, 1.5 equiv.), Pd(dba) (82.4 mg, 0.09 mmol, 0.15 equiv.), BINAP (112 mg, 0.18 mmol, 0.3 equiv.), and cesium carbonate (498.5 mg, 1.53 mmol, 2.5 equiv.) were added to 1,4-dioxane (15 mL). The mixture was reacted in a sealed tube at 120 °C for 16 h under a nitrogen atmosphere. When no starting material remained as detected by TLC, water (20 mL) was added to the reaction solution and extracted with ethyl acetate (20 mL x 3). The organic phases were combined, washed with hydrochloric acid solution (0.2 mol / L, 30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the crude product, which was purified by silica gel column chromatography (EA:PE=1:5 to 1:2) to give the product (183 mg, yield: 73.1%).
[0296] Step 2: Synthesis of (R)-1-(isopropylamino)-7-(piperidin-3-ylamino)-2,6-naphthyridine-3-carbonitrile [ka] tert-Butyl (R)-3-((7-cyano-5-(isopropylamino)-2,6-naphthyridin-3-yl)amino)piperidine-1-carboxylate (180 mg, 0.44 mmol, 1.0 equiv.) was dissolved in DCM (3 mL). Hydrogen chloride ethanol solution (10 mol / L, 3 mL) was added dropwise to the reaction solution, and the mixture was allowed to react at room temperature for 2 hours. When no starting material remained as detected by TLC, water (30 mL) was added to the reaction solution, and the mixture was back-extracted with ethyl acetate (30 mL × 2). The aqueous phase was retained, adjusted to pH 8 with sodium carbonate, and extracted with DCM (30 mL × 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the crude product, which was purified by preparative thin-layer chromatography (MeOH:DCM = 1:10) to give the product (100 mg, yield: 73.2%). 1 HNMR(400MHz,CD3OD)δ(ppm):8.71(s,1H),7.38(s,1H),6.95(s,1H),4.47-4.44(m,1H),4.14-4.12(m,1H),3.49-3.46(m,1H),3.23-3.20(m ,1H),2.93-2.86(m,1H),2.83-2.77(m,1H),2.19-2.14(m,1H),2.04- 1.99 (m, 1H), 1.86-1.80 (m, 1H), 1.69-1.67 (m, 1H), 1.35-1.33 (m, 6H). Molecular formula:C 17 H 22 N6Exact mass:310.19 LC-MS(Pos,m / z)=311.31[M+H] + .
[0297] Example 40: Synthesis of 7-(((1S,3R)-3-aminocyclohexyl)amino)-1-(isopropylamino)-2,6-naphthyridine-3-carbonitrile (Compound 40) [ka]
[0298] Step 1: Synthesis of tert-butyl ((1R,3S)-3-((7-cyano-5-(isopropylamino)-2,6-naphthyridin-3-yl)amino)cyclohexyl)carbamate [ka] 7-Chloro-1-(isopropylamino)-2,6-naphthyridine-3-carbonitrile (150 mg, 0.61 mmol, 1.0 equiv.), tert-butyl ((1R,3S)-3-aminocyclohexyl)carbamate (169.3 mg, 0.79 mmol, 1.3 equiv.), Pd(dba) (82.4 mg, 0.09 mmol, 0.15 equiv.), BINAP (112 mg, 0.18 mmol, 0.3 equiv.), and cesium carbonate (498.5 mg, 1.53 mmol, 2.5 equiv.) were added to 1,4-dioxane (15 mL). The mixture was reacted in a sealed tube at 120 °C for 17 h under a nitrogen atmosphere. When no starting material remained as detected by TLC, water (20 mL) was added to the reaction solution and extracted with ethyl acetate (20 mL x 3). The organic phases were combined, washed with hydrochloric acid solution (0.1 mol / L, 30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the crude product, which was purified by preparative thin-layer chromatography (MeOH:DCM=1:20) to give the product (150 mg, yield: 57.9%).
[0299] Step 2: Synthesis of 7-(((1S,3R)-3-aminocyclohexyl)amino)-1-(isopropylamino)-2,6-naphthyridine-3-carbonitrile [ka] tert-Butyl ((1R,3S)-3-((7-cyano-5-(isopropylamino)-2,6-naphthyridin-3-yl)amino)cyclohexyl)carbamate (150 mg, 0.35 mmol, 1.0 equiv.) was dissolved in DCM (3 mL). Hydrogen chloride in ethanol (10 mol / L, 3 mL) was added dropwise to the reaction solution, and the reaction was allowed to proceed at room temperature for 0.5 h. When no starting material remained as detected by TLC, the reaction solution was concentrated under reduced pressure, water (20 mL) was added, and back-extracted with DCM (20 mL × 2). The aqueous phase was retained, adjusted to pH 8 with sodium carbonate, and extracted with ethyl acetate (20 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the crude product, which was purified by preparative thin-layer chromatography (MeOH:DCM=1:10) to give the product (30 mg, yield: 26.4%). 1 HNMR(400MHz,CD3OD)δ(ppm):8.68(s,1H),7.37(s,1H),6.93(s,1H),4.49-4.93(m,1H),3.96-3.90(m,1H),3.26-3.23(m,1H), 2.47-2.44(m,1H),2.14-2.07(m,2H),2.03-1.98(m,1H),1.61-1.54(m,1H),1.43-1.39(m,2H),1.35-1.33(m,6H),1.31(m,1H). Molecular formula:C 18 H 24 N6Exact mass:324.21 LC-MS(Pos,m / z)=325.45[M+H] + .
[0300] Example 41: Synthesis of 7-(((1S,3R)-3-hydroxycyclohexyl)amino)-1-(isopropylamino)-2,6-naphthyridine-3-carbonitrile (Compound 41) [ka]
[0301] Process: [ka] 7-Chloro-1-(isopropylamino)-2,6-naphthyridine-3-carbonitrile (100 mg, 0.40 mmol, 1.0 equiv.), (1R,3S)-3-aminocyclohexyl-1-ol hydrochloride (121.3 mg, 0.80 mmol, 2.0 equiv.), Pd(dba) (55 mg, 0.06 mmol, 0.15 equiv.), BINAP (74.7 mg, 0.12 mmol, 0.3 equiv.), and cesium carbonate (456.1 mg, 1.4 mmol, 3.5 equiv.) were added to 1,4-dioxane (10 mL). The mixture was reacted in a sealed tube at 120 °C for 17 h under a nitrogen atmosphere. When no starting material remained as detected by TLC, water (20 mL) was added to the reaction solution and extracted with ethyl acetate (30 mL x 3). The organic phases were combined, washed with hydrochloric acid solution (0.1 mol / L, 30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the crude product, which was purified by preparative thin-layer chromatography (MeOH:DCM=1:20) to give the product (45 mg, yield: 34.5%). 1 HNMR(400MHz,MeOD)δ(ppm):8.64(s,1H),7.35(s,1H),6.91(s,1H),4.49-4.43(m,1H),3.85-3.70(m,2H),2.33-2.30 (m,1H),2.03-1.96(m,2H),1.90-1.85(m,1H),1.50-1.43(m,1H),1.34-1.33(m,6H),1.31-1.29(m,2H),1.27(m,1H). Molecular formula:C 18 H 23 N5O Exact mass:325.19 LC-MS(Pos,m / z)=326.27[M+H] + .
[0302] Example 42: Synthesis of 7-(((3R,4S)-4-fluoropiperidin-3-yl)amino)-1-(isopropylamino)-2,6-naphthyridine-3-carbonitrile (Compound 42) [ka]
[0303] Step 1: Synthesis of tert-butyl (3R,4S)-3-((7-cyano-5-(isopropylamino)-2,6-naphthyridin-3-yl)amino)-4-fluoropiperidine-1-carboxylate [ka] 7-Chloro-1-(isopropylamino)-2,6-naphthyridine-3-carbonitrile (150 mg, 0.61 mmol, 1.0 equiv.), tert-butyl (3R,4S)-3-amino-4-fluoropiperidine-1-carboxylate (174.6 mg, 0.80 mmol, 1.3 equiv.), Pd(dba) (82.4 mg, 0.09 mmol, 0.15 equiv.), BINAP (112 mg, 0.18 mmol, 0.3 equiv.), and cesium carbonate (498.5 mg, 1.53 mmol, 2.5 equiv.) were added to 1,4-dioxane (15 mL). The mixture was reacted in a sealed tube at 100 °C for 17 h under a nitrogen atmosphere. When no starting material remained as detected by TLC, water (30 mL) was added to the reaction solution and extracted with ethyl acetate (30 mL x 2). The organic phases were combined, washed with hydrochloric acid solution (0.5 mol / L, 50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the crude product, which was purified by silica gel column chromatography (EA:PE=1:5 to 1:3) to give the product (100 mg, yield: 38.2%).
[0304] Step 2: Synthesis of 7-(((3R,4S)-4-fluoropiperidin-3-yl)amino)-1-(isopropylamino)-2,6-naphthyridine-3-carbonitrile [ka] tert-Butyl (3R,4S)-3-((7-cyano-5-(isopropylamino)-2,6-naphthyridin-3-yl)amino)-4-fluoropiperidine-1-carboxylate (100 mg, 0.23 mmol, 1.0 equiv.) was dissolved in DCM (5 mL). Hydrogen chloride ethanol solution (10 mol / L, 3 mL) was added dropwise to the reaction solution, and the mixture was allowed to react at room temperature for 1 hour. When no starting material remained as detected by TLC, water (20 mL) was added to the reaction solution, and the mixture was back-extracted with DCM (20 mL × 2). The aqueous phase was retained, the pH was adjusted to approximately 8 with potassium carbonate, and the mixture was extracted with DCM (20 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the crude product, which was purified by preparative thin-layer chromatography (MeOH:DCM = 1:10) to give the product (62 mg, yield: 82.1%). 1 HNMR(400MHz,CD3OD)δ(ppm):8.75(s,1H),7.39(s,1H),7.07(s,1H),5.19-5.06(s,1H),4.77-4.66(m,1H),4.47-4.4 2(m,1H),3.56-3.52(m,1H),3.40-3.37(m,1H),3.26-3.21(m,2H),2.41(m,1H),2.31-2.14(m,1H),1.35-1.33(m,6H). Molecular formula:C 17 H 21 FN6Exact mass:328.18 LC-MS(Pos,m / z)=329.31[M+H] + .
[0305] Example 43: Synthesis of (S)-7-((5,5-difluoropiperidin-3-yl)amino)-1-(isopropylamino)-2,6-naphthyridine-3-carbonitrile (Compound 43) [ka]
[0306] Step 1: Synthesis of tert-butyl (S)-5-((7-cyano-5-(isopropylamino)-2,6-naphthyridin-3-yl)amino)-3,3-difluoropiperidine-1-carboxylate [ka] 7-Chloro-1-(isopropylamino)-2,6-naphthyridine-3-carbonitrile (150 mg, 0.61 mmol, 1.0 equiv.), tert-butyl (S)-5-amino-3,3-difluoropiperidine-1-carboxylate (189 mg, 0.80 mmol, 1.3 equiv.), Pd(dba) (82.4 mg, 0.09 mmol, 0.15 equiv.), BINAP (112 mg, 0.18 mmol, 0.3 equiv.), and cesium carbonate (498.5 mg, 1.53 mmol, 2.5 equiv.) were added to 1,4-dioxane (15 mL). The mixture was reacted in a sealed tube at 100 °C for 15 h under a nitrogen atmosphere. When no starting material remained as detected by TLC, water (30 mL) was added to the reaction solution and extracted with ethyl acetate (30 mL x 2). The organic phases were combined, washed with hydrochloric acid solution (0.5 mol / L, 50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the crude product, which was purified by silica gel column chromatography (EA:PE=1:5 to 1:3) to give the product (164 mg, yield: 60.2%).
[0307] Step 2: Synthesis of (S)-7-((5,5-difluoropiperidin-3-yl)amino)-1-(isopropylamino)-2,6-naphthyridine-3-carbonitrile [ka] tert-Butyl (S)-5-((7-cyano-5-(isopropylamino)-2,6-naphthyridin-3-yl)amino)-3,3-difluoropiperidine-1-carboxylate (164 mg, 0.36 mmol, 1.0 equiv.) was dissolved in DCM (5 mL). Hydrogen chloride ethanol solution (10 mol / L, 3 mL) was added dropwise to the reaction solution, and the mixture was allowed to react at room temperature for 2 hours. When no starting material remained as detected by TLC, water (20 mL) was added to the reaction solution, and the mixture was back-extracted with DCM (20 mL × 2). The aqueous phase was retained, the pH was adjusted to approximately 8 with potassium carbonate, and the mixture was extracted with DCM (20 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the crude product, which was purified by preparative thin-layer chromatography (MeOH:DCM = 1:10) to give the product (56.3 mg, yield: 45.1%). 1 HNMR(400MHz,CD3OD)δ(ppm):8.78(s,1H),7.38(s,1H),6.97(s,1H),4.48-4.42(m,1H),4.24-4.19(m,1H),3.26-3.23(m ,1H),3.16-3.11(m,1H),2.98-2.94(m,1H),2.92-2.88(m,1H),2.59-2.50(m,2H),2.10-2.00(m,1H),1.35-1.33(m,6H). Molecular formula:C 17 H 20 F2N6Exact mass:346.17 LC-MS(Pos,m / z)=347.34[M+H] + .
[0308] Example 44: Synthesis of (S)-1-(isopropylamino)-7-(quinuclidin-3-ylamino)-2,6-naphthyridine-3-carbonitrile (Compound 44) [ka]
[0309] Process: [ka] 7-Chloro-1-(isopropylamino)-2,6-naphthyridine-3-carbonitrile (150 mg, 0.61 mmol, 1.0 equiv.), (S)-quinuclidin-3-amine (100.9 mg, 0.80 mmol, 1.3 equiv.), Pd(dba) (82.4 mg, 0.09 mmol, 0.15 equiv.), BINAP (112 mg, 0.18 mmol, 0.3 equiv.), and cesium carbonate (498.5 mg, 1.53 mmol, 2.5 equiv.) were added to 1,4-dioxane (15 mL). The mixture was reacted in a sealed tube at 100 °C for 22 h under a nitrogen atmosphere. When no starting material remained as detected by TLC, water (30 mL) was added to the reaction solution and back-extracted with ethyl acetate (30 mL x 3). The aqueous phase was retained, adjusted to pH 8 with sodium carbonate, and extracted with ethyl acetate (30 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the crude product, which was purified by preparative thin-layer chromatography (MeOH:DCM = 1:10) to give the product (125 mg, yield: 60.9%). 1 HNMR(400MHz,MeOD)δ(ppm):8.78(s,1H),7.38(s,1H),7.02(s,1H),4.49-4.42(m,2H),3.97-3.91(m,1H),3.47-3.37(m ,4H),3.25-3.21(m,1H),2.43-2.41(m,1H),2.35-2.34(m,1H),2.17-2.13(m,2H),1.99-1.95(m,1H),1.35-1.33(m,6H). Molecular formula:C 19 H 24 N6Exact mass:336.21 LC-MS(Pos,m / z)=337.39[M+H] + .
[0310] Example 45: Synthesis of 2-(((1S,3S)-3-aminocyclopentyl)amino)-8-(isopropylamino)pyrido[3,4-d]pyrimidine-6-carbonitrile (Compound 45) [ka]
[0311] Step 1: Synthesis of 8-(isopropylamino)-2-(methylthio)pyrido[3,4-d]pyrimidine-6-carbonitrile [ka] 6-Chloro-N-isopropyl-2-(methylthio)pyrido[3,4-d]pyrimidin-8-amine (1.0 g, 3.72 mmol, 1.0 equiv.), zinc cyanide (874 mg, 7.44 mmol, 2.0 equiv.), and tetrakis(triphenylphosphine)palladium(0) (855 mg, 0.74 mmol, 0.2 equiv.) were dissolved in DMAC (10 mL), and the reaction solution was reacted at 120 °C for 1.5 h under a nitrogen atmosphere. After completion of the reaction as detected by TLC, the reaction solution was poured into water (20 mL) and extracted with MTBE (20 mL × 2). The organic phase was washed with water (20 mL), dried, and concentrated to give the crude product, which was purified by silica gel column chromatography (PE:EA = 30:1) to give the product (400 mg, yield: 41.1%).
[0312] Step 2: Synthesis of 8-(isopropylamino)-2-(methylsulfonyl)pyrido[3,4-d]pyrimidine-6-carbonitrile [ka] 8-(Isopropylamino)-2-(methylthio)pyrido[3,4-d]pyrimidine-6-carbonitrile (400 mg, 1.54 mmol, 1.0 equiv.) was dissolved in DCM (8 mL), and m-chloroperbenzoic acid (mass fraction: 80%, 664 mg, 3.08 mmol, 2.0 equiv.) was added to the reaction solution. After completion of the reaction as detected by TLC, the reaction solution was concentrated under reduced pressure to obtain the crude product, which was purified by silica gel column chromatography (PE:EA = 2:1) to obtain the product (360 mg, yield: 80.0%).
[0313] Step 3: Synthesis of tert-butyl ((1S,3S)-3-((6-cyano-8-(isopropylamino)pyrido[3,4-d]pyrimidin-2-yl)amino)cyclopentyl)carbamate [ka] 6-Chloro-N-isopropyl-2-(methylsulfonyl)pyrido[3,4-d]pyrimidin-8-amine (360 mg, 1.23 mmol, 1.0 equiv.), tert-butyl ((1S,3S)-3-aminocyclopentyl)carbamate (270 mg, 1.35 mmol, 1.1 equiv.), and DIPEA (477 mg, 3.69 mmol, 3.0 equiv.) were dissolved in ethanol (5 mL), and the reaction solution was reacted at 85° C. for 2.5 hours. After completion of the reaction as detected by LC-MS, the reaction solution was concentrated to give the crude product, which was purified by silica gel column chromatography (PE:EA=3:1) to give the product (230 mg, yield: 45.4%).
[0314] Step 4: Synthesis of 2-(((1S,3S)-3-aminocyclopentyl)amino)-8-(isopropylamino)pyrido[3,4-d]pyrimidine-6-carbonitrile [ka] tert-Butyl ((1S,3S)-3-((6-cyano-8-(isopropylamino)pyrido[3,4-d]pyrimidin-2-yl)amino)cyclopentyl)carbamate (220 mg, 0.53 mmol, 1.0 equiv) was dissolved in EA (5 mL), and a solution of hydrogen chloride in 1,4-dioxane (4 mol / L, 3 mL) was added dropwise to the reaction solution, followed by reaction at room temperature for 4 hours. After the reaction was substantially complete as detected by TLC, the reaction solution was filtered under reduced pressure. The filter cake was dissolved in (MeOH:DCM=1:10, 10 mL), washed with saturated aqueous sodium carbonate (10 mL × 2), dried, and concentrated to give the crude product, which was slurried with EA (5 mL), and the filter cake was dried to give the product (110 mg, yield: 66.6%). 1HNMR(400MHz,MeOD)δ(ppm):8.95(s,1H),7.33(s,1H),4.71-4.68(t,1H),4.37-4.31(m,1H),3 .87-3.80(m,1H),2.40-2.33(m,2H),2.20-2.17(t,2H),1.81-1.76(m,2H),1.35-1.34(d,6H). Molecular formula:C 16 H 21 N7Exact mass:311.19 LC-MS(Pos,m / z)=312.14[M+H] + .
[0315] Example 46: Synthesis of N-((1S,3S)-3-((6-cyano-8-(isopropylamino)pyrido[3,4-d]pyrimidin-2-yl)amino)cyclopentyl)acetamide (Compound 46) [ka]
[0316] Step 1: Synthesis of 2-(((1S,3S)-3-aminocyclopentyl)amino)-8-(isopropylamino)pyrido[3,4-d]pyrimidine-6-carbonitrile [ka] 2-(((1S,3S)-3-Aminocyclopentyl)amino)-8-(isopropylamino)pyrido[3,4-d]pyrimidine-6-carbonitrile (30 mg, 0.096 mmol, 1.0 equiv.), DIPEA (37 mg, 0.29 mmol, 3.0 equiv.), and acetic anhydride (15 mg, 0.15 mmol, 1.5 equiv.) were dissolved in DCM (2 mL), and the reaction solution was reacted at room temperature for 10 minutes. After the reaction was completed as detected by TLC, the reaction solution was concentrated under reduced pressure to give the crude product, which was slurried with MTBE (5 mL) and filtered under reduced pressure. The filter cake was dried to give the product (24 mg, yield: 70.6%). 1HNMR(400MHz,MeOD)δ(ppm):8.93(s,1H),7.33(s,1H),4.58-4.54(t,1H),4.36-4.30(m,2H),2.30 (s,1H),2.24-2.16(m,1H),2.03-2.01(d,2H),1.96(s,3H),1.70-1.54(m,2H),1.35-1.33(d,6H). Molecular formula:C 18 H 23 N7O Exact mass:353.20 LC-MS(Pos,m / z)=354.16[M+H] + .
[0317] Example 47: Synthesis of N-((1R,3S)-3-((7-cyano-5-(isopropylamino)-2,6-naphthyridin-3-yl)amino)cyclopentyl)acetamide (Compound 47) [ka]
[0318] Process: [ka]
[0319] Step 1: Synthesis of tert-butyl ((1R,3S)-3-((7-cyano-5-(isopropylamino)-2,6-naphthyridin-3-yl)amino)cyclopentyl)carbamate [ka] 7-Chloro-1-(isopropylamino)-2,6-naphthyridine-3-carbonitrile (246.7 mg, 1 mmol, 1.0 equiv.), tert-butyl ((1R,3S)-3-aminocyclopentyl)carbamate (240.3 mg, 1.2 mmol, 1.2 equiv.), Pd(dba) (137.4 mg, 0.15 mmol, 0.15 equiv.), BINAP (186.8 mg, 0.3 mmol, 0.3 equiv.), and cesium carbonate (814.6 mg, 2.5 mmol, 2.5 equiv.) were added to 1,4-dioxane (10 mL). The mixture was reacted in a sealed tube at 120 °C for 14 h under a nitrogen atmosphere. When no starting material remained as detected by TLC, water (20 mL) was added to the reaction solution, which was then extracted with ethyl acetate (20 mL x 3). The organic phases were combined, washed with hydrochloric acid solution (0.2 mol / L, 30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the crude product, which was purified by silica gel column chromatography (EA:PE=1:10 to 1:2) to give the product (196 mg, yield: 47.7%).
[0320] Step 2: Synthesis of 7-(((1S,3R)-3-aminocyclopentyl)amino)-1-(isopropylamino)-2,6-naphthyridine-3-carbonitrile [ka] tert-Butyl ((1R,3S)-3-((7-cyano-5-(isopropylamino)-2,6-naphthyridin-3-yl)amino)cyclopentyl)carbamate (196 mg, 0.48 mmol, 1.0 equiv.) was dissolved in DCM (5 mL). Hydrogen chloride ethanol solution (10 mol / L, 4 mL) was added dropwise to the reaction solution, and the reaction was allowed to proceed at room temperature for 2 hours. When no starting material remained as detected by TLC, water (20 mL) was added to the reaction solution, the pH was adjusted to approximately 8 with sodium bicarbonate, and the mixture was extracted with DCM (20 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the product (134 mg, yield: 89.9%).
[0321] Step 3: Synthesis of N-((1R,3S)-3-((7-cyano-5-(isopropylamino)-2,6-naphthyridin-3-yl)amino)cyclopentyl)acetamide [ka] 7-(((1S,3R)-3-aminocyclopentyl)amino)-1-(isopropylamino)-2,6-naphthyridine-3-carbonitrile (134 mg, 0.43 mmol, 1.0 equiv) was dissolved in DCM (4 mL). DIPEA (167.9 mg, 1.30 mmol, 3.0 equiv) and acetic anhydride (65.8 mg, 0.65 mmol, 1.5 equiv) were added to the reaction solution, and the mixture was allowed to react at room temperature for 1 hour. When no starting material remained as detected by TLC, water (20 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (20 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give the crude product, which was purified by preparative thin-layer chromatography (MeOH:DCM = 1:20) to give the product (45 mg, yield: 29.7%). 1 HNMR(400MHz,CD3OD)δ(ppm):8.66(s,1H),7.36(s,1H),6.93(s,1H),4.50-4.43(m,1H),4.23-4.16(m,2H),2.65-2.5 8(m,1H),2.23-2.13(m,1H),2.11-2.04(m,1H),1.95(s,3H),1.76-1.71(m,2H),1.49-1.42(m,1H),1.35-1.33(m,6H). Molecular formula:C 19 H 24 N6O Exact mass:352.20 LC-MS(Pos,m / z)=353.31[M+H] + .
[0322] Example 48: Synthesis of 7-(((1S,3S)-3-aminocyclopentyl)amino)-1-(pentan-3-ylamino)-2,6-naphthyridine-3-carbonitrile (Compound 48) [ka]
[0323] route: [ka]
[0324] Step 1: Synthesis of tert-butyl ((1S,3S)-3-((7-cyano-5-(methylthio-2,6-naphthyridin-3-yl)amino)cyclopentyl)carbamate: [ka] 7-Chloro-1-(methylthio)-2,6-naphthyridine-3-carbonitrile (500 mg, 2.12 mmol, 1.0 equiv.), tert-butyl ((1S,3S)-3-aminocyclopentyl)carbamate (508.7 mg, 2.54 mmol, 1.0 equiv.), Pd(dba) (293 mg, 0.32 mmol, 0.15 equiv.), BINAP (398.5 mg, 0.64 mmol, 0.3 equiv.), and cesium carbonate (1.7 g, 5.30 mmol, 2.5 equiv.) were added to 1,4-dioxane (25 mL). The mixture was reacted in a sealed tube at 120 °C for 16 h under a nitrogen atmosphere. When no starting material remained as detected by TLC, water (30 mL) was added to the reaction solution, which was then extracted with ethyl acetate (30 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the crude product, which was purified by silica gel column chromatography (EA:PE=1:10 to 1:3) to give the product (385 mg, yield: 45.4%).
[0325] Step 2: Synthesis of tert-butyl ((1S,3S)-3-((7-cyano-5-(methylsulfonyl)-2,6-naphthyridin-3-yl)amino)cyclopentyl)carbamate [ka] tert-Butyl ((1S,3S)-3-((7-cyano-5-(methylthio)-2,6-naphthyridin-3-yl)amino)cyclopentyl)carbamate (150 mg, 0.37 mmol, 1.0 equiv.) was dissolved in DCM (5 mL). mCPBA (mass fraction: 80%, 162 mg, 0.75 mmol, 2.0 equiv.) was added to the reaction solution and reacted at room temperature for 0.5 h. When no starting material remained as detected by TLC, water (20 mL) was added to the reaction solution and extracted with ethyl acetate (20 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the crude product, which was purified by preparative thin-layer chromatography (EA:PE = 1:2) to give the product (100 mg, yield: 61.8%).
[0326] Step 3: Synthesis of tert-butyl ((1S,3S)-3-((7-cyano-5-(pentan-3-ylamino)-2,6-naphthyridin-3-yl)amino)cyclopentyl)carbamate [ka] tert-Butyl ((1S,3S)-3-((7-cyano-5-(methylsulfonyl)-2,6-naphthyridin-3-yl)amino)cyclopentyl)carbamate (100 mg, 0.23 mmol, 1.0 equivalent) was dissolved in 3-pentylamine (2 mL). The reaction solution was reacted at 120° C. for 21 hours. When no starting material remained as detected by TLC, the reaction solution was concentrated under reduced pressure, water (20 mL) was added, and the mixture was extracted with ethyl acetate (20 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the crude product, which was purified by preparative thin-layer chromatography (EA:PE=1:2) to give the product (30 mg, yield: 29.7%).
[0327] Step 4: Synthesis of 7-(((1S,3S)-3-aminocyclopentyl)amino)-1-(pentan-3-ylamino)-2,6-naphthyridine-3-carbonitrile [ka] tert-Butyl ((1S,3S)-3-((7-cyano-5-(pentan-3-ylamino)-2,6-naphthyridin-3-yl)amino)cyclopentyl)carbamate (30 mg, 0.06 mmol, 1.0 equiv.) was dissolved in DCM (2 mL). Hydrogen chloride ethanol solution (10 mol / L, 1 mL) was added dropwise to the reaction solution, and the mixture was allowed to react at room temperature for 2 hours. When no starting material remained as detected by TLC, water (10 mL) was added to the reaction solution, the pH was adjusted to approximately 8 with sodium carbonate, and the mixture was extracted with DCM (10 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the crude product. This crude product was dissolved in methanol (0.5 mL) and water (3 mL) and lyophilized to give the product (20 mg, yield: 98.5%). 1 HNMR(400MHz,CD3OD)δ(ppm):8.65(s,1H),7.34(s,1H),6.93(s,1H),4.37-4.33(m,1H),4.24(m,1H),3.56-3.53(m,1 H),2.40-2.31(m,1H),2.21-2.13(m,1H),1.94-1.90(m,2H),1.78-1.64(m,5H),1.50-1.45(m,1H),1.00-0.96(m,6H). Molecular formula:C 19 H 26 N6Exact mass:338.22 LC-MS(Pos,m / z)=339.34[M+H] + .
[0328] Example 49: Synthesis of 7-(((1S,3S)-3-aminocyclopentyl)amino)-1-(cyclopentylamino)-2,6-naphthyridine-3-carbonitrile (Compound 49) [ka]
[0329] Step 1: Synthesis of 7-chloro-1-(methylsulfonyl)-2,6-naphthyridine-3-carbonitrile [ka] 7-Chloro-1-(methylthio)-2,6-naphthyridine-3-carbonitrile (1 g, 4.24 mmol, 1.0 equiv.) was dissolved in DCM (20 mL). m-Chloroperbenzoic acid (mass fraction: 80%, 1.83 g, 8.48 mmol, 2.0 equiv.) was added to the reaction solution and reacted at room temperature for 0.5 h. After completion of the reaction as detected by TLC, the reaction solution was poured into water (10 mL) and adjusted to pH 8 with sodium carbonate. The layers were separated. The aqueous phase was extracted with DCM (20 mL). The combined organic phases were dried and concentrated to give the crude product, which was slurried with (PE:EA = 10:1, 20 mL), filtered under reduced pressure, and the filter cake was dried to give the product (1.1 g, yield: 97.3%).
[0330] Step 2: Synthesis of 7-chloro-1-(cyclopentylamino)-2,6-naphthyridine-3-carbonitrile [ka] 7-Chloro-1-(methylsulfonyl)-2,6-naphthyridine-3-carbonitrile (200 mg, 0.75 mmol, 1.0 equiv.), cyclopentylamine (128 mg, 1.50 mmol, 2.0 equiv.), and DIPEA (290 mg, 2.25 mmol, 3.0 equiv.) were dissolved in THF (5 mL), and the reaction solution was reacted at 40 °C for 30 min. After completion of the reaction as detected by TLC, the reaction solution was poured into water (10 mL) and extracted with EA (10 mL × 2). The organic phase was dried and concentrated to give the product (200 mg, yield: 98%).
[0331] Step 3: Synthesis of tert-butyl ((1S,3S)-3-((7-cyano-5-(cyclopentylamino)-2,6-naphthyridin-3-yl)amino)cyclopentyl)carbamate [ka] 7-Chloro-1-(cyclopentylamino)-2,6-naphthyridine-3-carbonitrile (200 mg, 0.73 mmol, 1.0 equiv.), tert-butyl ((1S,3S)-3-aminocyclopentyl)carbamate (176 mg, 0.88 mmol, 1.2 equiv.), Pd(dba) (67 mg, 0.073 mmol, 0.1 equiv.), BINAP (91 mg, 0.146 mmol, 0.2 equiv.), and cesium carbonate (476 mg, 1.46 mmol, 2.0 equiv.) were dispersed in 1,4-dioxane (5 mL), and the reaction solution was reacted at 100°C for 19.5 hours under a nitrogen atmosphere. When no starting material remained as detected by TLC, the reaction solution was concentrated under reduced pressure to obtain a crude product, which was purified by silica gel column chromatography (PE:EA=2:1) to obtain the product (160 mg, yield: 50.3%).
[0332] Step 4: Synthesis of 7-(((1S,3S)-3-aminocyclopentyl)amino)-1-(cyclopentylamino)-2,6-naphthyridine-3-carbonitrile [ka] tert-Butyl ((1S,3S)-3-((7-cyano-5-(cyclopentylamino)-2,6-naphthyridin-3-yl)amino)cyclopentyl)carbamate (160 mg, 0.36 mmol, 1.0 equiv.) was dissolved in EA (4 mL). A solution of hydrogen chloride (4 mol / L, 2 mL) in 1,4-dioxane was added dropwise to the reaction solution, and the reaction was allowed to proceed at room temperature for 3.5 hours. After the reaction was substantially complete as detected by LC-MS, the reaction solution was filtered, and the filter cake was dissolved in water (5 mL) and adjusted to pH 9 with sodium carbonate. The aqueous phase was extracted with (MeOH:DCM=1:10, 10 mL×4). The organic phase was dried and concentrated to give the crude product, which was purified by preparative thin-layer chromatography (MeOH:DCM=1:5) to give the product (13 mg, yield: 10.7%). 1HNMR(400MHz,MeOD)δ(ppm):8.69(s,1H),7.38(s,1H),6.94(s,1H),4.58-4.49(m,2H),3.8 3-3.79(t,1H),2.38-2.35(m,2H),2.19-2.12(m,4H),1.84-1.82(t,2H),1.78-1.68(m,6H). Molecular formula:C 19 H 24 N6Exact mass:336.21 LC-MS(Pos,m / z)=337.38[M+H] + .
[0333] Example 50: Synthesis of 7-(((1S,3S)-3-aminocyclopentyl)amino)-1-((1-methylcyclopropyl)amino)-2,6-naphthyridine-3-carbonitrile (Compound 50) [ka]
[0334] Step 1: Synthesis of 7-chloro-1-((1-methylcyclopropyl)amino)-2,6-naphthyridine-3-carbonitrile [ka] 7-Chloro-1-(methylsulfonyl)-2,6-naphthyridine-3-carbonitrile (200 mg, 0.75 mmol, 1.0 equiv.), 1-methylcyclopropan-1-amine hydrochloride (161 mg, 1.50 mmol, 2.0 equiv.), and DIPEA (290 mg, 2.25 mmol, 3.0 equiv.) were dissolved in THF (5 mL), and the reaction solution was reacted at 80 °C for 3 h. After completion of the reaction as detected by TLC, the reaction solution was poured into water (10 mL) and extracted with EA (10 mL × 2). The organic phase was dried and concentrated to give the product (160 mg, yield: 82.5%).
[0335] Step 2: Synthesis of tert-butyl ((1S,3S)-3-((7-cyano-5-((1-methylcyclopropyl)amino)-naphthyridin-3-yl)amino)cyclopentyl)carbamate [ka] 7-Chloro-1-((1-methylcyclopropyl)amino)-2,6-naphthyridine-3-carbonitrile (160 mg, 0.62 mmol, 1.0 equiv.), tert-butyl ((1S,3S)-3-aminocyclopentyl)carbamate (149 mg, 0.74 mmol, 1.2 equiv.), Pd(dba) (57 mg, 0.062 mmol, 0.1 equiv.), BINAP (77 mg, 0.124 mmol, 0.2 equiv.), and cesium carbonate (404 mg, 1.24 mmol, 2.0 equiv.) were dispersed in 1,4-dioxane (5 mL), and the reaction solution was reacted at 100 °C for 23 hours under a nitrogen atmosphere. After the reaction was completed as detected by TLC, the reaction solution was concentrated under reduced pressure to obtain the crude product, which was purified by silica gel column chromatography (PE:EA=2:1) to obtain the product (70 mg, yield: 26.7%).
[0336] Step 3: Synthesis of 7-(((1S,3S)-3-aminocyclopentyl)amino)-1-((1-methylcyclopropyl)amino)-2,6-naphthyridine-3-carbonitrile [ka] tert-Butyl ((1S,3S)-3-((7-cyano-5-((1-methylcyclopropyl)amino)-naphthyridin-3-yl)amino)cyclopentyl)carbamate (70 mg, 0.16 mmol, 1.0 equiv.) was dissolved in EA (2 mL). A solution of hydrogen chloride (4 mol / L, 1 mL) in 1,4-dioxane was added dropwise to the reaction solution and reacted at room temperature for 18 hours. After the reaction was completed as detected by LC-MS, the reaction solution was poured into water (5 mL) and separated. The aqueous phase was retained, adjusted to pH 9 with sodium carbonate, and extracted with (MeOH:DCM=1:10, 10 mL × 4). The organic phase was dried and concentrated to give the crude product, which was purified by preparative thin-layer chromatography (MeOH:DCM=1:5) to give the product (20 mg, yield: 38.4%). 1HNMR(400MHz,MeOD)δ(ppm):8.69(s,1H),7.42(s,1H),6.82(s,1H),4.57-4.54(t,1H),3.80-3.77(t, 1H),2.37-2.33(m,2H),2.13-2.10(t,2H),1.76-1.68(m,2H),1.58(s,3H),0.87(s,2H),0.78(s,2H). Molecular formula:C 18 H 22 N6Exact mass:322.19 LC-MS(Pos,m / z)=323.24[M+H] + .
[0337] Example 51: Synthesis of 7-(((1S,3S)-3-aminocyclopentyl)amino)-1-isopropoxy-2,6-naphthyridine-3-carbonitrile (Compound 51) [ka]
[0338] Process: [ka]
[0339] Step 1: Synthesis of 7-chloro-1-isopropoxy-2,6-naphthyridine-3-carbonitrile [ka] Sodium hydride (mass fraction: 60%, 52.8 mg, 1.32 mmol, 1.1 equiv.) was dissolved in isopropanol (10 mL). The reaction mixture was allowed to react at room temperature for 0.5 h. A solution of 7-chloro-1-(methylsulfonyl)-2,6-naphthyridine-3-carbonitrile (300 mg, 1.12 mmol, 1.0 equiv.) in 1,4-dioxane (5 mL) was added and the mixture was heated at 60 °C for 1 h. When no starting material remained as detected by TLC, water (20 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (20 mL x 3). The organic phases were combined, dried over anhydrous magnesium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the product (274 mg, yield: 98.7%).
[0340] Step 2: Synthesis of tert-butyl ((1S,3S)-3-((7-cyano-5-isopropoxy-2,6-naphthyridin-3-yl)amino)cyclopentyl)carbamate [ka] 7-Chloro-1-isopropoxy-2,6-naphthyridine-3-carbonitrile (270 mg, 1.09 mmol, 1.0 equiv.), tert-butyl ((1S,3S)-3-aminocyclopentyl)carbamate (284.4 mg, 1.42 mmol, 1.2 equiv.), Pd(dba) (146.5 mg, 0.16 mmol, 0.15 equiv.), BINAP (199.3 mg, 0.32 mmol, 0.3 equiv.), and cesium carbonate (889.5 mg, 2.73 mmol, 2.5 equiv.) were added to 1,4-dioxane (20 mL). The mixture was reacted in a sealed tube at 120 °C for 17 h under a nitrogen atmosphere. When no starting material remained as detected by TLC, water (30 mL) was added to the reaction solution, which was then extracted with ethyl acetate (30 mL x 3). The organic phases were combined, washed with hydrochloric acid solution (0.2 mol / L, 40 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the crude product, which was purified by preparative thin-layer chromatography (EA:PE=1:3) to give the product (105 mg, yield: 23.4%).
[0341] Step 3: Synthesis of 7-(((1S,3S)-3-aminocyclopentyl)amino)-1-isopropoxy-2,6-naphthyridine-3-carbonitrile [ka] tert-Butyl ((1S,3S)-3-((7-cyano-5-isopropoxy-2,6-naphthyridin-3-yl)amino)cyclopentyl)carbamate (105 mg, 0.25 mmol, 1.0 equiv.) was dissolved in DCM (5 mL). The reaction solution was cooled in an ice-water bath, and 2,6-lutidine (401.8 mg, 3.75 mmol, 15.0 equiv.) and trimethylsilyl trifluoromethanesulfonate (555.6 mg, 2.5 mmol, 10.0 equiv.) were added. The reaction mixture was allowed to react at 0°C to 5°C for 2 hours. When no starting material remained as detected by TLC, water (30 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (30 mL x 3). The organic phases were combined, washed successively with saturated aqueous sodium carbonate (30 mL) and water (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the crude product, which was purified by preparative thin-layer chromatography (MeOH:DCM=1:10) to give the product (58 mg, yield: 64.3%). 1 HNMR(400MHz,CD3OD)δ(ppm):8.86(s,1H),7.76(s,1H),6.91(s,1H),5.54-5.48(m,1H),4.40-4.37(m,1H),3.57-3.54(m ,1H),2.35-2.83(m,1H),2.20-2.14(m,1H),1.96-1.92(m,2H),1.65-1.61(m,1H),1.59-1.50(m,1H),1.47-1.45(m,6H). Molecular formula:C 17 H 21 N5O Exact mass:311.17 LC-MS(Pos,m / z)=312.27[M+H] + .
[0342] Example 52:N 7 -((1S,3S)-3-aminocyclopentyl)-3-(difluoromethyl)-N 1Synthesis of -isopropyl-2,6-naphthyridine-1,7-diamine (compound 52) [ka]
[0343] Process: [ka]
[0344] Step 1: Synthesis of 7-chloro-3-(difluoromethyl)-N-isopropyl-2,6-naphthyridin-1-amine [ka] 7-Chloro-1-(isopropylamino)-2,6-naphthyridine-3-carbaldehyde (1 g, 4.0 mmol, 1.0 equiv.) was dissolved in DCM (20 mL). The reaction solution was cooled to 0-5 °C in an ice-water bath, and DAST (2.6 g, 16 mmol, 4.0 equiv.) was added dropwise. After the addition, the reaction mixture was allowed to react at 0-5 °C for 2 h and then incubated at room temperature for 16 h. When no starting material remained as detected by TLC, water (20 mL) was added to the reaction mixture, and the pH was adjusted to approximately 8 with sodium carbonate. The mixture was separated, and the organic phase was retained. The aqueous phase was extracted with DCM (20 mL x 2). The organic phases were combined, washed successively with water (20 mL) and brine (20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the crude product, which was purified by silica gel column chromatography (EA:PE=1:30) to give the product (982 mg, yield: 90.9%).
[0345] Step 2: Synthesis of tert-butyl ((1S,3S)-3-((7-(difluoromethyl)-5-(isopropylamino)-2,6-naphthyridin-3-yl)amino)cyclopentyl)carbamate [ka] 7-Chloro-3-(difluoromethyl)-N-isopropyl-2,6-naphthyridin-1-amine (166 mg, 0.61 mmol, 1.0 equiv.), tert-butyl ((1S,3S)-3-aminocyclopentyl)carbamate (146.2 mg, 0.73 mmol, 1.2 equiv.), Pd(dba) (82.4 mg, 0.09 mmol, 0.15 equiv.), BINAP (112 mg, 0.18 mmol, 0.3 equiv.), and cesium carbonate (498.5 mg, 1.53 mmol, 2.5 equiv.) were added to 1,4-dioxane (10 mL). The mixture was reacted in a sealed tube at 120 °C for 17 h under a nitrogen atmosphere. When no starting material remained as detected by TLC, water (10 mL) was added to the reaction solution and extracted with ethyl acetate (10 mL x 3). The organic phases were combined, washed with hydrochloric acid solution (0.2 mol / L, 30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the crude product, which was first purified by silica gel column chromatography (EA:PE=1:10 to 1:2) and then by preparative thin-layer chromatography (EA:PE=1:2) to give the product (93 mg, yield: 35%).
[0346] Process 3:N 7 -((1S,3S)-3-aminocyclopentyl)-3-(difluoromethyl)-N 1 Synthesis of 1,7-isopropyl-2,6-naphthyridine-1,7-diamine [ka] tert-Butyl ((1S,3S)-3-((7-(difluoromethyl)-5-(isopropylamino)-2,6-naphthyridin-3-yl)amino)cyclopentyl)carbamate (93 mg, 0.21 mmol, 1.0 equiv.) was dissolved in DCM (3 mL). Hydrogen chloride ethanol solution (10 mol / L, 3 mL) was added dropwise to the reaction solution, and the mixture was allowed to react at room temperature for 2 hours. When no starting material remained as detected by LC-MS, water (15 mL) was added to the reaction solution, and the mixture was back-extracted with DCM (15 mL × 2). The aqueous phase was retained, adjusted to pH 8 with sodium carbonate, and extracted with dichloromethane (15 mL × 2). The organic phases were combined, dried over anhydrous magnesium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was dissolved in methanol (1 mL) and water (5 mL) and lyophilized to give the product (45 mg, yield: 63.9%). 1 HNMR(400MHz,MeOD)δ(ppm):8.66(s,1H),7.07(s,1H),6.90(s,1H),6.65-6.37(s,1H),4.54-4.48(m,1H),4.35-4.31(m ,1H),3.59-3.56(m,1H),2.39-2.32(m,1H),2.21-2.16(m,1H),1.96-1.93(m,2H),1.64-1.48(m,2H),1.35-1.33(m,6H). Molecular formula:C 17 H 23 F2N5Exact mass:335.19 LC-MS(Pos,m / z)=336.20[M+H] + .
[0347] Example 53:N 7 -((1S,3R)-3-aminocyclopentyl)-3-(difluoromethyl)-N 1 Synthesis of -isopropyl-2,6-naphthyridine-1,7-diamine (compound 53) [ka]
[0348] Step 1: Synthesis of tert-butyl ((1R,3S)-3-((7-(difluoromethyl)-5-(isopropylamino)-2,6-naphthyridin-3-yl)amino)cyclopentyl)carbamate [ka] 7-Chloro-3-(difluoromethyl)-N-isopropyl-2,6-naphthyridin-1-amine (166 mg, 0.61 mmol, 1.0 equiv.), tert-butyl ((1R,3S)-3-aminocyclopentyl)carbamate (146.2 mg, 0.73 mmol, 1.2 equiv.), Pd(dba) (82.4 mg, 0.09 mmol, 0.15 equiv.), BINAP (112 mg, 0.18 mmol, 0.3 equiv.), and cesium carbonate (498.5 mg, 1.53 mmol, 2.5 equiv.) were added to 1,4-dioxane (15 mL). The mixture was reacted in a sealed tube at 120 °C for 20 h under a nitrogen atmosphere. When no starting material remained as detected by TLC, water (30 mL) was added to the reaction solution and extracted with ethyl acetate (30 mL × 3). The organic phases were combined, washed with hydrochloric acid solution (0.2 mol / L, 50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the crude product, which was purified by silica gel column chromatography (EA:PE=1:5 to 1:2) to give the product (100 mg, yield: 37.6%).
[0349] Process 2:N 7 -((1S,3R)-3-aminocyclopentyl)-3-(difluoromethyl)-N 1 Synthesis of 1,7-isopropyl-2,6-naphthyridine-1,7-diamine [ka] tert-Butyl ((1R,3S)-3-((7-(difluoromethyl)-5-(isopropylamino)-2,6-naphthyridin-3-yl)amino)cyclopentyl)carbamate (100 mg, 0.23 mmol, 1.0 equiv.) was dissolved in DCM (2 mL). Hydrogen chloride in ethanol (10 mol / L, 2 mL) was added dropwise to the reaction solution, and the reaction was allowed to proceed at room temperature for 1 hour. When no starting material remained as detected by TLC, the reaction solution was concentrated under reduced pressure, water (30 mL) was added, and the mixture was back-extracted with ethyl acetate (30 mL × 2). The aqueous phase was retained, adjusted to pH 8 with sodium carbonate, and extracted with DCM (30 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the crude product, which was purified by preparative thin-layer chromatography (MeOH:DCM=1:20) to give the product (45 mg, yield: 58.3%). 1 HNMR(400MHz,CD3OD)δ(ppm):8.68(s,1H),7.08(s,1H),6.94(s,1H),6.65-6.37(s,1H),4.53-4.50(m,1H),4.26-4.22(m ,1H),3.62-3.59(m,1H),2.69-2.63(m,1H),2.23-2.14(m,2H),1.83-1.81(m,2H),1.58-1.51(m,1H),1.35-1.33(m,6H). Molecular formula:C 17 H 23 F2N5Exact mass:335.19 LC-MS(Pos,m / z)=336.34[M+H] + .
[0350] Example 54: (S)-3-(difluoromethyl)-N 1 -Isopropyl-N 7 Synthesis of -(piperidin-3-yl)-2,6-naphthyridine-1,7-diamine (compound 54) [ka]
[0351] Step 1: tert-butyl (S)-3-((7-(difluoromethyl)-5-(isopropylamino)-2,6-naphthyridin-3-yl)amino)piperidine-1-carboxylate [ka] 7-Chloro-3-(difluoromethyl)-N-isopropyl-2,6-naphthyridin-1-amine (150 mg, 0.55 mmol, 1.0 equiv.), tert-butyl (S)-3-aminopiperidine-1-carboxylate (144.2 mg, 0.42 mmol, 1.3 equiv.), Pd(dba) (73.2 mg, 0.08 mmol, 0.15 equiv.), BINAP (99.6 mg, 0.16 mmol, 0.3 equiv.), and cesium carbonate (449.6 mg, 1.38 mmol, 2.5 equiv.) were added to 1,4-dioxane (15 mL). The mixture was reacted in a sealed tube at 100 °C for 18 h under a nitrogen atmosphere. When no starting material remained as detected by TLC, water (30 mL) was added to the reaction solution and extracted with ethyl acetate (30 mL x 3). The organic phases were combined, washed with hydrochloric acid solution (0.2 mol / L, 50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the crude product, which was purified by silica gel column chromatography (EA:PE=1:7 to 1:5) to give the product (160 mg, yield: 66.8%).
[0352] Step 2: (S)-3-(difluoromethyl)-N 1 -Isopropyl-N 7 Synthesis of -(piperidin-3-yl)-2,6-naphthyridine-1,7-diamine [ka] tert-Butyl (S)-3-((7-(difluoromethyl)-5-(isopropylamino)-2,6-naphthyridin-3-yl)amino)piperidine-1-carboxylate (160 mg, 0.36 mmol, 1.0 equiv.) was dissolved in DCM (3 mL). Hydrogen chloride ethanol solution (10 mol / L, 3 mL) was added dropwise to the reaction solution, and the mixture was allowed to react at room temperature for 1 hour. When no starting material remained as detected by TLC, water (20 mL) was added to the reaction solution, and the mixture was back-extracted with DCM (30 mL × 2). The aqueous phase was retained, the pH was adjusted to approximately 8 with potassium carbonate, and the mixture was extracted with DCM (20 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and...
Claims
1. A compound of formula (I), a pharma- ceutically acceptable salt or isomer thereof: 【Chemistry 1】 X 1 But N or CR 4 is selected from X 2 But N or CR 5 is selected from L is a bond, -C(O)-, -(CH 2 ) p-; A is selected from a bond, a 3- to 12-membered cycloalkyl, a 3- to 12-membered cycloalkenyl, a 3- to 12-membered heterocyclyl, an aryl, and a 5- to 10-membered heteroaryl, wherein the heteroatoms of said 3- to 12-membered heterocyclyl are selected from one or any combination of O, S, and N; the C atom can be optionally oxidized to C(O); the S atom can be S(O) or S(O) 2 wherein the heteroatoms of said 5-10 membered heteroaryl are selected from one or any combination of O, S, and N; R 1 is hydrogen, halogen, hydroxyl, carboxyl, amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkylaminocarbonyl, (C 1~6 Alkyl) 2 Aminocarbonyl, C 1~6 Alkoxycarbonyl, C 1~6 Alkylcarbonyl, C 1~6 Alkyl sulfonyl, amino sulfonyl, C 1~6 alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl, wherein the heteroatoms of said 3- to 12-membered heterocyclyl are selected from one or any combination of O, S, and N, and the C atom can be optionally oxidized to C(O), and the S atom can be S(O) or S(O) 2 the heteroatoms of said 5-10 membered heteroaryl are selected from one or any combination of O, S, and N; and said amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkylaminocarbonyl, (C 1~6 Alkyl) 2 Aminocarbonyl, C 1~6 Alkoxycarbonyl, C 1~6 Alkylcarbonyl, C 1~6 Alkyl sulfonyl, amino sulfonyl, C 1~6 Alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl are unsubstituted or substituted with hydroxyl, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, C 1~6 Alkylsulfonyl, HS(O)(=NH)-, C 1~6 Alkyl-S(O)(=NH)-, (C 1~6 Alkyl) 2 Aminocarbonyl, C 1~6 optionally substituted by one or more groups selected from alkylcarbonyl, 3- to 12-membered cycloalkyl, and 3- to 12-membered heterocyclyl; R 2 is halogen, cyano, hydroxyl, carboxyl, amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylthio, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl, 3- to 12-membered heterocyclyloxy, 3- to 12-membered cycloalkyloxy, 3- to 12-membered cycloalkylamino, 3- to 12-membered heterocyclyl-CH 2 -amino, wherein said amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylthio, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl, 3- to 12-membered heterocyclyloxy, 3- to 12-membered cycloalkyloxy, 3- to 12-membered cycloalkylamino, 3- to 12-membered heterocyclyl-CH 2 -amino is unsubstituted or is selected from halogen, cyano, hydroxyl, carboxy, amino, C 1~6 Alkyl, C 1~6 Alkoxy, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 optionally substituted by one or more groups selected from amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, aryl, 3- to 12-membered cycloalkenyl, and 5- to 10-membered heteroaryl; R 3 is hydrogen, hydroxy, amino, carboxy, aminocarbonyl, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonyl, C 1~6 Alkylsulfonyl, C 1~6 alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, 3- to 12-membered heterocyclyl; 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonyl, C 1~6 Alkylsulfonyl, C 1~6 Alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, 3- to 12-membered heterocyclyl are unsubstituted or substituted with hydroxyl, amino, carboxyl, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkoxy C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, C 1~6 Alkylcarbonylamino, and C 1~6 alkylsulfonylamino; n is 0 or 1; m is 0, 1, 2, or 3; p is 1, 2, or 3; R 4 , R 5 , and R 6 are each independently hydrogen, halogen, hydroxy, amino, carboxy, cyano, nitro, 1~6 Alkyl, C 2~8 Alkenyl, C 2~8 Alkynyl and halogenated C 1~6 is selected from alkyl.
2. The compound according to claim 1, or a pharma- ceutically acceptable salt or isomer thereof, wherein the following cases are excluded from the compound represented by formula (I): Case (i) X 1 is N and X 2 is N, n is 0, A is piperidinyl, R 1 But, C 1~6 Alkyl sulfonyl, amino sulfonyl, or C 1~6 alkylaminosulfonyl, Case (ii) X 1 is N and X 2 is N, n is 0, A is a bond, and R 1 is piperidinyl, said piperidinyl being 1~6 Alkyl sulfonyl, amino sulfonyl, or C 1~6 Substituted by alkylaminosulfonyl.
3. X 1 is N or CR 4 is selected from X 2 is N or CR 5 is selected from L is a bond, -C(O)-, -(CH 2 ) p-; A is selected from a bond, a 3- to 12-membered cycloalkyl, a 3- to 12-membered cycloalkenyl, a 3- to 12-membered heterocyclyl, an aryl, and a 5- to 10-membered heteroaryl, wherein the heteroatoms of said 3- to 12-membered heterocyclyl are selected from one or any combination of O, S, and N, and the C atom can be optionally oxidized to C(O), and the S atom can be S(O) or S(O) 2 wherein the heteroatoms of said 5-10 membered heteroaryl are selected from one or any combination of O, S, and N; R 1 is hydrogen, halogen, hydroxyl, carboxyl, amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkylaminocarbonyl, (C 1~6 Alkyl) 2 Aminocarbonyl, C 1~6 Alkoxycarbonyl, C 1~6 Alkylcarbonyl, C 1~6 Alkyl sulfonyl, amino sulfonyl, C 1~6 alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl, wherein the heteroatoms of said 3- to 12-membered heterocyclyl are selected from one or any combination of O, S, and N, and the C atom can be optionally oxidized to C(O), and the S atom can be S(O) or S(O) 2 the heteroatoms of said 5-10 membered heteroaryl are selected from one or any combination of O, S, and N; and said amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkylaminocarbonyl, (C 1~6 Alkyl) 2 Aminocarbonyl, C 1~6 Alkoxycarbonyl, C 1~6 Alkylcarbonyl, C 1~6 Alkyl sulfonyl, amino sulfonyl, C 1~6 Alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl are unsubstituted or substituted with hydroxyl, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, C 1~6 optionally substituted by one or more groups selected from alkylsulfonyl, 3- to 12-membered cycloalkyl, and 3- to 12-membered heterocyclyl; R 2 is halogen, cyano, hydroxyl, carboxyl, amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl, wherein said amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl are unsubstituted or are selected from the group consisting of halogen, cyano, hydroxyl, carboxy, amino, C 1~6 Alkyl, C 1~6 Alkoxy, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 optionally substituted with one or more groups selected from amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, aryl, and 5- to 10-membered heteroaryl; R 3 is hydrogen, hydroxy, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonyl, C 1~6 Alkylsulfonyl, C 1~6 alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, and 3- to 12-membered heterocyclyl; 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonyl, C 1~6 Alkylsulfonyl, C 1~6 Alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, 3- to 12-membered heterocyclyl are unsubstituted or substituted with hydroxyl, amino, carboxyl, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkoxy C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, C 1~6 Alkylcarbonylamino, and C 1~6 alkylsulfonylamino; n is 0 or 1; m is 0, 1, 2, or 3; p is 1, 2, or 3; R 4 , R 5 , and R 6 are each independently hydrogen, halogen, hydroxy, amino, carboxy, cyano, nitro, 1~6 Alkyl, C 2~8 Alkenyl, C 2~8 Alkynyl and halogenated C 1~6 selected from alkyl, 3. A compound according to claim 1 or 2, or a pharma- ceutically acceptable salt or isomer thereof.
4. X 1 is N, X 2 is N, L is a bond -C(O)- or -(CH 2 ) p-; A is selected from a bond, a 3- to 12-membered cycloalkyl, or a 3- to 12-membered heterocyclyl; the heteroatoms of the 3- to 12-membered heterocyclyl are selected from any one of O, S, and N, or any combination thereof; R 1 is hydrogen, hydroxyl, C 1~6 Alkyl, C 1~6 Alkoxy, amino, (C 1~6 Alkyl) 2 Amino, C 1~6 alkylcarbonyl, 3- to 12-membered heterocyclyl, halogen, carboxyl, or 3- to 12-membered cycloalkyl, wherein the heteroatoms of the 3- to 12-membered heterocyclyl are selected from any one of O, S, and N, or any combination thereof; 1~6 Alkyl, C 1~6 Alkoxy, amino, (C 1~6 Alkyl) 2 Amino, C 1~6 Alkylcarbonyl, 3- to 12-membered heterocyclyl, and 3- to 12-membered cycloalkyl are hydroxyl, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Aminocarbonyl, C 1~6 Alkylcarbonyl, (C 1~6 Alkyl) 2 Amino, C 1~6 optionally substituted by any one or more groups selected from alkylsulfonyl, 3- to 12-membered cycloalkyl, or 3- to 12-membered heterocyclyl; R 2 is amino, C 1~6 alkylamino, 3- to 12-membered heterocyclyl, or 3- to 12-membered cycloalkylamino, halogen, cyano, hydroxyl, or (C 1~6 Alkyl) 2 The heteroatoms of the 3- to 12-membered heterocyclyl are selected from any one of O, S, and N, or any combination thereof; 1~6 alkylamino, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkylamino, and (C 1~6 Alkyl) 2 Amino is C 1~6 Alkyl, C 1~6 optionally substituted by any one or more groups selected from alkoxy, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, or 3- to 12-membered cycloalkenyl; R 3 Cyano, C 1~6 Alkyl, aminocarbonyl, hydrogen, hydroxy, amino, halogen, or C 1~6 alkoxy, 1~6 Alkyl, aminocarbonyl, amino, and C 1~6 The alkoxy is optionally substituted with any one or more groups selected from halogen; R 6 is hydrogen, halogen, hydroxy, amino, or C 1~6 alkyl, n is 0 or 1; m is 0, 1, 2, or 3; p is 1, 2, or 3; where n is 0, A is a bond, and R 1 is piperidinyl, m is 1, said piperidinyl is C 1~6 except when substituted by alkylsulfonyl; 3. A compound according to claim 1 or 2, or a pharma- ceutically acceptable salt or isomer thereof.
5. When L is a bond and n is 0, the general formula (I) has the structure of general formula (II): 【Chemistry 2】 X 1 is N or CR 4 is selected from X 2 is N or CR 5 is selected from A is selected from 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, 3- to 12-membered heterocyclyl, aryl, and 5- to 10-membered heteroaryl, wherein the heteroatoms of said 3- to 12-membered heterocyclyl are selected from one or any combination of O, S, and N, and the C atom can be optionally oxidized to C(O), and the S atom can be S(O) or S(O) 2 wherein the heteroatoms of said 5-10 membered heteroaryl are selected from one or any combination of O, S, and N; R 1 is hydrogen, halogen, hydroxyl, carboxyl, amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkylaminocarbonyl, (C 1~6 Alkyl) 2 Aminocarbonyl, C 1~6 Alkoxycarbonyl, C 1~6 Alkylcarbonyl, C 1~6 Alkyl sulfonyl, amino sulfonyl, C 1~6 alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl, wherein the heteroatoms of said 3- to 12-membered heterocyclyl are selected from one or any combination of O, S, and N, and the C atom can be optionally oxidized to C(O), and the S atom can be S(O) or S(O) 2 the heteroatoms of said 5-10 membered heteroaryl are selected from one or any combination of O, S, and N; and said amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkylaminocarbonyl, (C 1~6 Alkyl) 2 Aminocarbonyl, C 1~6 Alkoxycarbonyl, C 1~6 Alkylcarbonyl, C 1~6 Alkyl sulfonyl, amino sulfonyl, C 1~6 Alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl are unsubstituted or substituted with hydroxyl, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, C 1~6 Alkylsulfonyl, HS(O)(=NH)-, C 1~6 optionally substituted by one or more groups selected from alkyl-S(O)(=NH)-, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl; R 2 is halogen, cyano, hydroxyl, carboxyl, amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl, 3- to 12-membered heterocyclyloxy, 3- to 12-membered cycloalkylamino, 3- to 12-membered heterocyclyl-CH 2 -amino, wherein said amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl, 3- to 12-membered heterocyclyloxy, 3- to 12-membered cycloalkylamino, 3- to 12-membered heterocyclyl-CH 2 -amino is unsubstituted or is selected from halogen, cyano, hydroxyl, carboxy, amino, C 1~6 Alkyl, C 1~6 Alkoxy, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 optionally substituted with one or more groups selected from amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, aryl, and 5- to 10-membered heteroaryl; R 3 is hydrogen, hydroxy, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonyl, C 1~6 Alkylsulfonyl, C 1~6 alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, and 3- to 12-membered heterocyclyl; 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonyl, C 1~6 Alkylsulfonyl, C 1~6 Alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, 3- to 12-membered heterocyclyl are unsubstituted or substituted with hydroxyl, amino, carboxyl, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkoxy C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, C 1~6 Alkylcarbonylamino, and C 1~6 alkylsulfonylamino; m is 0, 1, 2, or 3; R 4 , R 5 , and R 6 are each independently hydrogen, halogen, hydroxy, amino, carboxy, cyano, nitro, 1~6 Alkyl, C 2~8 Alkenyl, C 2~8 Alkynyl and halogenated C 1~6 alkyl, Preferably, X 1 and X 2 At least one of is N; 3. A compound according to claim 1 or 2, or a pharma- ceutically acceptable salt or isomer thereof.
6. X 1 is N or CR 4 is selected from X 2 is N or CR 5 is selected from A is selected from 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, 3- to 12-membered heterocyclyl, aryl, and 5- to 10-membered heteroaryl, wherein the heteroatoms of said 3- to 12-membered heterocyclyl are selected from one or any combination of O, S, and N, and the C atom can be optionally oxidized to C(O), and the S atom can be S(O) or S(O) 2 wherein the heteroatoms of said 5-10 membered heteroaryl are selected from one or any combination of O, S, and N; R 1 is hydrogen, halogen, hydroxyl, carboxyl, amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkylaminocarbonyl, (C 1~6 Alkyl) 2 Aminocarbonyl, C 1~6 Alkoxycarbonyl, C 1~6 Alkylcarbonyl, C 1~6 Alkyl sulfonyl, amino sulfonyl, C 1~6 alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl, wherein the heteroatoms of said 3- to 12-membered heterocyclyl are selected from one or any combination of O, S, and N, and the C atom can be optionally oxidized to C(O), and the S atom can be S(O) or S(O) 2 the heteroatoms of said 5-10 membered heteroaryl are selected from one or any combination of O, S, and N; and said amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkylaminocarbonyl, (C 1~6 Alkyl) 2 Aminocarbonyl, C 1~6 Alkoxycarbonyl, C 1~6 Alkylcarbonyl, C 1~6 Alkyl sulfonyl, amino sulfonyl, C 1~6 Alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl are unsubstituted or substituted with hydroxyl, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, C 1~6 optionally substituted by one or more groups selected from alkylsulfonyl, 3- to 12-membered cycloalkyl, and 3- to 12-membered heterocyclyl; R 2 is halogen, cyano, hydroxyl, carboxyl, amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl, wherein said amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl are unsubstituted or are selected from the group consisting of halogen, cyano, hydroxyl, carboxy, amino, C 1~6 Alkyl, C 1~6 Alkoxy, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 optionally substituted with one or more groups selected from amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, aryl, and 5- to 10-membered heteroaryl; R 3 is hydrogen, hydroxy, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonyl, C 1~6 Alkylsulfonyl, C 1~6 alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, and 3- to 12-membered heterocyclyl; 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonyl, C 1~6 Alkylsulfonyl, C 1~6 Alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, 3- to 12-membered heterocyclyl are unsubstituted or substituted with hydroxyl, amino, carboxyl, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkoxy C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, C 1~6 Alkylcarbonylamino, and C 1~6 alkylsulfonylamino; m is 0, 1, 2, or 3; R 4 , R 5 , and R 6 are each independently hydrogen, halogen, hydroxy, amino, carboxy, cyano, nitro, 1~6 Alkyl, C 2~8 Alkenyl, C 2~8 Alkynyl and halogenated C 1~6 alkyl, Preferably, X 1 and X 2 At least one of is N; 6. The compound of claim 5 or a pharma- ceutically acceptable salt or isomer thereof.
7. R 1 is hydrogen, halogen, hydroxyl, carboxyl, amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylaminocarbonyl, (C 1~6 Alkyl) 2 Aminocarbonyl, C 1~6 Alkoxycarbonyl, C 1~6 Alkylcarbonyl, C 1~6 Alkylsulfonyl, C 1~6 alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl; 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylaminocarbonyl, (C 1~6 Alkyl) 2 Aminocarbonyl, C 1~6 Alkoxycarbonyl, C 1~6 Alkylcarbonyl, C 1~6 Alkylsulfonyl, C 1~6 Alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl are unsubstituted or substituted with hydroxyl, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, C 1~6 Alkylsulfonyl, HS(O)(=NH)-, C 1~6 optionally substituted by one or more groups selected from alkyl-S(O)(=NH)-, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl; R 3 Cyano and halogenated C 1~6 selected from alkyl, 6. The compound of claim 5 or a pharma- ceutically acceptable salt or isomer thereof.
8. X 1 is N, X 2 is N, A is selected from a bond, a 3- to 12-membered cycloalkyl, or a 3- to 12-membered heterocyclyl, the heteroatoms of which are selected from any one of O, S, and N, or any combination thereof; R 1 is hydrogen, hydroxyl, C 1~6 Alkyl, C 1~6 Alkoxy, amino, (C 1~6 Alkyl) 2 Amino, C 1~6 alkylcarbonyl, 3- to 12-membered heterocyclyl, halogen, carboxyl, or 3- to 12-membered cycloalkyl, wherein the heteroatoms of the 3- to 12-membered heterocyclyl are selected from any one of O, S, and N, or any combination thereof; 1~6 Alkyl, C 1~6 Alkoxy, amino, (C 1~6 Alkyl) 2 Amino, C 1~6 Alkylcarbonyl, 3- to 12-membered heterocyclyl, and 3- to 12-membered cycloalkyl are hydroxyl, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Aminocarbonyl, C 1~6 Alkylcarbonyl, (C 1~6 Alkyl) 2 Amino, C 1~6 optionally substituted by any one or more groups selected from alkylsulfonyl, 3- to 12-membered cycloalkyl, or 3- to 12-membered heterocyclyl; R 2 is amino, C 1~6 alkylamino, 3- to 12-membered heterocyclyl or 3- to 12-membered cycloalkylamino, halogen, cyano, hydroxyl, or (C 1~6 Alkyl) 2 The heteroatoms of the 3- to 12-membered heterocyclyl or 3- to 12-membered cycloalkylamino are selected from any one of O, S, and N, or any combination thereof; 1~6 alkylamino, 3- to 12-membered heterocyclyl, and (C 1~6 Alkyl) 2 Amino is C 1~6 Alkyl, C 1~6 optionally substituted by any one or more groups selected from alkoxy, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, or 3- to 12-membered cycloalkenyl; R 3 Cyano, C 1~6 Alkyl, aminocarbonyl, hydrogen, hydroxy, amino, halogen, or C 1~6 alkoxy, 1~6 Alkyl, aminocarbonyl, amino, and C 1~6 The alkoxy is optionally substituted with any one or more groups selected from halogen; R 6 is hydrogen, halogen, hydroxy, amino, or C 1~6 alkyl, m is 0, 1, 2, or 3; p is 1, 2, or 3; 6. The compound of claim 5 or a pharma- ceutically acceptable salt or isomer thereof.
9. When L is -C(O)- and n is 1, the general formula (I) has the structure of general formula (III): 【Chemistry 3】 X 1 is N or CR 4 is selected from X 2 is N or CR 5 is selected from A is selected from 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, 3- to 12-membered heterocyclyl, aryl, and 5- to 10-membered heteroaryl, wherein the heteroatoms of said 3- to 12-membered heterocyclyl are selected from one or any combination of O, S, and N, and the C atom can be optionally oxidized to C(O), and the S atom can be S(O) or S(O) 2 wherein the heteroatoms of said 5-10 membered heteroaryl are selected from one or any combination of O, S, and N; R 1 is hydrogen, halogen, hydroxyl, carboxyl, amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkylaminocarbonyl, (C 1~6 Alkyl) 2 Aminocarbonyl, C 1~6 Alkoxycarbonyl, C 1~6 Alkylcarbonyl, C 1~6 Alkyl sulfonyl, amino sulfonyl, C 1~6 alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl, wherein the heteroatoms of said 3- to 12-membered heterocyclyl are selected from one or any combination of O, S, and N, and the C atom can be optionally oxidized to C(O), and the S atom can be S(O) or S(O) 2 the heteroatoms of said 5-10 membered heteroaryl are selected from one or any combination of O, S, and N; and said amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkylaminocarbonyl, (C 1~6 Alkyl) 2 Aminocarbonyl, C 1~6 Alkoxycarbonyl, C 1~6 Alkylcarbonyl, C 1~6 Alkyl sulfonyl, amino sulfonyl, C 1~6 Alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl are unsubstituted or substituted with hydroxyl, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, C 1~6 Alkylsulfonyl, HS(O)(=NH)-, C 1~6 optionally substituted by one or more groups selected from alkyl-S(O)(=NH)-, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl; R 2 is halogen, cyano, hydroxyl, carboxyl, amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl, 3- to 12-membered heterocyclyloxy, 3- to 12-membered cycloalkylamino, 3- to 12-membered heterocyclyl-CH 2 -amino, wherein said amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl, 3- to 12-membered heterocyclyloxy, 3- to 12-membered cycloalkylamino, 3- to 12-membered heterocyclyl-CH 2 -amino is unsubstituted or is selected from halogen, cyano, hydroxyl, carboxy, amino, C 1~6 Alkyl, C 1~6 Alkoxy, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 optionally substituted with one or more groups selected from amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, aryl, and 5- to 10-membered heteroaryl; R 3 is hydrogen, hydroxy, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonyl, C 1~6 Alkylsulfonyl, C 1~6 alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, and 3- to 12-membered heterocyclyl; 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonyl, C 1~6 Alkylsulfonyl, C 1~6 Alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, 3- to 12-membered heterocyclyl are unsubstituted or substituted with hydroxyl, amino, carboxyl, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkoxy C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, C 1~6 Alkylcarbonylamino, and C 1~6 alkylsulfonylamino; m is 0, 1, 2, or 3; R 4 , R 5 , and R 6 are each independently hydrogen, halogen, hydroxy, amino, carboxy, cyano, nitro, 1~6 Alkyl, C 2~8 Alkenyl, C 2~8 Alkynyl and halogenated C 1~6 alkyl, Preferably, X 1 and X 2 At least one of is N; 3. A compound according to claim 1 or 2, or a pharma- ceutically acceptable salt or isomer thereof.
10. X 1 is N or CR 4 is selected from X 2 is N or CR 5 is selected from A is selected from 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, 3- to 12-membered heterocyclyl, aryl, and 5- to 10-membered heteroaryl, wherein the heteroatoms of said 3- to 12-membered heterocyclyl are selected from one or any combination of O, S, and N, and the C atom can be optionally oxidized to C(O), and the S atom can be S(O) or S(O) 2 wherein the heteroatoms of said 5-10 membered heteroaryl are selected from one or any combination of O, S, and N; R 1 is hydrogen, halogen, hydroxyl, carboxyl, amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkylaminocarbonyl, (C 1~6 Alkyl) 2 Aminocarbonyl, C 1~6 Alkoxycarbonyl, C 1~6 Alkylcarbonyl, C 1~6 Alkyl sulfonyl, amino sulfonyl, C 1~6 alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl, wherein the heteroatoms of said 3- to 12-membered heterocyclyl are selected from one or any combination of O, S, and N, and the C atom can be optionally oxidized to C(O), and the S atom can be S(O) or S(O) 2 the heteroatoms of said 5-10 membered heteroaryl are selected from one or any combination of O, S, and N; and said amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkylaminocarbonyl, (C 1~6 Alkyl) 2 Aminocarbonyl, C 1~6 Alkoxycarbonyl, C 1~6 Alkylcarbonyl, C 1~6 Alkyl sulfonyl, amino sulfonyl, C 1~6 Alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl are unsubstituted or substituted with hydroxyl, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, C 1~6 optionally substituted by one or more groups selected from alkylsulfonyl, 3- to 12-membered cycloalkyl, and 3- to 12-membered heterocyclyl; R 2 is halogen, cyano, hydroxyl, carboxyl, amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl, wherein said amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl are unsubstituted or are selected from the group consisting of halogen, cyano, hydroxyl, carboxy, amino, C 1~6 Alkyl, C 1~6 Alkoxy, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 optionally substituted with one or more groups selected from amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, aryl, and 5- to 10-membered heteroaryl; R 3 is hydrogen, hydroxy, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonyl, C 1~6 Alkylsulfonyl, C 1~6 alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, and 3- to 12-membered heterocyclyl; 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonyl, C 1~6 Alkylsulfonyl, C 1~6 Alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, 3- to 12-membered heterocyclyl are unsubstituted or substituted with hydroxyl, amino, carboxyl, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkoxy C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, C 1~6 Alkylcarbonylamino, and C 1~6 alkylsulfonylamino; m is 0, 1, 2, or 3; R 4 , R 5 , and R 6 are each independently hydrogen, halogen, hydroxy, amino, carboxy, cyano, nitro, 1~6 Alkyl, C 2~8 Alkenyl, C 2~8 Alkynyl and halogenated C 1~6 alkyl, Preferably, X 1 , and X 2 At least one of is N; 10. The compound of claim 9 or a pharma- ceutically acceptable salt or isomer thereof.
11. L is - (CH 2 ) p-, p is 1, and n is 1, the general formula (I) has the structure of general formula (IV), 【Chemistry 4】 X 1 is N or CR 4 is selected from X 2 is N or CR 5 is selected from A is selected from 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, 3- to 12-membered heterocyclyl, aryl, and 5- to 10-membered heteroaryl, wherein the heteroatoms of said 3- to 12-membered heterocyclyl are selected from one or any combination of O, S, and N, and the C atom can be optionally oxidized to C(O), and the S atom can be S(O) or S(O) 2 wherein the heteroatoms of said 5-10 membered heteroaryl are selected from one or any combination of O, S, and N; R 1 is hydrogen, halogen, hydroxyl, carboxyl, amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkylaminocarbonyl, (C 1~6 Alkyl) 2 Aminocarbonyl, C 1~6 Alkoxycarbonyl, C 1~6 Alkylcarbonyl, C 1~6 Alkyl sulfonyl, amino sulfonyl, C 1~6 alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl, wherein the heteroatoms of said 3- to 12-membered heterocyclyl are selected from one or any combination of O, S, and N, and the C atom can be optionally oxidized to C(O), and the S atom can be S(O) or S(O) 2 the heteroatoms of said 5-10 membered heteroaryl are selected from one or any combination of O, S, and N; 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkylaminocarbonyl, (C 1~6 Alkyl) 2 Aminocarbonyl, C 1~6 Alkoxycarbonyl, C 1~6 Alkylcarbonyl, C 1~6 Alkyl sulfonyl, amino sulfonyl, C 1~6 Alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl are unsubstituted or substituted with hydroxyl, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, C 1~6 Alkylsulfonyl, HS(O)(=NH)-, C 1~6 optionally substituted by one or more groups selected from alkyl-S(O)(=NH)-, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl; R 2 is halogen, cyano, hydroxyl, carboxyl, amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl, 3- to 12-membered heterocyclyloxy, 3- to 12-membered cycloalkylamino, 3- to 12-membered heterocyclyl-CH 2 -amino, wherein said amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl, 3- to 12-membered heterocyclyloxy, 3- to 12-membered cycloalkylamino, 3- to 12-membered heterocyclyl-CH 2 -amino is unsubstituted or is selected from halogen, cyano, hydroxyl, carboxy, amino, C 1~6 Alkyl, C 1~6 Alkoxy, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 optionally substituted with one or more groups selected from amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, aryl, and 5- to 10-membered heteroaryl; R 3 is hydrogen, hydroxy, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonyl, C 1~6 Alkylsulfonyl, C 1~6 alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, and 3- to 12-membered heterocyclyl; 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonyl, C 1~6 Alkylsulfonyl, C 1~6 Alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, 3- to 12-membered heterocyclyl are unsubstituted or substituted with hydroxyl, amino, carboxyl, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkoxy C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, C 1~6 Alkylcarbonylamino, and C 1~6 alkylsulfonylamino; m is 0, 1, 2, or 3; R 4 , R 5 , and R 6 are each independently hydrogen, halogen, hydroxy, amino, carboxy, cyano, nitro, 1~6 Alkyl, C 2~8 Alkenyl, C 2~8 Alkynyl and halogenated C 1~6 alkyl, Preferably, X 1 , and X 2 At least one of is N; 3. A compound according to claim 1 or 2, or a pharma- ceutically acceptable salt or isomer thereof.
12. X 1 is N or CR 4 is selected from X 2 is N or CR 5 is selected from A is selected from 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, 3- to 12-membered heterocyclyl, aryl, and 5- to 10-membered heteroaryl, wherein the heteroatoms of said 3- to 12-membered heterocyclyl are selected from one or any combination of O, S, and N, and the C atom can be optionally oxidized to C(O), and the S atom can be S(O) or S(O) 2 wherein the heteroatoms of said 5-10 membered heteroaryl are selected from one or any combination of O, S, and N; R 1 is hydrogen, halogen, hydroxyl, carboxyl, amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkylaminocarbonyl, (C 1~6 Alkyl) 2 Aminocarbonyl, C 1~6 Alkoxycarbonyl, C 1~6 Alkylcarbonyl, C 1~6 Alkyl sulfonyl, amino sulfonyl, C 1~6 alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl, wherein the heteroatoms of said 3- to 12-membered heterocyclyl are selected from one or any combination of O, S, and N, and the C atom can be optionally oxidized to C(O), and the S atom can be S(O) or S(O) 2 the heteroatoms of said 5-10 membered heteroaryl are selected from one or any combination of O, S, and N; 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkylaminocarbonyl, (C 1~6 Alkyl) 2 Aminocarbonyl, C 1~6 Alkoxycarbonyl, C 1~6 Alkylcarbonyl, C 1~6 Alkyl sulfonyl, amino sulfonyl, C 1~6 Alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl are unsubstituted or substituted with hydroxyl, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, C 1~6 optionally substituted by one or more groups selected from alkylsulfonyl, 3- to 12-membered cycloalkyl, and 3- to 12-membered heterocyclyl; R 2 is halogen, cyano, hydroxyl, carboxyl, amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl, wherein said amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl are unsubstituted or are selected from halogen, cyano, hydroxyl, carboxy, amino, C 1~6 Alkyl, C 1~6 Alkoxy, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 optionally substituted with one or more groups selected from amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, aryl, and 5- to 10-membered heteroaryl; R 3 is hydrogen, hydroxy, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonyl, C 1~6 Alkylsulfonyl, C 1~6 alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, and 3- to 12-membered heterocyclyl; 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonyl, C 1~6 Alkylsulfonyl, C 1~6 Alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, 3- to 12-membered heterocyclyl are unsubstituted or substituted with hydroxyl, amino, carboxyl, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkoxy C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, C 1~6 Alkylcarbonylamino, and C 1~6 alkylsulfonylamino; m is 0, 1, 2, or 3; R 4 , R 5 , and R 6 are each independently hydrogen, halogen, hydroxy, amino, carboxy, cyano, nitro, 1~6 Alkyl, C 2~8 Alkenyl, C 2~8 Alkynyl and halogenated C 1~6 alkyl, Preferably, X 1 , and X 2 At least one of is N; 12. The compound of claim 11 or a pharma- ceutically acceptable salt or isomer thereof.
13. A is selected from the group consisting of 3-8 membered cycloalkyl, 6-11 membered ortho-fused cycloalkyl, 6-11 membered bridged cycloalkyl, 7-12 membered spirocycloalkyl, 3-8 membered monocycloalkenyl, 7-11 membered spirocycloalkenyl, 7-11 membered ortho-fused cycloalkenyl, 6-11 membered bridged cycloalkenyl, 3-8 membered heterocyclyl, 6-12 membered ortho-fused heterocyclyl, 6-12 membered spiroheterocyclyl, 6-12 membered bridged heterocyclyl, and 5-10 membered heteroaryl, wherein the heteroatoms of the 3-8 membered heterocyclyl, 6-12 membered ortho-fused heterocyclyl, 6-12 membered spiroheterocyclyl, and 6-12 membered bridged heterocyclyl are selected from one or any combination thereof, and the C atom can be optionally oxidized to C(O), and the S atom can be selected from S(O) or S(O) 2 wherein the heteroatoms of said 5-10 membered heteroaryl are selected from one or any combination of O, S, and N; 3. A compound according to claim 1 or 2, or a pharma- ceutically acceptable salt or isomer thereof.
14. A is, 【Chemistry 5】 14. The compound of claim 13, selected from:
15. X 1 is N, X 2 is CR 5 and L is selected from a bond or -C(O)-; A is selected from 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkyl, or 5- to 10-membered heteroaryl, wherein the heteroatom of the 3- to 12-membered heterocyclyl and the 5- to 10-membered heteroaryl are N; R 1 is hydrogen, hydroxyl, amino, C 1~6 Alkyl, or C 1~6 alkylcarbonylamino, wherein said amino, C 1~6 Alkyl, or C 1~6 Alkylcarbonylamino is unsubstituted or is selected from the group consisting of HS(O)(=NH)-, C 1~6 optionally substituted with one or more groups selected from alkyl-S(O)(=NH)-; R 2 is amino, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, C 1~6 alkoxy, 3- to 12-membered heterocyclyloxy, 3- to 12-membered heterocyclyl or 3- to 12-membered cycloalkenyl, 3- to 12-membered cycloalkylamino, wherein the heteroatoms of the 3- to 12-membered heterocyclyl and 3- to 12-membered heterocyclyloxy are N, O, or any combination thereof, and the amino, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, C 1~6 Alkoxy, 3- to 12-membered heterocyclyloxy, 3- to 12-membered heterocyclyl, or 3- to 12-membered cycloalkenyl, 3- to 12-membered cycloalkylamino are unsubstituted or are selected from the group consisting of 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, aryl, C 1~6 Optionally substituted with one or more groups selected from alkyl, R 3 is cyano or halogenated C 1~6 alkyl, R 5 and R 6 are each independently hydrogen; n is 0 or 1; m is 0 or 1; 3. A compound according to claim 1 or 2, or a pharma- ceutically acceptable salt or isomer thereof.
16. X 1 is N or CR 4 is selected from X 2 is N or CR 5 is selected from L is a bond, -C(O)-, -(CH 2 ) p-; A is a bond; R 1 is hydrogen, halogen, hydroxyl, carboxyl, amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkylaminocarbonyl, (C 1~6 Alkyl) 2 Aminocarbonyl, C 1~6 Alkoxycarbonyl, C 1~6 Alkylcarbonyl, C 1~6 Alkyl sulfonyl, amino sulfonyl, C 1~6 alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl, wherein the heteroatoms of said 3- to 12-membered heterocyclyl are selected from one or any combination of O, S, and N, and the C atom can be optionally oxidized to C(O), and the S atom can be S(O) or S(O) 2 the heteroatoms of said 5-10 membered heteroaryl are selected from one or any combination of O, S, and N; 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkylaminocarbonyl, (C 1~6 Alkyl) 2 Aminocarbonyl, C 1~6 Alkoxycarbonyl, C 1~6 Alkylcarbonyl, C 1~6 Alkyl sulfonyl, amino sulfonyl, C 1~6 Alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl are unsubstituted or substituted with hydroxyl, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, C 1~6 optionally substituted by one or more groups selected from alkylsulfonyl, 3- to 12-membered cycloalkyl, and 3- to 12-membered heterocyclyl; R 2 is halogen, cyano, hydroxyl, carboxyl, amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl, wherein said amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl are unsubstituted or are selected from halogen, cyano, hydroxyl, carboxy, amino, C 1~6 Alkyl, C 1~6 Alkoxy, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 optionally substituted with one or more groups selected from amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, aryl, and 5- to 10-membered heteroaryl; R 3 is hydrogen, hydroxy, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonyl, C 1~6 Alkylsulfonyl, C 1~6 alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, and 3- to 12-membered heterocyclyl; 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonyl, C 1~6 Alkylsulfonyl, C 1~6 Alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, 3- to 12-membered heterocyclyl are unsubstituted or substituted with hydroxyl, amino, carboxyl, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkoxy C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, C 1~6 Alkylcarbonylamino, and C 1~6 alkylsulfonylamino; n is 0 or 1; m is 0, 1, 2, or 3; p is 1, 2, or 3; R 4 , R 5 , and R 6 are each independently hydrogen, halogen, hydroxy, amino, carboxy, cyano, nitro, 1~6 Alkyl, C 2~8 Alkenyl, C 2~8 Alkynyl and halogenated C 1~6 selected from alkyl, 3. A compound according to claim 1 or 2, or a pharma- ceutically acceptable salt or isomer thereof.
17. X 1 is N, X 2 is N, L is a bond; A is selected from 3- to 12-membered cycloalkyl or 3- to 12-membered heterocyclyl, the heteroatom of said 3- to 12-membered heterocyclyl is N; R 1 is hydrogen, hydroxyl, C 1~6 Alkyl, C 1~6 Alkoxy, amino, (C 1~6 Alkyl) 2 Amino, C 1~6 alkylcarbonyl, or 3- to 12-membered heterocyclyl, the heteroatoms of which are selected from any one of N and O, or any combination thereof; 1~6 Alkyl, C 1~6 Alkoxy, amino, (C 1~6 Alkyl) 2 Amino, C 1~6 Alkylcarbonyl and 3- to 12-membered heterocyclyl are hydroxyl, amino, C 1~6 Alkyl, (C 1~6 Alkyl) 2 Aminocarbonyl, or C 1~6 Optionally substituted by any one or more groups selected from alkylcarbonyl, R 2 is amino, C 1~6 alkylamino, 3- to 12-membered heterocyclyl, or 3- to 12-membered cycloalkylamino, wherein the heteroatom of the 3- to 12-membered heterocyclyl is selected from any one of O and N, or any combination thereof; 1~6 Alkylamino, 3- to 12-membered heterocyclyl, or 3- to 12-membered cycloalkylamino is C 1~6 Alkyl, C 1~6 optionally substituted by any one or more groups selected from alkoxy, 3- to 12-membered cycloalkyl, or 3- to 12-membered heterocyclyl; R 3 Cyano, C 1~6 Alkyl, aminocarbonyl, hydrogen, hydroxy, amino, halogen, or C 1~6 alkoxy, 1~6 The alkyl and aminocarbonyl are optionally substituted with one or more halogens; R 6 is hydrogen, n is 0, m is 0, 1, 2, or 3; p is 1, 2, or 3; 3. A compound according to claim 1 or 2, or a pharma- ceutically acceptable salt or isomer thereof.
18. X 1 is N, X 2 teeth 、 CR 5 and L is a bond; n is 0, A is selected from 3- to 12-membered cycloalkyl or 3- to 12-membered heterocyclyl, the heteroatom of said 3- to 12-membered heterocyclyl is N, and said 3- to 12-membered cycloalkyl is substituted by amino; R 1 is hydrogen, R 2 is amino, C 1~6 alkoxy, or 3- to 12-membered heterocyclyloxy, wherein the amino is substituted by a 3- to 12-membered heterocyclyl; R 3 is cyano or halogenated C 1~6 alkyl, R 5 and R 6 are each independently hydrogen; m is 1; 2. A compound according to claim 1 or a pharma- ceutically acceptable salt or isomer thereof.
19. below: 【Chemistry 6-1】 【Chemistry 6-2】 【Chemistry 6-3】 【Chemistry 6-4】 【Chemistry 6-5】 【Chemistry 6-6】 【Chemistry 6-7】 【Chemistry 6-8】 【Chemistry 6-9】 【Chemistry 6-10】 【Chemistry 6-11】 【Chemistry 6-12】 【Chemistry 6-13】 【Chemistry 6-14】 【Chemistry 6-15】 【Chemistry 6-16】 or a pharma- ceutically acceptable salt or isomer thereof.
20. X 1 is N or CR 4 is selected from X 2 is N or CR 5 is selected from L is a bond, -C(O)-, -(CH 2 ) p-; A is selected from a bond, a 3- to 12-membered cycloalkyl, a 3- to 12-membered cycloalkenyl, a 3- to 12-membered heterocyclyl, an aryl, and a 5- to 10-membered heteroaryl, wherein the heteroatoms of said 3- to 12-membered heterocyclyl are selected from one or any combination of O, S, and N, and the C atom can be optionally oxidized to C(O), and the S atom can be S(O) or S(O) 2 wherein the heteroatoms of said 5-10 membered heteroaryl are selected from one or any combination of O, S, and N; R 1 is hydrogen, halogen, hydroxyl, carboxyl, amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkylaminocarbonyl, (C 1~6 Alkyl) 2 Aminocarbonyl, C 1~6 Alkoxycarbonyl, C 1~6 Alkylcarbonyl, C 1~6 Alkyl sulfonyl, amino sulfonyl, C 1~6 alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl, wherein the heteroatoms of said 3- to 12-membered heterocyclyl are selected from one or any combination of O, S, and N, and the C atom can be optionally oxidized to C(O), and the S atom can be S(O) or S(O) 2 the heteroatoms of said 5-10 membered heteroaryl are selected from one or any combination of O, S, and N; 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkylaminocarbonyl, (C 1~6 Alkyl) 2 Aminocarbonyl, C 1~6 Alkoxycarbonyl, C 1~6 Alkylcarbonyl, C 1~6 Alkyl sulfonyl, amino sulfonyl, C 1~6 Alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl are unsubstituted or substituted with hydroxyl, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, C 1~6 Alkylsulfonyl, HS(O)(=NH)-, C 1~6 Alkyl-S(O)(=NH)-, (C 1~6 Alkyl) 2 Aminocarbonyl, C 1~6 optionally substituted by one or more groups selected from alkylcarbonyl, 3- to 12-membered cycloalkyl, and 3- to 12-membered heterocyclyl; R 2 is halogen, cyano, hydroxyl, carboxyl, amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl, 3- to 12-membered heterocyclyloxy, 3- to 12-membered cycloalkylamino, 3- to 12-membered heterocyclyl-CH 2 -amino, wherein said amino, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, 3- to 12-membered cycloalkenyl, 3- to 12-membered heterocyclyloxy, 3- to 12-membered cycloalkylamino, 3- to 12-membered heterocyclyl-CH 2 -amino is unsubstituted or is selected from halogen, cyano, hydroxyl, carboxy, amino, C 1~6 Alkyl, C 1~6 Alkoxy, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 optionally substituted with one or more groups selected from amino, 3- to 12-membered cycloalkyl, 3- to 12-membered heterocyclyl, aryl, and 5- to 10-membered heteroaryl; R 3 is hydrogen, hydroxy, amino, carboxy, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonyl, C 1~6 Alkylsulfonyl, C 1~6 alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, and 3- to 12-membered heterocyclyl; 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, halogenated C 1~6 Alkyl, halogenated C 1~6 Alkoxy, C 2~8 Alkenyl, C 2~8 Alkynyl, C 1~6 Alkylcarbonyl, C 1~6 Alkylsulfonyl, C 1~6 Alkylthio, 3- to 12-membered cycloalkyl, 3- to 12-membered cycloalkenyl, 3- to 12-membered heterocyclyl are unsubstituted or substituted with hydroxyl, amino, carboxyl, cyano, nitro, halogen, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkoxy C 1~6 Alkoxy, C 1~6 Alkylamino, (C 1~6 Alkyl) 2 Amino, C 1~6 Alkylcarbonylamino, and C 1~6 alkylsulfonylamino; n is 0 or 1; m is 0, 1, 2, or 3; p is 1, 2, or 3; R 4 , R 5 , and R 6 are each independently hydrogen, halogen, hydroxy, amino, carboxy, cyano, nitro, 1~6 Alkyl, C 2~8 Alkenyl, C 2~8 Alkynyl and halogenated C 1~6 selected from alkyl, 3. A compound according to claim 1 or 2, or a pharma- ceutically acceptable salt or isomer thereof.
21. 21. A pharmaceutical composition comprising a compound according to any one of claims 1 to 20, or a pharma- ceutically acceptable salt or isomer thereof, and one or more second therapeutically active agents.
22. A pharmaceutical formulation having cyclin-dependent kinase 9 inhibitory activity, comprising the compound according to any one of claims 1 to 20 or a pharma- ceutically acceptable salt or isomer thereof and one or more pharma- ceutically acceptable carriers.
23. 21. Use of a compound according to any one of claims 1 to 20, or a pharma- ceutically acceptable salt or isomer thereof, in the manufacture of a medicament for the treatment or prevention of a CDK9 mediated related disease.
24. 24. The use of claim 23, wherein the CDK9 mediated associated disease is cancer, preferably the cancer is a solid tumor or a hematological malignancy, more preferably the cancer is selected from adrenal tumor, melanoma, head and neck cancer, kidney cancer, bladder cancer, prostate cancer, endometrial cancer, cervical cancer, gastric cancer, colon cancer, pancreatic cancer, rectal cancer, esophageal cancer, liver cancer, lung cancer, sarcoma, breast cancer, ovarian cancer, non-Hodgkin's lymphoma, acute myeloid leukemia, acute lymphoblastic leukemia, or myeloma.
Citation Information
Patent Citations
Inhibitor compounds
JP2015527387A
PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
WO2016194831A1
Crystal of pyrido[3, 4-d]pyrimidine derivative or solvate thereof
WO2018097295A1
Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof
WO2018097297A1
Aza-quinoline compounds and uses thereof
WO2021057853A1
Cited By
Diester compound or salt thereof, production method therefor, and pyridopyridazine compound production method
WO2026204302A1
